Kingdom of Saudi Arabia

Ministry of Health
Saudi Cancer Registry

Cancer Incidence Report
Saudi Arabia
2006

Report prepared by:
Haya S. Al-Eid, BDS, DFE, CTR
Marielen S. Manalo, Secretary
Reviewed by:
Shouki Bazarbashi, MD
Ali Al-Zahrani, MD, PhD

Foreword

Acknowledgment

The 2006 cancer incidence report represents the
tenth publication for the cancer registry since its
establishment in 1992. We have maintained the same
standard format as in the previous reports and added
a section of the collective data variables since the
start of the Saudi Cancer Registry on January 1994.

The Saudi Cancer Registry is funded by The
Ministry of health. The work of the Saudi Cancer
Registry including the production of this report
is the result of teamwork by our valuable cancer
registrars, main office staff and members of the
board of directors. Special warm thanks to our
registrar who travel to every part of the kingdom
to collect the cases that are included in this report

It is clear from the report that the number and
the incidence of cancer is on the rise. Despite
our continued effort to ascertain comprehensive
case finding which in part might be one of the
reasons behind the increasing number of cancer
cases reported, we do believe that there is
a genuine rise in the cancer incidence in our
country. Nevertheless, we believe there is
considerable room for improvement. Our
main obstacle is medical record availability in
many hospitals. This leads to under-reporting
of clinically diagnosed cases in our population.
We continue to struggle and face many challenges.
Of most importance is the finding of well qualified
tumor registrars. This year we were able to
conduct a high quality education and training
program for our registrar that was most useful.
This will hopefully continue on an annual basis
and will aim at transforming our centre as the
hub for cancer registrar training in the gulf area.

Special thanks to the support provided by the
Ministry of Health represented by his Excellency
the Minister of Health Dr. Abdullah Al Rabeeah
and the deputy Minister of Health Dr. Mansour
Al Hawasi. Special thanks to The Counsel for
health services represented by the secretary
general Dr. Othman Al Rabieah who spared
no effort in helping us to overcome the many
problems we faced and supported the funding of
the SCR. In addition we continue to be in debt
for the support of King Faisal Specialist Hospital
and Research Center leadership represented
by Dr. Qasem Al Qasabi and Dr. Adnan Ezzat.
We also would like to record our thanks to the
support from many of the pharmaceutical companies
who have supported unrestricted grants to the SCR.
In particular we would like to thank Roche oncology,
GlaxoSmithKline for their generous support.

Mortality and survival data continue to be one of
our biggest challenge. It is unclear if we will be
able to publish this data in the near future but we
would like to assure you that we will spare no
effort until we are able to present them to you.
We have established our own website. The
address is www.scr.org.sa. All previous annual
reports are available to the public on the website
and we encourage everyone to make use of it.
Shouki Bazarbashi, MD
Chairman

3

Introduction
This is the ninth incidence report published by
the Saudi Cancer Registry. Previous publications
include the 1994 Summary Report, 1994-1996
Incidence Report, 1997-1998 Incidence Report,
1999-2000 Incidence Report, 2001 Incidence
Report, 2002, 2003, 2004 and 2005 Incidence
Reports.

Part IV Cancer Incidence among NonSaudis

The structure of this report can be outlined as
follows:

This part presents the incidence of cancer cases
among Non-Saudis including the most common
types of cancer. The analysis of the Non-Saudis
is performed separately due to the nature of the
expatriate population in Saudi Arabia in which a
large part of the population, particularly among
males, falls in the 25-44 age group.

Part I Materials and Methods

Part V Incidence Tables

This part of the report contains information about
the background of the Saudi Cancer Registry and
methods used in collecting and analyzing the data.
We present the basics of coding and classification
of tumor topography, morphology and extent of
disease at the time of diagnosis. Also we describe
the software programs we have used to analyze
the data.

Part V contains the following detailed tables for all
newly diagnosed cancer types among Saudis and
Non-Saudis for 2006:

Part II Overview of Cancer Incidence
Part II contains figures and tables that show overall
cancer incidence in Saudi Arabia for the year 2006.
We present these figures and tables mainly by sex
and in certain areas we have it analyzed by different
age groups. There are bar charts representing the
age distribution of cancer incidence for the year
2006 among Saudis by sex and age groups. We
present incidence and morphology tables for the
most common types of cancers among adults and
children. In addition, tables list the total number of
cases, the Age-Standardized Incidence Rate (ASR)
per 100,000 population, Crude Incidence Rate
(CIR) and Cumulative rates by primary site and sex.
Separate bar charts depict the most common types
of cancer, by sex, in each of the 13 administrative
regions of Saudi Arabia.
Part III Incidence of Selected-Sites
In this part the incidence of the most common
cancers among Saudi males and females are
outlined. A standardized layout presents data for all
patients and for both sexes where applicable. For
each selected site the number and the percentage
of all newly diagnosed cases for the year 2006, the
ASR for each sex and the specific cancer rank for
both sexes is presented. In addition, ASR for the
specified cancer among Saudis is compared with ASR
among other populations from selected countries.

• Distribution of cancer cases among Saudis
by age group and sex
• Distribution of cancer cases among NonSaudis by age group and sex
• Cancer Incidence (per 100,000 population)
among Saudis by age group and sex
• Cancer Incidence (per 100,000 population)
among Non-Saudis by age group and sex
• Age-standardized incidence rate and relative
frequencies among Saudis by cancer site, sex
and administrative regions
Part VI Appendices
Appendix A: Regional listing of all health care
facilities from which cancer cases have been
reported. The objective is to receive feedback
from facilities that have not been included in
order to improve our case-finding and reporting
processes.
Appendix B: Names of the members of the
Board of Directors.
Appendix C: Copy of the cancer registration
abstract form which is completed by cancer
registrars for each cancer case
Appendix D: Arabic Summary of Cancer
Statistics in Saudi Arabia for the year 2006

5

Table of Contents
Foreword........................................................................................................................................................................ 3
Acknowledgement........................................................................................................................................................ 3
Introduction................................................................................................................................................................... 5

PART I.................................................................................................................................................. 9
Background on Saudi Arabia.................................................................................................................................... 10
Saudi Cancer Registry................................................................................................................................................ 10
Definitions of Statistical Terms............................................................................................................................... 13

PART II....................................................................................................................15
Cancer in Saudi Arabia 2006.................................................................................................................................... 16
Adult Cancers in Saudi Arabia, 2006 (above 14 years)...................................................................................... 21
Childhood Cancers in Saudi Arabia 2006 (14 years and below)..................................................................... 24
Cancer in the 13 Administrative Regions of the Kingdom............................................................................... 27
International Comparison of Age-Standardized Incidence Rates ................................................................... 32

PART III..................................................................................................................33
Cancer Incidence for Most Common Sites, 2006............................................................................................... 35
Female Breast (C 50)................................................................................................................................................. 36
Colo-rectal (C18-C20).............................................................................................................................................. 38
Non-Hodgkin Lymphoma (C82-C85; C96)........................................................................................................... 40
Thyroid (C73).............................................................................................................................................................. 42
Leukemia (C91-C95)................................................................................................................................................. 44
Liver (C22)................................................................................................................................................................... 46
Skin (Non-Melanoma) (C44).................................................................................................................................... 48
Lung (C33-C34).......................................................................................................................................................... 50
Hodgkin Disease (C81)............................................................................................................................................. 52
Stomach (C16)............................................................................................................................................................ 54
Prostate (C61)............................................................................................................................................................. 56
Bladder (C67).............................................................................................................................................................. 58
Corpus Uteri (C55)................................................................................................................................................... 60
Ovarian Cancer (C56)............................................................................................................................................... 62
References.................................................................................................................................................................... 64

PART IV..................................................................................................................65
Cancer Among Non-Saudi Population 2006....................................................................................................... 67

..................000)......2..................... Makkah.....3 Number.....................................3.... 1994-2006................... 72 Table 5.........4.................2........ Relative Frequencies.... Age Standardized Rates and Crude Rates for all Cancer Cases among Saudi Females by Cancer Site and Administrative Region (Riyadh... 80 Table 5........ 2006.....4 Incidence Rates for Cancer Cases among non-Saudi Females by Age Group (per 100...5. 89 PART VI............................. 2006..................................................91 APPENDIX APPENDIX APPENDIX APPENDIX A: Reporting Health Care Facilities..................5.1 Number.................................... Relative Frequencies........... Relative Frequencies.......000)........................2..................... 85 Table 5....................1....................................................... Baha.................................4...... Baha.....2 Number of Cases by Primary Site and Years among Saudi Females.................. Qassim)....... 84 Table 5.. Northern Region)......... 2006...........................4.. 82 Table 5........ Hail....................................... 79 Table 5.. Relative Frequencies........ Relative Frequencies........5... Jazan)................1 Age Distribution of Cancer among non-Saudi Males.69 Table 5......................................................................................... Tabuk............. Qassim)..........5... 2006.....................000).................... Tabuk. Age Standardized Rates and Crude Rates for all Cancer Cases among Saudi Males by Cancer Site and Administrative Region (Madinah.. 83 Table 5.2 Number.................................................................... 71 Table 5...................... 92-95 B: Members of SCR Board of Directors.. 2006... Relative Frequencies... 86 Table 5.......................................................................... Makkah................ 2006......................3........................1 Number.....4 Cancer Incidence Cases among Saudi Females by Age Group (per 100....................2 Age Distribution of Cancer Cases among Saudi Females...... Relative Frequencies.......................2 Age Distribution of Cancer among non-Saudi Females........................................2............... 70 Table 5......................... Age Standardized Rates and Crude Rates for all Cancer Cases among Saudi Males by Cancer Site and Administrative Region (Riyadh. 2006...........................................1. 2006.................PART V......... Northern)... Jouf.................................... 74 Table 5...................1 Number of Cases by Primary Site and Years among Saudi Males. 2006...................................... Eastern Province)...2 Number......... 1994-2006................. 1994-2006.................1................................................3 Number............................... Hail. 73 Table 5... Age Standardized Rates and Crude Rates for all Cancer Cases among Saudi Males by Cancer Site and Administrative Region (Asir.........4 Age Adjusted Incidence Rate by Primary Site and Years among Saudi Females....4 Number................................. 98 D: Arabic Summary of Cancer Statistics in Saudi Arabia for the Year 2006......................................1............................................................. 2006.......1 Age Distribution of Cancer Cases among Saudi Males.... Age Standardized Rates and Crude Rates for all Cancer Cases among Saudi Females by Cancer Site and Administrative Region (Madinah................. Eastern Province)................. 96-97 C: Cancer Registration Abstract Form......... Jouf..............000)........ Jazan)..........3.....3 Incidence Rates for Cancer Cases among non-Saudi Males by Age Group (per 100................ 2006.... 81 Table 5............ 2006. 75 Table 5............... 2006.... 78 Table 5..........4 Number.........................101 ......................... 88 Table 5.......3 Age Adjusted Incidence Rate by Primary Site and Years among Saudi Males.......... Relative Frequencies........ 1994-2006..3..... 2006................... 77 Table 5.............3 Cancer Incidence Cases among Saudi Males by Age Group (per 100.. 2006............ Age Standardized Rates and Crude Rates for all Cancer Cases among Saudi Females by Cancer Site and Administrative Region (Asir................................ 76 Table 5.......................................... 87 Table 5............................................ 2006......................... Age Standardized Rates and Crude Rates for all Cancer Cases among Saudi Males by Cancer Site and Administrative Region (Najran.4........................................ Age Standardized Rates and Crude Rates for all Cancer Cases among Saudi Females by Cancer Site and Administrative Region (Najran.....

.

PART I MATERIALS AND METHODS .

668**.4 265.1 930. Ministry of Interior.006.978 8.533 7.149. approving research requests.1 790. Central Department for Statistics (CDS) data.1 641. The Non-Saudi population in 2006 was 6.3 8.115 26. It stretches from the Arabian Gulf in the east to the Red Sea in the west.035 3.4 779. Figures 1-2 and 1-3 show the Saudi and NonSaudi population pyramids by sex and age group respectively.948 83. King Faisal Specialist Hospital and Research Center (KFSH&RC).9 65-69 0.838 1.427.614 2. It is approximately 2.243 Figure 1.8 20-24 10.981.606.663.503 1.1 10.128.455 6.3 107.4 30-34 223.249 223. WHO. Additional objectives include programs for early detection and cancer screening.1 441.903 0.555 542.2 182.8 248. Of these.924 1.587 177.0 769.338 4. 2006 Saudi Cancer Registry Figure 1.41% growth rate for Saudis and 2.7 75.053.745 953.382 4.415 5.5 8.2 Population Pyramid of Saudis (%) by Sex and Age Group.584 were females.277 921.737 8.553 0.648 1.962 10-14 11. King Abdul-Aziz University and King Khalid University.410 10-14 5.700* square kilometers in area and is divided into 13 administrative regions (Figure 1-1). 2006 A Board of Directors was appointed to include representatives from the MOH. 8. Ministry of Planning with a 2.0 25-29 12. defining demographic and cancerrelated data to be collected. 1999 ** Source: SCR Estimation based on 2007 demographic survey.1 17.2 42.937 7.0 1.838 180.2 82.083 1.270 4.4 65-69 0.6 140.427.905 75+ 0.0 205.181**.6 8.1 538.550 17.425 females. 234.798 243. Objectives: 1.663.270. as well as disseminating information collected while ensuring the confidentiality of all data reported to the SCR.474 25-29 13.408.897 3.883 0. King Saud University.9 14.3 132.5% for non-Saudis 10 .9 756.1 0-4 20 18 16 14 12 10 8 6 4 2 0 Male 71.4 5-9 13.355 60-64 148.915 3.4 546.741 0 2 4 6 8 10 12 14 16 18 20 Female 1. as well as cancer research projects.387 5.387 45-49 40-44 35-39 30-34 2.1 134. the National Guard.027 The primary goal of the SCR is to define the population-based incidence of cancer in Saudi Arabia.597 50-54 0 2 4 6 8 10 12 14 16 18 20 Female 8.6 221.425 4.6 3.729 947.596 12.150.597 were males and 8.0 75+ 1.132 15-19 11.4 140.3 55-59 45-49 12. of these 4.4 70-74 0.003 15-19 6.014 2.1 436. The Board is charged with the responsibility of overseeing the SCR’s establishment.379 5.9 60-64 1.607 Organizational Structure: 55-59 2.516 0.6 2.063 17.503 10.901 89.2 357.0 5-9 12.5 75.3 Population Pyramid of non-Saudis (%) by Sex and Age Group.108 12.4 175.5 46.5 229.498 5. * Source: Demographic and Health Indicators for Countries of the East Mediterranean.6 1. The SCR commenced reporting cancer cases from 01 January 1994. King Faisal University.8 992.243 were males and 1.066.3 338. The Saudi Cancer Registry (SCR) of Saudi Arabia is a population-based registry established in 1992 under the jurisdiction of the Ministry of Health (MOH) by the order of His Excellency the Minister of Health.5 11.785 208. Regional Office for the EM.197 6. 1.981.011 20-24 10.7 297.1 Administrative Regions of Saudi Arabia The estimated Saudi national population for year 2006 was 17.3 0. and reporting findings.0 70-74 0.223 6.606.7 40-44 560.410 7.302 7.9 649.9 10.3 15.568 9.201 1.584 Figure 1.9 11.Background on Saudi Arabia Saudi Arabia is a vast country extending over fourfifths of the Arabian Peninsula.3 50-54 35-39 372.7 137. and the Medical Services Departments of the Ministry of Defense and Aviation.945 8.3 0-4 Male 73.293 12.717 20 18 16 14 12 10 8 6 4 2 0 11.

Madinah. covering Riyadh. Jeddah. Taif and Qunfudah Health Regions. covering Madinah. Quality control processes include verification of site. Qassim & Hail) King Faisal Specialist Hospital & Research Centre (Riyadh) National Guard Hospitals Armed Forces Hospitals Offices at the Medical Service Division or Oncology Department of the following establishment Security Forces Hospital 1 Ministry of Defense and Aviation. Makkah. covering Dammam. Additionally. and consolidation of data. covering Asir.4 Organizational Chart of the Saudi Cancer Registry of Saudi Arabia Format The format of the current report is similar to the previous reports. Tabuk. Makkah. Security Forces Hospital. is located in the premises of the KFSH&RC in Riyadh. Abha. Ahsa & Hafr Al Batin) Each of the SCR offices operates under the supervision of a member of the Board of Directors who is responsible for the daily management of that office. Jeddah 3 Ministry of Interior.4). Jouf and Northern Health Regions. Central Region (Riyadh. Jouf & Northern Region) Southern Region (Asir. international organizations and the media. government establishments. Baha. Jazan & Najran) Eastern Region (Dammam. Al Ahsa. Al Khobar. 5 King Abdul Aziz University Hospital. Western Region (Jeddah. Staffing consists of tumor registrars and secretarial staff. Riyadh. 4 Southern Region: Asir Central Hospital. Qassim. including administrative and technical staff. and Hafr Al-Batin Health Regions. Ministry of Health Saudi Arabia Regional Offices: Saudi Cancer Registry Main Office 1 Central Region: King Fahad Medical City in Riyadh. Jeddah Madinah Region (Madinah. Jazan and Bisha Health Regions. and Hail Health Regions. 5 Madinah/Northern Region: Maternity and Children Hospital. and staging information as well as case linkage (tumor and patient). Najran. Baha.The SCR Main Office. Abdulaziz Medical City. 2 Eastern Region: King Fahad Hospital of the University. 3 Western Region: King Abdulaziz Hospital and Cancer Center. covering Jeddah. Tabuk. Armed Forces Hospital. 11 . The Main Office also prepares periodic reports for dissemination of information to the medical community. Princess Nourah Oncology Center. Riyadh 2 National Guard. five regional branches and four hospital-based offices were set up to ensure comprehensive data collection from all over the Kingdom (Figure 1. 4 King Faisal Specialist Hospital and Research Centre. morphology. Riyadh. The SCR Main Office indirectly supervises the regional offices and is responsible for ensuring the accuracy and quality of data collected in all of the regions. Taif & Qunfudah) Figure 1.

It should be noted that ICD-O-3 codes are converted to ICD-10 for analysis purposes. changes were made in coding of cancer types and behaviors as well as staging according to International guidelines. so that each malignancy is counted only once for statistical analysis. Improvements in the understanding of cancer pathology over the last decade are reflected in the changes to ICD-O-3. as appropriate. as well as clinics and laboratories throughout the Kingdom. The new SEER Summary Stage 2000 guidelines should result in increased accuracy and consistency in the coding of stage. Every effort is made to accurately code patient and tumor information. The second part of the report includes the overall cancer incidence in Saudi Arabia and the relevant epidemiological and clinicopathological details for the 14 most common cancers among Saudi nationals for the year 2006. Since the WHO has not yet converted the ICD-10 hematopoietic disease behavior changes. France. our software. Useful international statistics for specified cancer include the ranking of cancer worldwide. The computer software programs used for data entry and incidence tables output are CanReg 4.Data management A ministerial decree has categorized cancer as a mandatory notifiable disease. is available on the web at: http:/seer. histology. However. lymphomas and leukemias as well as some hematopoietic diseases will change due to changes in either reportability or definition. Some cases that were previously considered benign are now 12 counted as malignant. to ensure that all data can be reviewed. The primary site (topography) and histology (morphology) of the malignancies are identified and coded according to the International Classification of Diseases for Oncology 3rd Edition (ICD-O-3). The data abstract (see appendix D) includes personal identification (name. For each cancer site. particularly are affected. The SCR strives for full access to cancer data from all Ministry of Health. . telephone number.000 population for each sex. stage. sex. based on clinical and/or histopathological diagnosis. and tumor details (diagnosis date. age). as with the new staging guidelines. (IARC) Lyon. The references for this information is summarized on page 64.gov/tools/ssm/. developed by the International Agency for Research on Cancer. the number and percentage of all newly diagnosed cases for the year 2006. by SCR-trained cancer registrars. While there have not been any changes in the primary site codes. behavior. CanReg 4. the ICD-O changes reflect advances in the understanding of the pathology and behavior of cancers. nationality). Leukemias and lymphomas. Effective from year 2001. and specific cancer rank in comparison to all cancers for both sexes are presented. there are significant changes regarding histology (cell types). age-standardized incidence rate (ASR) per 100. Cases diagnosed on or after 01 January 2006 are classified according to the updated ICD-O-3. Cancer data are abstracted from patients’ medical records. Also small number of cancers that were previously coded as borderline tumors are now considered benign. and consolidated. However.33. cannot include these cases for analysis and they have been excluded. 2000. There are some differences in the timing rules for determining stage and some sites are coded differently using the new guidelines. SEER Summary Stage Manual 2000. ID Number. This ensures the opportunity for comprehensive data collection. primary site. governmental and private hospitals. basis of diagnosis).cancer.33. demographic information (address. linked. Counts of ovarian cancers. published by the World Health Organization (WHO). grade. the new criteria and guidelines should improve the usefulness of staging as a predictor of prognosis and survival as the changes reflect a new understanding of the natural history of cancer. The new guidelines.

5.000 5. Standardization is necessary when comparing several popu­lations that differ with respect to age structure. I. its collection and analysis. This situation is partially resolved through tumor and patient linkage of cases from all regions based on identifiers such as national ID. Arithmetic line graph represents the agespecific incidence rate (AIR) for all age groups at five-year intervals. In reviewing the data. Table lists the percentages of the most common histology sub-types for each specific cancer.000 8. The number of patients presenting with malignant disease from Riyadh region exceeds the expected number per population. Definitions of Statistical Terms Age-Specific Incidence Rate (AIR) The number of cancer cases occurring during a specific period in a population of a specific age and sex group. b. but instead. 3.The relevant data incorporate details for all patients presented over the year 2006.000 8.000 2. International Union Against Cancer. 4.000 6. Cancer incidence in Five Continents Vol.000 9. The rate is expressed per 100. incident cases which are identified after this date (late reporting) will be noted in subsequent incidence reports.000 populations. 2. Age Class Population 0-4 5-9 10-14 15-19 20-24 25-29 30-34 35-39 40-44 45-49 50-54 55-59 60-64 65-69 70-74 75+ Total 12.000 10.000 100.Waterhouse J. Pie chart shows the distribution of the clinical stages of each cancer such as localized. The calculated incidence is known as the World Stan­dardized Incidence Rate. provide a temporary Riyadh address.000 4. Bar chart shows comparison of agestandardized incidence rate (ASR) for each cancer type in Saudi Arabia with ASR in selected countries. regional. does not include in situ cases in the incidence tables. The reason for this is that Riyadh has many referral centers providing patients from outside the region with cancer-related care.000 6. distant metastasis and unknown. The most frequently used standard population is the World Standard Population (see below). Payne P.000 9.000 6. 1966 13 .000 2. Age-Standardized Rate (ASR) The Age-standardized rate is a summary measure of a rate that a population would have if it had a standard age structure.000 4. For each cancer there are five figures: 1. Notification The data included in this report were abstracted up to June 2009. As previously noted. the software used in analyzing this report. The graph is plotted by sex.33.000 * Doll R. Bar chart shows regional distribution of ASR for particular cancer across the administrative regions by males and females. These cases were added to the total cancer cases in the overview. divided by the number of midyear population of that age and sex group. where applicable. CanReg 4. It is anticipated that the number of late-reported cases will decrease as case ascertainment processes are improved.000 3. two qualifying statements can be made: a. Some of these patients don’t provide their permanent address.000 6.

It is calculated as the number of new cases of disease arising in a population over a defined time period. Summary Stage Staging is the grouping of cancer cases into broad categories based on the extent of disease. or 75) if they had the rates of cancers currently observed. one-digit code for behavior and a one-digit code for tumor aggressiveness (grade). ICD-O-3 The World Health Organization’s International Classification of Diseases for Oncology.000 population. including lymph nodes. The coding system includes a four character code for primary site. In this report the age ranges 0-64 and 0-74 years are used. All rates are thus. skeletal and or visceral organs.000 individuals. It denotes the approximate number of cases occurring in each 100. Hence. tenth edition. Median The midpoint of the range numbers that are arranged in order of value. The first quantity as numerator and the second as denominator Relative Frequency This statistic is defined as the number of specific cancer cases registered relative to the total number of all cancer. expressed as per 100. Mean Cumulative Incidence rate Cumulative incidence is the probability or risk of individuals developing the disease during a specified period. Therefore. in terms of the number of registrations. it permits comparison between populations of different age structures. Rank This measure reflects the importance of a specific cancer site relative to other sites. It is not appropriate to com­pare crude rates across geographical areas of cancer registries with different population age structures. divided by the population at risk of developing that disease. a four-digit numeric code for cell type. . in order to assess time trends in registration data or compare incidence across geographical areas or between registries it is necessary to first standardize the rates with respect to age. which are computed for five-year age intervals. Metastasis Metastasis is the distant spread of cancer from its original site to other organs of the body. 3rd Edition has been the standard coding system for neoplasms for over 25 years. Cancer rates vary greatly with age and the crude rate is strongly influenced by the de­mographic structure of the population. Range Is the difference between the maximum and minimum values in a set of observations. The cumulative rate is the summation of the cancer age-specific rates. or 1000) who would be expected to develop a particular cancer before the age of 65 (or 70. Ratio The relation between two quantities. it is expressed as the number of new born children (out of 100. Ranking illustrates the most and least frequent cancer sites in a population according to their frequency. ICD-10 The World Health Organization’s International Classification of Diseases. An incidence rate is defined as the rate at which a new event occurs in a population.Crude Incidence Rate Incidence Rate The crude incidence rate for a cancer site is the total number of cases registered as a pro­portion of the total population. 14 The simple mathematical average of two or more numbers. if the population structure changes over time the crude rate over that period may be artificially altered. It is expressed as a percentage. The cumulative rate is five times the sum of the age-specific rates calculated over the five-year age groups. For cancer. Like the age standardized rate.

PART II OVERVIEW OF CANCER INCIDENCE 2006 .

4%) were Non-Saudis.000 among males and 48. The current software program CanReg-4 version 4.000 among females). After the age of 64 years.000 (45/100.6% of the cases.000. Cancers affected 5.8% of the cases were confirmed by other methods. Makkah region at 77.1 illustrates the distribution of the cases by sex. radiologically confirmed cases were 2.6%) were Saudis and 2. and Madinah region at 77. Also. 58 were ICD-O-3 coded cases that failed to convert to ICD-10 codes as described in the Data Management (see page 12). This puts the total number of exclusions from the analysis as 662 cases. the agespecific incidence rate (AIR) increased with age for both males and females. Among the Saudis.564 (50.253 cases were reported among Saudis. in situ cases and ICD-10 conversion failures are excluded from analysis 16 .6/100.000.33.6/100.6%) males and 5. the total number of cancer incident cases reported to the SCR was 11. cancer was slightly more among women than men.2%.6/100.0/100.4%) females. Clinically confirmed cases were 0. As shown on table 2.476 (49.6 %) were female. and hematological & cytologically in 6.395 among Non-Saudis. Diagnosis of malignancy was confirmed histologically in 86% of the cases.1. Total of 8.156 (51.2% and 1. For all sites. Overall and for the first time.000. The male to female ratio was 94:100.8/100.040. cases confirmed by Death Certificate Only were 3.000. the increase was nearly 1. 2006. 10. Eastern region at 94. does not include in situ cases in the statistical analysis. 3. The total number of cases excluded from analysis included 392 cases of unknown nationalities.898 (48.2 %. and 2.324 (22. Tabuk region at 89.2/100. The median age at diagnosis was 60 years for men and 50 years for women.4/100. Table 2.1 Distribution of Cancer Cases in Saudi Arabia by Nationality and Sex 2006 * ICD-10 conversion failure ** Unknown nationalities.4%) were male and 4. The crude incidence rate (CIR) of all cancers among the Saudi population was 44. with a male to female ratio of 98:100.1/100.Reported Cancer Incidence Cases in Saudi Arabia. The five geographic regions with the highest ASR were Riyadh region at 98.5 folds for males compared to females.054 (77.000 (83. The overall age-standardized incidence rate (ASR) for all Saudis with a world standard population reference was 83. 2006 Between January 01 and December 31.7/100.000.2/100. The method of diagnosis was unknown for 1. Saudis Non-Saudis Unknown Nationality All Behavior Male Female Total Male Female Total Male Female Total Total Total 4003 4250 8253 1276 1119 2395 197 195 392 11040 Invasive 3923 4178 8101 1238 1093 2331 189 193 382 10814 In-Situ 77 72 149 37 26 63 8 2 10 222 ICD 10 * 25 22 47 4 3 7 3 1 4 58 3898 4156 8054 1234 1090 2324 186 192 378 10378 Analyzed ** Table 2. Other exclusions were 222 in situ cases.7 % of cases.000 in females). of which 8.000 in males and 82.378 cases were analyzed.

2 2.0 Corpus Uteri Ovary Bladder 5.4 Lung Leukemia 3.3 Kidney 34.0 29.6 Leukemia Brain.8 2.6 3.8 5 0 9.9 10 14.3 4.7 12.2 3.7 2.2 Percentage Distribution of Most Frequent Types of Cancer by Sex among Saudis.5 3.6 Testis 18.9 Thyroid 4.5 30 14.4 38.9 Hodgkin disease 30.3 Ovary Bladder 4.0 3.6 NHL 5.5 NHL 20 30 40 Other sites 50 Female (1042) 75+ Years Prostate 26.1 Connective.9 Thyroid Stomach 5.5 Thyroid 8.8 Kidney 4.2 Bladder 4.2 Gallbladder.4 4.0 5.1 8.4 Stomach Bladder 5.0 13.4 20 30-44 Years NHL Colo-rectal 10.8 40 Hodgkin Disease Other sites 16.5 Thyroid 6.8 1.6 Thyroid 5. CNS Bone Ovary Colo-rectal Stomach Placenta Other sites 6.5 Other sites 30 20 Male (360) 7.6 Colo-rectal Skin NHL Lung Stomach Bladder Leukemia Esophagus Gallbladder.6 Brain.2 22.9 30 20 10 0 Male (3898)* 10 20 30 Other sites 40 50 Female (4156)* 40 14.3 12.1 Skin 3.5 Breast 17.1 Percentage Distribution of Cancer Incidence among Saudis by Sex according to Age Group.8 2. Soft Tissue Nasopharynx Other Sites Breast 11.7 4.0 NHL Leukemia 7.5 4.9 40 30 20 Male (720) 10 0 10 20 30 40 50 Female (401) Figure 2.8 3.3 3.9 Corpus Uteri 6.2 2.3 Bone 5.5 0 Colo-rectal Thyroid 7.7 Leukemia Stomach Skin 4.0 19.5 Skin 9.1 3. 2006 * 4 male cases and 8 female of unknown age are included only in the total as they may not be added to any age group 17 .6 Ovary Pancreas 4.8 2.3 4.0 7.0 Prostate 5.1 22.1 10 20 30 40 50 NHL 5. Following are figures presenting the percentage distributions of cancer incidence and most frequent types of cancers among Saudis by sex.1 3. etc.3 Lung 6.7 11. CNS Hodgkin Disease NHL Bone Eye Kidney Connective.3 Leukemia Brain. etc.7 40 33.8 3.3 Other sites 50 24.0 2.9 Leukemia 6.3 7.9 30 20 10 0 10 20 30 40 50 Female (948) Male (424) 9.4 Liver 9.Cancer among Saudis 2006 The total number of cancer cases analyzed among Saudis during the year 2006 were 8.2 6.4 12.1 Leukemia Lung 6.5 8.5 8.5 3.0 2.0 Liver Stomach 4.1 7.4 3.2 2.5 Ovary 35.8 NHL 4.2 Skin Hodgkin Disease 4.054.1 8.4 10.9 8.5 8.6 15-29 30-44 45-59 Age Group 60-74 75+ 16.1 Skin 2.0 5.5 Thyroid 50 8.5 6.3 Other Sites Figure 2.2 Colo-rectal NHL Liver Stomach Esophagus 8.9 Colo-rectal 12.7 4.4 Liver Prostate 3.0 2.6 2.0 3.6 Female 27.5 45-59 Years 0-14 Other sites Colo-rectal 4.3 Leukemia 35.1 4.2 3.8 3.4 5.5 Leukemia 4.9 6.5 Lung 9.4 Corpus Uteri Skin 5.6 40 30 20 10 0 10 20 Male (794) 30 Other sites 40 50 Female (1124) 60-74 Years 30 40 15.3 3.3 1.7 6.6 Nasopharynx 5.6 Liver 7.9 Brain.3 20 10 0 Male (327) 10 20 33.4 5. CNS NHL Hodgkin Disease Bone Eye Kidney Adrenal Gland Connective.8 5. Soft Tissue 1. Other sites 50 Female (393) Breast 9.4 Leukemia 11. 35 Male 30 Percentage 32.2 Other sites 50 40 30 20 10 0 10 Male (1269) 50 Thyroid Hodgkin Disease Breast Leukemia NHL Brain. 2006 50 Cervix Uteri Brain.1 11.9 Colo-rectal 5.1 7.0 Skin Skin 3.8 1.8 20.0 11.6 1.6 NHL All Ages 50 Stomach Corpus Uteri 23.6 Colo-rectal 23.4 NHL 8.4 Testis 3.8 4.3 3.4 3.1 3.5 Liver Skin 5. CNS Stomach 2.7 Hodgkin Disease 15 10 16. Thyroid Lung Corpus Uteri Other sites 36.3 3. Soft Tissue Adrenal Gland Thyroid Other sites Hodgkin Disease 20.5 Breast Colo-rectal 12.2 9.9 8.6 Breast 10.8 Kidney 2.3 5.2 9.7 Nasopharynx 4.0 25 25.4 4. CNS 4.4 1.6 10.3 5.7 3.7 Colo-rectal Liver 10.7 5.6 11.3 Female (240) 15-29 Years 40 Liver Prostate 0-14 Years 30. CNS Colo-rectal 50 NHL 2.2 3.

Cancer No.6% Colo-rectal 370 8.3% Liver 125 3. 2006 (All Ages) Male 3898 Female Colo-rectal 414 10.0% Thyroid 424 10.9 Hodgkin Disease 293 3.4 Table 2.2 Skin 327 4.8% Corpus Uteri 140 3.7 Leukemia 508 6.3 Liver 416 5.4 Colo-rectal 784 9.0% Skin 134 3. % Breast 999 12.2% Hodgkin Disease 173 4.2 Ten Most Common Cancers among Saudis.3 Thyroid 541 6.2% Hodgkin Disease 120 2.4% Skin 193 5. 2006 18 4156 .7 NHL 585 7.5% NHL 234 5.1% Prostate 228 5.0% Leukemia 212 5.2% Leukemia 296 7.2% Bladder 169 4.6 Stomach 275 3.6% Breast 981 23.9% Figure 2.6% NHL 351 9.3 Ten Most Common Cancers among Saudis by Sex.0% Stomach 162 4.1 Lung 312 3.6% Lung 232 6.9% Liver 291 7.4% Ovary 132 3.

2006 19 .1 62.0 45.2 94.000) 900 male 800 female 700 600 500 400 300 200 100 0 0- 5- 10- 15- 20- 25- 30- 35- 40- 45- 50- Age Groups 55- 60- 65- 70- 75+ Figure 2.7 40 60 80 100 120 Figure 2.6 30.4 69.3 Tabuk 76.8 81.3 Baha Jazan 20.4 Makkah Madinah 62.8 95.8 Asir Qassim 38.0 Najran 51.8 59.4 92.2 75.2 43.5 Age Standardized Rate ( ASR) Regional Distribution (per 100.8 0 20 101.000) of All Sites of Cancer among Saudis.1000 AIR (per 100.3 Hail 73.5 55.2 36.4 Age-Specific Incidence Rates (AIR) for All Cancers among Saudis.6 Jouf 55.2 Northern 66. 2006 Riyadh Eastern 83.9 78.4 95.0 42.

2 0.3 0.1 14.9 2 1.2 0.4 0.1 1.8 0.5 1.3 0.4 1.2 0.ICD-10 Site No.2 0.4 0.4 0.3 1.8 1.5% − − − − 1.8% 3.4 6.2 4.0 35.8 1.7% 0.4 2.1 0.8% 0.2% 1.0 0.6 0.1 0.1 0.0% 96.3 2.4 82.3 0.6 0.2 0.0% 0 0 0.5% 2.2 0.9 0.2 0.9 1.0% 2.6 1.CIR.9 2.5 0.3 1.8 79.4 0.1 4.0% 0.7 4.3 0.1 4.1 0.2 0.8% 0.7 0 0.6 2.2% 0.0 2.8% 2.2% 0.0% 0.9 1.2% 0.4% 0. Larynx Trachea.6% 0.1 0.3 6.6 1.5 6.9 0.2 0.5 0.0 0.3% 0.3% 0.7 3.0 0 0 0.3 0.0 1.2 0.2 0.5% 3.4 0.0 0.5% 0.3 0.0 0.1 0.7 1.6% 0.0 0.5 6.1 0.1 0.2% 0.4% 1.2 0.8 79.5 0.4 0.5 1.5% 10.8 1 1.0 0.1 0.1% 0 0.0 0.3 0.4 0. Pancreas Nose.C49 C50 C51 C52 C53 C54 C55 C56 C57 C58 C60 C61 C62 C63 C64 C65 C66 C67 C68 C69 C70-C72 C73 C74 C75 C81 C82-C85.2% 0.1 0.6 8.0 0.2 0.3 5.2 0.4% 0.0 1.8 0.7 0.6 0.1 1.8 0.3 0.0 83.4 0.0% 1.5 3.2 0.2 0.1 1.7 1.1 0.2% 0.8 0.3 0.2 0 0 0.4 0.9% 5.1% 0.0 0.2 0.0 0.1 0.2 1.3 0. Percentage. Bronchus.1 2.2 0.7 0.1 4.2 3.5 0.7 3.5 2.3 − − − − − − − − − − − − − − − − − − − − − − − − − − − − − − − − − − − − − − − − 0.3 Number.0 0.4 0.2 0.2% 0.2 0.9 1.3 2.3 0.7 0.0 0.5 9.9 3.0% 42.6% 0. Multiple Myeloma Lymphoid Leukemia Myeloid Leukemia Leukemia unspecified Other & unspecified 3898 3705 6 37 30 14 0 0 95 9 3 55 162 18 232 182 8 291 46 93 10 62 232 14 64 11 193 8 22 57 18.2% 0.1 0.0 0.0 89.7 0.9% 0.0 0.1 1.8 2.2 0.0% 1.3 7.6 2.9 0.1 0.4 0.4 7.1 0.3 0.1 0.9 6.8 5.3 0.0 3.7 6.1 0.1% 0.6 6.4% 1.1 0.0 0.2 2.1 − − − − − − − − 1 228 38 3 111 5 1 169 0 26 149 117 19 5 173 351 0 48 155 115 26 186 Male Crude ASR Cumulative Rate Rate World 0-64 0-74 100.8 50.8 0.8 0.0% 1.7 4.1% 0.4 1.2% 2.1 0.3% 0.2% 0.2 0.5% 0.2 0.3 2.C96 C88 C90 C91 C92-C94 C95 Other All sites Total All sites but C 44 Lip Tongue Mouth Salivary glands Tonsil Other Oropharynx Nasopharynx Hypopharynx Pharynx unspecified Oesophagus Stomach Small intestine Colon Rectum Anus Liver Gallbladder etc.3 0.5 2.9 Table 2.7 2.0% 0 0 0.0 0.3 3.8 0.9 5.4 0.6 0.7 1.5 4. Lung Other Thoracic organs Bone Melanoma of Skin Other Skin Mesothelioma Kaposi sarcoma Connective.7% 2.2 0.6 0.9 4.9% 0.0% 0 0 0.3% 0.1 0.3 1.1 0.1 0.4% 0.6 94.5 0.1 0.1 0.4 1.0% 0 0 0.4% 0.0% 0.3 2.2 0.6 93.1 0 0 0.0% 0.5 0 0.7 0.3 0.2 0.1 0.6 1.2 0.3% Female Crude ASR Cumulative Rate Rate World 0-64 0-74 48.2 0.0 0.1 5.3 3.0 0.6% 2.8 0.0% 4.5 1.6 4.0% 0.7 1.0% 0.1 0.0 0.0% 2.1 6.1 0.0% 1. All Not C 44 C00 C01-C02 C03-C06 C07-C08 C09 C10 C11 C12-C13 C14 C15 C16 C17 C18 C19-C20 C21 C22 C23-C24 C25 C30-C31 C32 C33-C34 C37-C38 C40-C41 C43 C44 C45 C46 C47.3 0.1 0.2 0.0 3.1 4.1 1.2 0.6% 0.1% 2.6% 0.8% 0.2 0.3 3.2 1.1 0.2 0 0 0.1% 0.1 0.5 0.1 0.1 % No.8 1. % 4156 4022 4 26 34 12 2 0 43 11 1 64 113 14 227 143 9 125 70 73 10 9 80 10 36 12 134 5 14 37 981 4 1 74 140 22 132 9 19 − − − − 78 4 2 42 0 19 103 424 10 5 120 234 0 26 90 113 9 177 100.1 0.0% 0 0 0.2 0.5 1.4 0.2 0.3% 5.4 1.1 0.3 0.5% 2.1% 0.6 1.2% 4.2% 0.7 4.4% 0.8 0.0 0.0% 1.0 0.0% 2.5 0.1 0 0 0.8 1.9 6.3 1.4 1.9 0.1 0.2 1.0 4.9 1. ASR.1 0.1% 0 0.9% 0.1 1.7% 1.7% 0.3 5.7 0.8% 1.1 0.1% 0.2 0.5 0.1 1.1 3.8 0.5 1 0.7 1.1 0.2% 0.5 11.0 1.9 1.2 0.1 0.4 1.8 3.5 0.8 0.2% 3.6% 0.1 0.1 1.1 0.0% 1.7 5.0 0.1 0.6 3.3 8.6 2.0 0.2 4.3% 3.0 1.6 0.7 1.2 0.9 49.1 1.0 0.5 0.5% 3.2 0 0 0.2 0.2 − − − − − − − − − − − − − − − − 0. 2006 20 .3 0.5% 0.1 0.3 0.5 0. Soft tissue Breast Vulva Vagina Cervix Uteri Corpus Uteri Uterus unspecified Ovary Other Female Genital Placenta Penis Prostate Testis Other male genital Kidney Renal Pelvis Ureter Bladder Other Urinary organs Eye Brain.4 18.1 0.5 91.3 0.3% 0.7% 0.4 0.6 5.6 0.0 0.4 2.2 1.1 0.4 2.3 0.8 0.7 0.5% 0.1 3.7 3.1 0.2 0.8 2.6 0.0 2.2 0.3 0.2 0.2 0.9 1.1 0.6 0 0 0.0 2.8 1.9% 0.4 4.7 6.5 0.5 0.1 0.1 0.0 0.3 0.2% 1.3 2 1.3 1.4 2.5 0.3 0.2 0.8% 0.4 0. Nervous system Thyroid Adrenal gland Other Endocrine Hodgkin disease Non-Hodgkin lymphoma Immunoproliferative dis.9% 23.9 0.3% 2 4.4 2.2% 0. sinuses etc.1 0.2 0.8 4.0 19.3 0.1 95.6 1.6 36. and Cumulative Rates (per 1000) of New Cases by Primary Site and Sex among Saudis.2 0.0 0.8 1.0% 0 0 0.2 2.8 0.0 6.2 4.6 1.3 0.6 3 1.5 0.5 0.0% 1.0 0.0 0.1 0.5 0.2 2.7% 0.2 0.1 0.4% 2 2.9 46.8% 1.0 0.0 0.8 2.5% 3.7 1.9 1.1 2.0 0.2% 0.3 2.4 0.1 0.6 3.2 0.0% 45.8% 2.0 0 0.3 4.0% 1.7 4.

0% NHL 313 8. the total number of adult cancer incidence cases reported was 10. 2.287 of Non-Saudis and 265 of unknown nationalities.4.7% Ovary 130 3. in situ cases and ICD-10 conversion failures are excluded from analysis 21 .3% Skin 131 3.6% Lung 227 6.4% Leukemia 132 3.5% NHL 220 5. with a Saudis Non-Saudis Unknown Nationality All Behavior Male Female Total Male Female Total Male Female Total Total Total 3669 3997 7666 1216 1071 2287 129 136 265 10218 Invasive 3591 3926 7517 1178 1045 2223 123 136 259 9999 In-Situ 76 71 147 37 26 63 6 0 6 216 ICD 10 * 24 18 42 4 3 7 3 1 4 53 3567 3908 7475 1175 1042 2216 120 135 255 9691 Analyzed ** Table 2.6% Breast 979 25.1% Hodgkin Disease 139 3.Adult Cancers in Saudi Arabia.014 (49.8% Figure 2.7% Thyroid 417 10.666 Saudis.6 Ten Most Common Cancers among Saudi Adults.3% Stomach 190 5.5% Liver 122 3.4 Distribution of Reported Adult Cancer Cases in Saudi Arabia by Nationality and Sex 2006 Male 3567 Female 3908 Colo-rectal 414 11.9%) females. Overall cancer was slightly more in females than in males.218. there were 7.9% Stomach 112 2. 2006 * ICD-10 conversion failure ** Unknown nationalities.3% Skin 162 4.0% Colo-rectal 370 9. Between January and December 2006.3% Corpus Uteri 139 3. the total number of analyzed cases were 9691. Of all cases.3% Bladder 169 4.1.204 (50.6% Liver 251 7. Cancer affected 5.4% Leukemia 232 6.As shown on table 2.5% Prostate 195 5.%) males and 5. 2006 (>14 years) ratio of 96:100.

1 2.0 Thyroid 82603 83403 83413 83433 83353 83303 80003 85103 80213 82903 83443 Papillary adenocarcinoma.3 7. encapsulated Follicular carcinoma.5 4.4 1.0 2.3 5. 2006 22 .9 1.0 0.0 3. NOS Malignant lymphoma.0 6.4 2.7 2.3 2.3 228 67 34 14 12 9 8 8 6 6 7 18 54.0 4.6 29 26 11 7 3 6 6 4 8 4 2 1 2 5 3 0 4 11 22.9 2.7 4.9 0.6 0.6 Table 2.1 3.9 1. NOS Carcinoma.3 4.6 1.9 1.0 11. small B lymphocytic.4 1.9 1.2 1.8 2. NOS Adenocarcinoma.9 15.0 108 18 16 12 6 10 11 6 4 2 6 2 3 5 11 49.2 1. NOS Squamous cell carcinoma.5 5. NOS Neoplasm.0 1. NOS Malignant lymphoma.5 0.0 0.2 1.4 5. columnar cell All Others 70 12 6 2 3 5 3 2 3 3 1 5 60.4 277 27 22 8 6 6 7 5 7 5 74.q11-12) Leukemia.6 4.6 1.0 % Female 739 62 40 22 15 13 11 12 12 10 43 75.7 53 33 8 9 7 5 4 3 3 0 6 40.3 5. NOS Mature T-cell lymphoma.0 8.2 7.4 1.5 3.0 0. NOS Neoplasm.5 2.0 12. NOS B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma Precursor cell lymphoblastic leukemia.2 6. grade 3 Malignant lymphoma.3 0.5 25.2 2.1 0.2 5.5 1.17) (q22.2 1.8 0.1 8.0 4.7 16. NOS Anaplastic large cell lymphoma.4 0.1 8.2 4. intestinal type Mucin-producing adenocarcinoma Adenocarcinoma in tubulovillous adenoma Carcinoma.4 22.1 4. NOS Precursor B-cell lymphoblastic leukemia Acute monocytic leukemia Acute promyelocytic leukemia. NOS Follicular lymphoma. malignant All Others Male 14 0 2 0 0 0 1 0 0 0 0 82.9 6.0 3. NOS Mycosis fungoides Burkitt lymphoma.6 2.2 1.9 2.3 1. NOS Oxyphilic adenocarcinoma Papillary carcinoma.3 5.6 5.3 2.2 3.4 1.9 2.0 19.3 2. NOS Squamous cell carcinoma.9 5.7 4.7 2.0 2. anaplastic.8 7. NOS Malignant lymphoma.8 0.4 4.4 % Colo-rectal 81403 84803 80003 82613 81443 84813 82633 80103 84903 Adenocarcinoma. diffuse Follicular lymphoma.5 1.0 7.9 1. minimal differentiation Lymphoid leukemia.6 1.5 Number and Proportion of Morphological Types for the Most Common Types of Cancer among Saudi Adults.6 1.6 0.1 2.2 1.9 14.2 1.6 1.5 1. non-Hodgkin.0 0.7 0. follicular variant Papillary microcarcinoma Papillary carcinoma.2 78 17 9 5 4 63.5 3.1 3.2 3.8 3.3 Liver 81703 80003 81603 80103 81403 Hepatocellular carcinoma.6 3.6 8.7 1.2 1.2 1. T cell and Null cell type Follicular lymphoma.1 1. NOS Acute myeloid leukemia without maturation All Others 29 29 31 21 14 11 10 9 3 6 7 7 4 1 2 4 0 7 14.3 2.9 13.1 0.5 2. NOS Acute myelomonocytic leukemia Acute myeloid leukemia with maturation Acute leukemia. malignant Adenocarcinoma in villous adenoma Adenocarcinoma. NOS Mucinous adenocarcinoma Neoplasm. malignant Infiltrating duct and lobular carcinoma Medullary carcinoma. grade 2 Follicular lymphoma.5 6.1 4.7 2.1 8.9 1.8 3.7 1. malignant Cholangiocarcinoma Carcinoma. NOS Acute myeloid leukemia. NOS Acute myeloid leukemia.9 2. keratinizing.3 3.7 8.2 2. NOS Dermatofibrosarcoma.3 Skin 80903 80703 80713 88323 80973 80943 84103 80983 80913 80923 Basal cell carcinoma.4 NHL 96803 95903 95913 96993 97023 96703 97003 96873 97143 96903 96983 96753 96913 96953 Malignant lymphoma.8 1. NOS Papillary carcinoma. NOS Neoplasm.4 0. NOS Carcinoma. large B-cell. t(15.6 3.3 5.1 7.9 4. NOS Marginal zone B-cell lymphoma.5 1.0 5. NOS Infiltrating duct mixed with other types of carcinoma Paget disease and infiltrating duct carcinoma of breast Phyllodes tumor.9 10.9 7.4 2.7 2.7 8.9 7. diffuse.5 3. NOS Lobular carcinoma.2 1.6 2.2 3. NOS Adenocarcinoma. NOS All Others 90 42 17 10 5 6 3 3 1 4 9 47. nodular Basosquamous carcinoma Sebaceous adenocarcinoma Adenoid basal carcinoma Multifocal superficial basal cell carcinoma Infiltrating basal cell carcinoma. NOS Precursor T-cell lymphoblastic leukemia Hairy cell leukemia Chronic myelomonocytic leukemia.0 0.3 4.3 0.1 3.Primary Site Code Morphology Breast 85003 85203 80103 80003 85223 85103 81403 85233 85413 90203 Infiltrating duct carcinoma. mixed small and large cell. NOS Basal cell carcinoma. NOS Signet ring cell carcinoma All Others 313 34 11 11 9 9 6 6 1 14 75. NOS All Others 218 35 13 5 4 12 76. minimally invasive Follicular adenocarcinoma.1 6.6 3.0 4.9 10. grade 1 All Others 140 28 19 22 15 10 6 8 10 11 6 7 6 3 22 44.9 5. malignant Medullary carcinoma.4 Leukemia 98633 98613 98233 98353 98363 98913 98663 98003 98673 98743 98013 98373 99403 99453 98723 98203 98733 Chronic myeloid leukemia.9 2.4 4.

NOS Large cell carcinoma.3 3. nodular sclerosis.8 9.7 2.4 5.1 5. NOS Papillary transitional cell carcinoma Squamous cell carcinoma.3 10.1 1.4 0.2 3.3 Corpus Uteri 83803 81403 89503 89303 84603 85603 88903 89313 Endometrioid adenocarcinoma.9 19.8 0. mixed cellularity.4 17 11 7 1 0 1 1 3 41.4 7.4 18. NOS Neoplasm.9 0. Primary Site Code Morphology Male % Female Lung 81403 80703 80003 80413 80463 80103 80123 82503 80713 82603 80133 80203 Adenocarcinoma.0 Hodgkin Disease 96633 96523 96503 96513 96593 96653 96673 96533 96643 Hodgkin lymphoma. NOS Papillary serous cystadenocarcinoma Serous cystadenocarcinoma.0 % Stomach 81403 84903 81443 80103 80003 84803 80703 81453 82603 Adenocarcinoma.9 6.5 5.0 1. NOS Papillary serous cystadenocarcinoma Adenosquamous carcinoma Leiomyosarcoma.9 2. keratinizing. cellular phase 51 27 22 9 10 6 6 6 2 36. grade 1 Hodgkin lymphoma.7 22.4 3.8 2. NOS All Others - - 25 24 13 11 10 9 8 4 4 4 2 2 2 12 19. NOS Carcinoma.5 continued .3 0. NOS Neoplasm.5 10.3 3.0 3. NOS Hodgkin lymphoma.9 2.6 2. NOS Large cell neuroendocrine carcinoma Carcinoma.9 3. NOS Endometrial stromal sarcoma. NOS Mucinous adenocarcinoma Dysgerminoma Carcinosarcoma.6 2.9 2.3 4.4 4. NOS Germinoma Teratoma.0 5.5 1.4 4. NOS Adenocarcinoma. NOS Acinar cell carcinoma All Others 199 12 7 3 6 87. lymphocyte depletion.9 3.4 0.2 Prostate 81403 80003 80103 85503 Adenocarcinoma. undifferentiated.. malignant Adenocarcinoma.6 - Bladder 81203 81303 80703 80713 80003 81403 80103 Transitional cell carcinoma.5 26.9 6.4 39 18 14 5 4 4 4 2 3 41.5 7.4 2. keratinizing..3 4.8 Ovary 81403 84603 84413 80003 84703 84613 83803 80103 84803 90603 89803 90643 90803 Adenocarcinoma. low grade All Others - - 70 25 8 5 4 4 4 4 15 50. NOS Non-small cell carcinoma Carcinoma. NOS Mullerian mixed tumor Endometrial stromal sarcoma. diffuse type Papillary adenocarcinoma.3 1. NOS Squamous cell carcinoma.0 45 34 6 5 6 3 3 1 0 9 40.1 3.0 2.5 0.0 19. intestinal type Carcinoma.1 2.9 2.9 0.8 6.1 1.5 1.6 1. NOS Squamous cell carcinoma.5 9..5 7. lymphocyte-rich Hodgkin lymphoma. nodular sclerosis.0 2. NOS Signet ring cell carcinoma Adenocarcinoma.0 8.3 2.1 3. NOS Serous surface papillary carcinoma Endometrioid adenocarcinoma.. malignant Mucinous cystadenocarcinoma.9 12. malignant. nodular sclerosis. NOS All Others 81 64 5 5 5 4 1 4 47. NOS Others 51 46 23 29 27 10 8 9 9 1 3 2 14 22.5 8.0 32 5 11 5 6 4 3 2 0 3 0 1 8 40.2 18. nodular lymphocyte predominance Hodgkin lymphoma.7 5.4 15. malignant Small cell carcinoma.0 3.2 - 23 .3 2. malignant Mucinous adenocarcinoma Squamous cell carcinoma. NOS Neoplasm.9 2.0 8.4 1.5 5.4 2.9 10.3 7.6 4. nodular sclerosis. grade 2 Hodgkin lymphoma. malignant Carcinoma.7 6.0 6.2 30.2 4.8 11.8 17. NOS Bronchiolo-alveolar adenocarcinoma. NOS All Others 74 37 18 5 3 4 1 3 4 13 45. NOS Hodgkin lymphoma.5 11. NOS Papillary adenocarcinoma. NOS Hodgkin lymphoma.3 4.0 3.1 3. NOS Carcinoma.1 1.7 0.0 3.7 19.4 15.8 3.Table 2.3 4. NOS Hodgkin lymphoma.5 0. NOS Carcinoma.3 13.2 3. NOS Neoplasm.8 6. NOS Squamous cell carcinoma.9 37. NOS Neoplasm.

6% Hodgkin Disease 27 11.5% Thyroid 7 2. Figure 2.7%. Among Saudis. 2006 * ICD-10 conversion failure ** Unknown nationalities.3% then Hodgkin’s disease 12. Soft Tissue 11 3.6%) non-Saudis. Non-Saudis Saudis Unknown Nationality All Behavior Male Female Total Male Female Total Male Female Total Total Total 330 243 573 58 48 106 15 12 27 706 Invasive 328 243 571 58 48 106 15 12 27 704 In-situ 1 0 1 0 0 0 0 0 0 1 ICD 10 * 1 3 4 0 0 0 0 0 0 4 327 240 567 58 48 106 15 12 2 673 Analyzed ** Table 2.1%) cases were reported among boys and 303 (42.6 Distribution of Reported Childhood Cancer Cases in Saudi Arabia by Nationality and Sex. the total number of cases analyzed was 673 including 567 (82. 327(57.2% Connective.1% NHL 14 5. followed by Brain (CNS) 14.6% NHL 38 11. Based on table 2. This represents 6. The leading cancer Male 327 Leukemia among Saudi children was leukemia.6% Leukemia 80 33.0% Adrenal Gland 12 3. 106 non-Saudis and 27 of “unknown nationality”. 2006 Childhood cancer is very important.8%) were male and 240 (42.9% of all cancer among Saudis.9% and NHL 8.4% Eye 18 5.9%) among girls. and table 2. Soft Tissue 10 4. 2006 (≤ 14 years) The total incident cases reported among children (0-14 years) between January and December 2006 were 706.2%) Saudis and 106 (16.1% Brain 35 14.7 shows the top ten sites by sex and frequency.4% Adrenal Gland 9 3.5% Eye 13 5. not only because of the age of occurrence.7% Connective. 403 (57. which accounted for 31.6.4% Kidney 14 4.7 Ten Most Common Cancers among Saudi Children by Sex.3% Kidney 12 5. Of all the cases reported there were 573 Saudis. recent years have shown a breakthrough for the cure of many childhood cancers.7 shows the number and proportion of the morphological types for the most common types of cancer.1%.3%) were female.9% Nasopharynx Figure 2. In addition to this. with a male to female ratio of 133:100.8% 5 1.3% Brain 46 14. The male to female ratio among Saudis was 137:100. Female 240 100 30.4 % of the total number of cancers in Saudi Arabia. The reported incidents show that cancer was more common among boys than girls.0% Bone 13 5. in situ cases and ICD-10 conversion failures are excluded from analysis 24 .8% Bone 23 7. Childhood cancers accounted for 6.7% of the Saudi population is under 15 years of age.3% Hodgkin Disease 33 10. but also because 41.Childhood Cancers in Saudi Arabia.

5 99103 Acute megakaryoblastic leukemia 2 2.8 98613 Acute myeloid leukemia.0 1 7.Primary Site Code Morphology Leukemia 98363 Precursor B-cell lymphoblastic leukemia 39 39. NOS 3 7.9 97293 Precursor T-cell lymphoblastic lymphoma 4 10.4 14 51. NOS 7 15. malignant 2 4.3 95903 Malignant lymphoma.2 2 7.7 94733 Primitive neuroectodermal tumor. NOS 13 39.0 91833 Telangiectatic osteosarcoma 0 0. NOS 10 43.6 0 0. NOS 33 33.6 0 0.7 94003 Astrocytoma.0 Table 2. lymphocyte depletion.0 4 5.0 3 3. NOS 2 4.3 98263 Burkitt cell leukemia 1 1. CNS Hodgkin Disease NHL Bone Male % Female % 98013 Acute leukemia.1 1 3.0 97003 Mycosis fungoides 1 2.4 5 38. NOS 1 2.5 98743 Acute myeloid leukemia with maturation 2 2.2 1 2.0 93903 Choroid plexus carcinoma 1 2.9 0 0. grade 3 1 2. NOS 2 5.5 2 5.9 2 14. NOS 1 2.0 1 1.0 1 7.6 0 0. malignant 7 15. grade 1 1 3.0 96653 Hodgkin lymphoma. NOS 0 0.0 1 1.6 0 0. NOS 3 7.2 1 2.1 96803 Malignant lymphoma.3 0 0.4 96503 Hodgkin lymphoma.5 5 38.2 5 18.0 2 2.9 96523 Hodgkin lymphoma.7 93913 Ependymoma.9 96633 Hodgkin lymphoma.7 96533 Hodgkin lymphoma.2 2 5.2 2 5. NOS 0 0.2 1 2.3 2 14.0 Brain.0 4 5. nodular sclerosis.0 96703 Malignant lymphoma.1 96983 Follicular lymphoma. non-Hodgkin.8 98913 Acute monocytic leukemia 3 3.0 1 3. nodular sclerosis. NOS 3 6.9 95083 Atypical teratoid/rhabdoid tumor 3 6.3 95913 Malignant lymphoma.8 94703 Medulloblastoma.7 94713 Desmoplastic nodular medulloblastoma 1 2.5 0 0.3 0 0. nodular lymphocyte predominance 5 15. small B lymphocytic. large B-cell. mixed cellularity.0 0.0 96993 Marginal zone B-cell lymphoma.3 93803 Glioma. NOS 3 9. lymphocyte-rich 3 9.0 4 14.0 2 2.9 All Others 7 15. NOS Primitive neuroectodermal tumor. NOS 3 3.5 92603 Ewing sarcoma 7 30.4 94403 Glioblastoma.3 1 7.0 91803 Osteosarcoma.0 98633 Chronic myeloid leukemia.0 27 33.0 96873 Burkitt lymphoma.8 96513 Hodgkin lymphoma.7 Number and Proportion of Morphological Types for the Most Common Types of Cancer among Saudi Children. NOS 2 5.0 3 3.3 4.7 93703 94733 Chordoma.6 6 42. NOS 2 2.1 0 0.2 8 22.3 0 0 0.1 12 34. diffuse.3 All Others 9 9.7 88063 Desmoplastic small round cell tumor 0 0. NOS 1 1 4.5 96593 Hodgkin lymphoma. NOS 7 21. NOS 12 26.9 95053 Ganglioglioma. 2006 25 .3 97273 Precursor cell lymphoblastic lymphoma.0 1 7.0 1 7.0 4 11. nodular sclerosis.7 96673 Hodgkin lymphoma. grade 2 1 3. anaplastic 1 2.0 80003 Neoplasm.0 0 0. NOS 6 6.7 91823 Fibroblastic osteosarcoma 1 4.0 96733 Mantle cell lymphoma 0 0.3 98353 Precursor cell lymphoblastic leukemia.5 91813 Chondroblastic osteosarcoma 3 13.3 2 5.0 33 41. NOS 20 52.5 2 14.

0 1 11.0 88063 Desmoplastic small round cell tumor 0 0.0 91503 Hemangiopericytoma. NOS 1 7.0 95003 Neuroblastoma. NOS 0 1 0. NOS 1 50.3 0 0.1 0 0.0 1 8.0 0 0.Table 2.0 95133 Retinoblastoma.8 95123 Retinoblastoma.0 1 10. malignant 1 9. NOS 1 20.0 1 10.1 1 10.1 83403 Papillary carcinoma.0 88003 Sarcoma.0 2 28.1 0 0.0 . follicular variant 0 0.0 89603 Nephroblastoma.3 85103 Medullary carcinoma. NOS 1 7.0 1 0 100.0 80203 Carcinoma.0 93643 Peripheral neuroectodermal tumor 2 18.0 94733 Primitive neuroectodermal tumor.0 1 10.0 1 14. NOS 2 18.0 1 10.6 83503 Nonencapsulated sclerosing carcinoma 0 0.6 0 0.3 80003 Neoplasm. Primary Site Eye Kidney Connective Tissue Adrenal Gland Thyroid Nasopharynx 26 Code Morphology Male % Female % 95103 Retinoblastoma. NOS 0 0. undifferentiated 2 11. NOS 3 60.1 89103 Embryonal rhabdomyosarcoma..2 1 10.1 82603 Papillary adenocarcinoma. NOS Rhabdomyosarcoma. diffuse 1 5. NOS 1 5..0 89643 Clear cell sarcoma of kidney 0 0.0 0 0.1 0 0..1 94903 Ganglioneuroblastoma 2 16.3 6 46. differentiated 6 33. nonkeratinizing.1 0 0.2 1 10.7 continued .0 88913 Epithelioid leiomyosarcoma 0 0.3 83123 Renal cell carcinoma. large cell.1 0 0.3 90643 Germinoma 1 7.0 2 20. NOS 10 71. NOS 3 27.1 3 23.7 0 0. NOS 1 50. NOS 0 0.0 0 0. NOS 2 11.1 0 0.0 0.0 89003 Rhabdomyosarcoma.0 89203 Alveolar rhabdomyosarcoma 1 9.0 88523 Myxoid liposarcoma 0 0.0 80103 Carcinoma.3 4 30.0 95003 Neuroblastoma. NOS 0 0.0 89633 Malignant rhabdoid tumor 1 7.0 89633 Malignant rhabdoid tumor 1 9. NOS 9 75.4 10 83.1 0 0.0 1 10.1 0 0.0 89103 Embryonal rhabdomyosarcoma.0 4 57.0 80723 89003 Squamous cell carcinoma.2 95113 Retinoblastoma. malignant 0 0.0 93703 Chordoma.0 7 77.0 94903 Ganglioneuroblastoma 1 9. NOS 6 33.0 88063 Desmoplastic small round cell tumor 0 0..3 1 11.8 83703 Adrenal cortical carcinoma 1 8.0 20.0 95003 Neuroblastoma.6 0 0.0 1 8. undifferentiated.

2 Prostate 7.9 Breast 23.2 3.3 Leukemia 5.2 Lung 3. In most regions breast cancer was the leading cancer among women. liver and 12.3 6.6 Prostate 3.4 Thyroid NHL 8. 2006 (Percentage Distribution) NHL 25.6 Leukemia 5. 2006 The following bar charts list the most common cancer sites in the 13 administrative regions of Saudi Arabia by sex.5 Breast Liver Leukemia Leukemia interchange.7 4.9 Thyroid Hodgkin Disease 11.1 NHL 6.1 Skin 3.3 Colo-rectal 9.4 NHL 7.9 Skin 3. CNS 3. Makkah and Eastern Province represent the majority of cases.9 Liver 6.5 Thyroid Lung 7.6 Liver 6.6 Corpus Uteri 3.6 Hodgkin Disease 2.2 3.8 5.7 Lung 4.0 Breast Colo-rectal 9.0 Colo-rectal 12.1 Ovary 10 20 30 27.7 Liver 3.3 3.2 Colo-rectal 8.9 Colo-rectal 7.6 Skin 2.4 Cervix Uteri 2.8 40 Females (958) 0 10 20 30 40 All (1887) Figure 2.6 13.9 Stomach 4. 2006 (Percentage Distribution) 27 .9 Liver 4.7 Other Sites 31.7 NHL 10. These sites are listed on the basis of the total number of cases for each site reported by permanent address (region) of the patient at the time of diagnosis.9 Brain.2 Stomach 2.8 Stomach 5.6 Other Sites 0 10 20 30 Males (929) 40 Other Sites 0 10 20 30 39.1 Breast 11.0 Skin 4.Cancer in the 13 Administrative Regions of the Kingdom.6 Bladder 5.2 Leukemia 4.1 Hodgkin Disease 3.4 Lung Bladder 4.8.1 Other sites 0 12.1 Corpus Uteri 4.3 Thyroid 5. 40 0 10 Males (1022) 20 34.2 Skin 2. while among men Colo-rectal.8.8 Prostate 3. It is worth noting that the major regions such as Riyadh.3 Other Sites 30 40 0 10 Females (1170) 20 30 40 All (2192) Figure 2.4 Hodgkin Disease 34.1 9.1 Riyadh Region.5 Leukemia 6.4 Skin 3.4 NHL 5.9 Prostate 6. NHL.9 Thyroid 8.2 Colo-rectal 8.2 Makkah Region.7 Leukemia 4.1 Ovary 2. This can be attributed to the increasing number of people seeking medical attention in these urbanized cities with modern hospital facilities where permanent addresses may not be documented in source records.3 Other Sites 30.

8 Lung 5.4 Kidney 3.5 Leukemia 17.9 Hodgkin Disease 4.2 2.8.4 Hodgkin Disease Lung 4. NHL 5.3 Breast NHL 9.4 Madinah Region.1 Lung 4.4 5.8 Liver 4.4 Brain.4 Colo-rectal 10.4 Thyroid 4.9 Lung Ovary 2.2 Thyroid 6.0 Leukemia Prostate 5.3 NHL 8.9 Leukemia 2.7 Other Sites 0 5.9 Cervix Uteri 3.7 Colo-rectal NHL 9. CNS 4.4 Stomach 3.5 Brain.3 Liver 7.8 Skin 5.3 0 10 20 Males (53) 30 29.4 Lung 3.9 Other Sites 40 Females (38) Figure 2.6 Bladder 3.4 Liver 3.1 Other Sites 25.1 Thyroid 5.7 Kidney 3.5 Liver 10.2 Leukemia 6.4 Thyroid 6. CNS 5.7 Skin 6.5 Breast 28.8 Corpus Uteri 5.8 Thyroid Leukemia 8. CNS 4.4 Kidney 4.Cancer in the 13 Administrative Regions of the Kingdom 10.0 3.5 9.9 Breast 9.7 3.9 5.0 Other Sites 0 10 20 30 40 0 10 Males (621) 20 30 37.5 Other Sites 40 0 10 20 30 28.2 Other Sites 27. CNS Breast 10 20 30 40 0 10 Males (279) 20 30 35.6 Leukemia 8.6 Hodgkin Disease 4.3 Brain.8 39.2 NHL Colo-rectal 15.7 Liver 6.8 8.5 Skin 5.1 Colo-rectal 10.8 Brain.9 Liver 3.3 Skin 4.7 Ovary 3.3 Thyroid 3.7 Lung 5.0 28.5 Other Sites 0 40 10 Females (314) 20 30 40 All (593) Figure 2. 2006 (Percentage Distribution) 20.8.8 Kidney 5.6 Esophagus 4.8 Leukenia Colo-rectal 7.4 Pancreas 3.2 Leukemia 5. CNS 2.4 5.5 Hodgkin Disease 4.8 Leukemia 18.8 Thyroid 5.4 Bladder 0 10 20 All (91) 30 40 .3 Eastern Region.6 Colo-rectal 5.0 Breast 11.5 Hodgkin Disease 7.8.9 Brain.2 NHL 7.5 Northern Region.5 Lung 4. 2006 (Percentage Distribution) 28 7.4 Brain.4 Other Sites 0 40 10 20 Females (716) 30 40 All (1337) Figure 2. CNS 3.5 Hodgkin Disease 3.4 Pancreas 3. 2006 (Percentage Distribution) 21.6 Brain.7 Bladder 5.5 5. etc.4 Skin 3. CNS 3.7 Gall bladder.9 Thyroid Hodgkin Disease 11.5 Colo-rectal 6.3 NHL 3.0 NHL 7.7 Bladder 4.7 Colo-rectal Lung 8.8 Colo-rectal 9.7 Other Sites 24.5 Stomach 3.8 Breast 13.

CNS 16.1 4.3 Skin 4.4 10 Males (159) 7.0 Leukemia 20 NHL 5.0 3. 2006 (Percentage Distribution) 19.0 Breast 10.4 Hodgkin Disease 6.7 Nasopharynx 5. CNS 5.1 Skin Gall bladder.7 Tongue 6. CNS 3. CNS 4.8 NHL 8.9 Esophagus Lung 2. etc.5 Other Sites 0 10 20 Males (79) 16.6 Other Sites 30 8.6 Colo-rectal 6.6 5.4 Skin Stomach 6.1 Liver 3.0 Brain.9 Liver Thyroid 5.0 Liver 3.8 4.0 Brain. etc.0 Skin 5.4 4.3 2.8.8.5 2.5 0 40 10 Females (99) 20 30 40 All (177) Figure 2.9 5.5 Thyroid 7.8 10 9.5 Hodgkin Disease 4. CNS 7.6 Leukemia Brain. 2006 (Percentage Distribution) Mouth 11. 3.8 Hodgkin Disease 3.6 Hodgkin Disease Kidney 3.2 Hodgkin Disease 8. 5.5 Breast 5. CNS 3.8.9 0 9.8 Skin Stomach 4.0 Hodgkin Disease Other Sites 40 10.7 Jazan Region.5 Colo-rectal 14.1 21.3 0 10 Males (78) 20 30 39.3 27.3 Corpus Uteri NHL 2.1 7.1 Mouth Mouth 14.8 Stomach 3.1 NHL 3. 2006 (Percentage Distribution) 29 .0 32.2 Breast 15.6 Qassim Region.2 Nasopharynx 3.1 Skin 8.8 Hodgkin Disease Connective.8 Corpus Uteri 2.3 Multiple Myeloma 2.0 Thyroid 30 0 40 10 Females (173) 20 30 40 All (332) Figure 2.1 NHL 5.8 12.6 Nasopharynx 6.5 NHL Skin 9.8 Hail Region.8 Kidney 2.2 Esophagus Nasopharynx 0 NHL 6. Soft Tissue 3.1 Tongue 40 Other Sites 29.4 Kidney 3.1 Pancreas 20 Tongue 4.7 Brain.3 6.2 Brain.4 Nasopharynx 3.2 Other Sites 30 40 Females (84) 0 10 20 30 40 All (163) Figure 2.4 Other Sites 0 10 20 30 Colo-rectal 6.3 Breast 10.5 6.0 25.6 3.4 Breast Leukemia 7.8 Hodgkin Disease Leukemia 8.0 Leukemia 7.1 10.4 Lung 6.4 Skin 4.0 3.0 Prostate 4.0 Leukemia Colo-rectal 3.5 Stomach 4.8 Thyroid Thyroid 9.0 Hodgkin Disease 6.8 Liver 4.0 Colo-rectal 7.4 Stomach 6.2 Brain.1 Thyroid Other Sites 9.3 Colo-rectal 7.6 Colo-rectal 5.5 Leukemia Ovary 3.0 5.0 Colo-rectal Stomach 31.3 7.Cancer in the 13 Administrative Regions of the Kingdom Breast 10.8 Gall bladder.2 Other Sites 17.4 Brain.7 Colo-rectal 27.6 Larynx 3.9 Thyroid 7. CNS 31.9 Other Sites 30 40 0 10 20 4.3 2.

9 Leukemia 7.7 Ovary 6.4 Hodgkin Disease 5.0 Hodgkin Disease 3.8.2 Kidney 3.2 Lung Prostate 3.0 Liver 3.2 Leukemia Nasopharynx Stomach 3.3 Bladder 3.8 Liver 5. CNS 3.9 NHL 9. Colo-rectal 20 30 6.2 3.6 Bladder 11.0 9. 2006 (Percentage Distribution) 9.5 Skin 8.5 Skin 7.0 7.3 6.4 Other Sites 40 0 10 Females (50) 20 30 40 All (111) Figure 2.1 Lung 3.7 Ovary 3.5 5.2 Bladder Eye Colo-rectal 6.2 Breast 8. 2006 (Percentage Distribution) Colo-rectal 11.7 4.3 Thyroid 5.4 Brain.5 Skin 4.2 NHL Prostate 6.Cancer in the 13 Administrative Regions of the Kingdom 23.7 Other Sites 0 10 20 All (597) 30 40 .9 Liver 4.6 3.6 NHL 6.7 5.8 Liver Colo-rectal 6.2 14.3 Hodgkin Disease 6.4 4.6 32.5 Skin 13. CNS 3.3 NHL 0 10 Ovary 4.0 Placenta 4.9 Bone 3.0 Stomach 4.0 Gall bladder.0 20 30 40 28. 2006 (Percentage Distribution) 30 34.9 Stomach 5. etc.5 Colo-rectal NHL 7.7 NHL Colo-rectal Hodgkin Disease Stomach Other Sites 16.4 30 5.9 Liver 7.0 Breast Thyroid 12.6 Skin 6.3 Breast 12.6 Cervix Uteri Kidney 20 6.3 Melanoma of Skin 3.8.4 Prostate 3.4 Esophagus 3.4 Other Sites 4.2 Thyroid 3.5 Leukemia 11.9 Cervix Uteri 9.7 4.2 Breast Other Sites 16.5 32.2 Skin 16.6 Colo-rectal 9.5 Skin 8.2 NHL 22.7 Liver 8.7 Leukemia 6.10 Baha Region.4 Breast Leukemia 9.2 Thyroid Colo-rectal 8.3 6.11 Asir Region.6 4.9 Leukemia Skin 6.4 Other Sites 40 0 10 20 30 40 Females (292) Figure 2.2 Hodgkin Disease 8.7 Pancreas 0 9.1 Other Sites 0 10 20 30 Males (305) 27.0 Colo-rectal 8.3 3.5 Thyroid 6.0 Leukemia 8.2 Stomach 7.0 Esophagus 6.0 Lung 6.4 12.0 0 10 Males (61) 9.1 Stomach 5.6 Other Sites 30 0 40 10 20 Females (45) 30 40 All (108) Figure 2.7 Brain.5 Stomach 4.7 3.9 Najran Region.7 Liver 6.4 10 Leukemia 3.5 NHL 11.4 3.2 Other Sites 0 40 Breast Kidney 4.4 Bladder 3.7 Brain.0 Leukemia 8.6 Lung 3.8. CNS 6.6 Liver 3.6 Corpus Uteri 6.2 9.7 NHL 10 Males (63) 20 30.6 Stomach 3.

1 4.9 Lung 3. CNS 3. 2006 (Percentage Distribution) 31 .6 Mouth 11.8 Stomach 4.9 Breast 12.3 4.0 Thyroid 3.2 Hodgkin Disease 3.0 Thyroid Hodgkin Disease 7.9 Bladder 3.3 4.2 Other Sites 37.3 4.8 Lung Colo-rectal 22.Cancer in the 13 Administrative Regions of the Kingdom NHL 8. Soft Tissue Prostate Kidney Brain.4 Brain.13 Jouf Region.6 Hodgkin Disease 2.0 Colo-rectal 4.3 0 18.3 4.7 Stomach 3.8 Skin Bladder 5. 2006 (Percentage Distribution) 12.7 5.7 4.4 Leukemia 7.5 Thyroid 8.8 Thyroid 4.7 Leukemia 3.2 25.3 4.4 Skin 5. CNS 5.9 NHL Skin Lung Thyroid Stomach Colo-rectal Liver Bone Connective.0 Other Sites 0 40 10 Males (138) 20 30 37.1 Lung 5.1 Thyroid 4.7 Breast Brain.0 Pancreas 4.7 10 20 Males (70) 30 Breast 3.3 25.4 Skin 7.8 4.6 0 10 20 30 27.7 Hodgkin Disease 4.4 4.3 4. CNS 8.8.1 Other Sites 40 Females (54) 0 10 20 30 40 50 All (124) Figure 2.7 Lung 3.9 NHL 7.3 4.3 4.12 Tabuk Region.7 Corpus Uteri Skin 7. CNS Hodgkin Disease Leukemia Other Sites NHL Pancreas 7.2 Colo-rectal 6.5 NHL 5.3 5.3 Ovary 4.1 10.7 5.3 Bone 2.2 Leukemia Leukemia 7.1 Ovary 3.3 5.7 Brain.5 Breast 7.6 Liver 3.9 Other Sites 40 8.8 Pancreas Skin 5.7 Colo-rectal 3.2 Other Sites 40 0 10 20 Females (136) 30 40 All (274) Figure 2.0 3.7 Hodgkin Disease 5.1 0 10 20 30 41.1 8.3 NHL 9.9 Colo-rectal 5.8.

Bangkok 116.7 137.8 Thailand. while in developing countries.3 United States (All Races) 282. the most common cancer site was breast followed by cervix uteri then colo-rectal then lung cancers. 53.6 Kuwait 125. While in the developing countries breast cancer was the leading cancer followed by cancers of the cervix.0 Wales 320.9 Norway 293.8 Jordan 70.6 United Arab Emirates 74.3 0 50 100 150 200 250 300 350 Figure 2.9. According to 2002 estimates. Bangkok 117.8 Jordan 79.B Comparison of ASR* for Saudi Females with Selected Countries** * ASR Per 100.000 ** Source for this information is summarized on page 64 32 400 450 .1 Oman 87.496 people developed cancer in 2002.9 Australia 421.International Comparison of Age-Standardized Incidence Rates was first followed by stomach.8 United Arab Emirates Saudi Arabia 82.9.6 Poland 189. breast cancer was the most common followed by colo-rectal.6 Bahrain 156.5 Qatar 179. Of these.6 Saudi Arabia 83.7% were in developing countries and 46. followed by prostate then stomach then colo-rectal.2 Kuwait Thailand.8 United States (All Races) 354. Among women.6 Bahrain 157. and stomach. However. colo-rectal.9 0 50 100 150 200 250 300 350 400 450 500 Figure 2.8 Qatar 168.5% were in developed countries.862. Worldwide.6 Canada 356. lung and corpus uteri cancers in developed countries.7 Australia 301.4 Oman 97. liver.0 101.0 Poland 249. stomach and lung.A Comparison of ASR* for Saudi Males with Selected Countries** Croatia 401.6 Croatia 451. it is estimated that 10.8 Wales 269. esophagus and colo-rectal cancers.8 Norway 348. the most common cancer site worldwide among men was lung cancer. lung cancer Canada 459. In women. in developed countries prostate was the leading cancer followed by lung.

PART III CANCER INCIDENCE FOR MOST COMMON SITES 2006 .

.

6 3.0 Table 3.6 1.6 28. Cancer Male Female All % Breast Colo-rectal NHL Thyroid Leukemia Liver Skin Lung Hodgkin Disease Stomach Prostate Bladder Corpus Uteri Ovary Others 18 414 351 117 296 291 193 232 173 162 228 169 1254 981 370 234 424 212 125 134 80 120 113 42 140 132 1049 999 784 585 541 508 416 327 312 293 275 228 211 140 132 2303 12.7 7. The relevant data incorporate details for all patients presented over the period of January through December 2006.8 2.3 6.4 2.9 3.3 5. 2006 35 .Cancer Incidence for Most Common Sites.1 Most Common Cancers among Saudis.2 4.4 9.7 1. 2006 In this section.1 3.7 6. the incidence of the most common cancers among Saudi males and females are outlined in accordance to their relative frequencies.6 Total 3898 4156 8054 100.

3 8523 Infiltrating duct mixed with other types of carcinoma 12 1.000. The five regions with the highest ASR were Eastern region at 25.4 Table 3. NOS 62 6.0/100.000.000) 60 50 40 30 20 10 0 0- 5- 10- 15- 20- 25- 30- 35- 40- 45- 50- 55- 60- 65- 70- 75+ Age Groups Figure 3.1.5 8500 Infiltrating duct carcinoma. malignant 10 1.1 Morphological Distribution of Female Breast Cancer in Saudi Arabia.3 8010 Carcinoma. NOS 8520 Lobular carcinoma.2 8140 Adenocarcinoma. malignant 22 2.000.156) in year 2006.Female Breast (C 50) There were 981 female breast cancer cases for year 2006.1.2 8522 Infiltrating duct and lobular carcinoma 15 1.0 Others 43 4.5% Regional Unknown Figure 3.1. NOS 13 1. NOS 40 4. NOS 11 1.2 8541 Paget disease and infiltrating duct carcinoma of breast 12 1.5 8510 Medullary carcinoma.1 9020 Phyllodes tumor. 70 female AIR (per 100.0% Distant Localised 26. 2006 36 .9% 13.6% of all newly diagnosed female cancers (4. 2006 14.1/100. 2006 ICD-O-3 Code Morphology Total % 741 75. Makkah region at 18.000. Riyadh region at 22.2 Stage Distribution of Female Breast Cancer.1 Age-Specific Incidence Rate (AIR) for Female Breast Cancer in Saudi Arabia. Breast cancer ranked first among females accounting for 23.000 and Tabuk region at 17/100. Madinah region at 17/100. The median age at diagnosis was 47 years (Range 19-107 years).0/100.1 8000 Neoplasm. The ASR was 18.6% 45.000 for female population.6/100.

4 48.8 United Arab Emirates Oman 21.6 Jordan 24.6 44.6 Jazan 0 5 10 15 20 25 30 Figure 3.7 Bahrain 53.1.4 Hail 15.2 Poland 27.000 ** Source for this information is summarized on page 64 37 .2 Qatar Kuwait 46.5 Najran 2.0 Northern 9.9 Saudi Arabia 18.25.3 United States (All Races) 89.0 15.5 Wales 89.0 Tabuk 17. Bangkok 22.0 Makkah Madinah 17.4 Comparison of ASR for Female Breast Cancer among Saudi Females with ASR in Selected Countries** * ASR Per 100.0 Qassim 13.3 Thailand.0 Eastern 22. 2006 Australia 117.6 Riyadh 18.2 Baha 4.0 Norway 73.4 Asir 5.8 Jouf 9.1 0 20 40 60 80 100 120 Figure 3.1.3 Canada 97.3 ASR* Regional Distribution of Female Breast Cancer in Saudi Arabia.

4/100.1% 22.000.000 and for females 8.3 5. Madinah region at 8.000 and Tabuk region at 6. 80 AIR (per 100.2 2. NOS Mucinous adenocarcinoma Neoplasm. The five regions with the highest ASR were Riyadh region at 12.7 2.000. 2006 38 Unknown . It affected 414 (52. NOS Signet ring cell carcinoma Others Male % Female % 313 34 11 11 9 9 6 6 1 14 75.4 1.000) 70 male female 60 50 40 30 20 10 0 0- 5- 10- 15- 20- 25- 30- 35- 40- 45- 50- 55- 60- 65- 70- 75+ Age Groups Figure 3.2 3.2/100.3% Distant Localised Regional 26.8% 39.9% 13.000. 2006 12.2 Stage Distribution of Colo-rectal Cancer.000.5% 23. malignant Adenocarcinoma in villous adenoma Adenocarcinoma.Colo-rectal (C18-C20) There were 784 cases of colo-rectal cancer accounting for 9. intestinal type Mucin-producing adenocarcinoma Adenocarcinoma in tubulovillous adenoma Carcinoma. 2006 ICD-O-3 Code 8140 8480 8000 8261 8144 8481 8263 8010 8490 Morphology Adenocarcinoma.9 1.1% 24.6% Female 24.4/100.1% Male 21.6 1.9% All Figure 3.6 1.6/100.9 7.4 0.9 2.6 8.2%) females with a male to female ratio of 112:100.1 Age-Specific Incidence Rate (AIR) for Colo-rectal Cancer in Saudi Arabia.2 2.6 /100.2.000.7 2.4 1.4 277 27 22 8 6 6 7 5 7 5 74.2% 38.7/100.2.7% of all newly diagnosed cases in year 2006.2 1.0/100. The median age at diagnosis was 61 years among males (range 17-110 years) and 57 years among females (range 20-109 years).8%) males and 370 (47. The overall ASR was 9.2 1. ASR for males was 9.7/100.000.0% 15.4% 38.4 Table 3. Eastern region at 10. This cancer ranked first among male population and third among female population.9 1. Makkah region at 8.2.1 Morphological Distribution of Colo-rectal Cancer in Saudi Arabia.

3 3.6 9.5 1.7 8.0 16.8 Asir Baha 9.4 3.0 Northern 3.0 Canada 59.2 Qatar Kuwait 8.4 Comparison of ASR for Colo-rectal Cancer among Saudis with ASR in Selected Countries** * ASR Per 100.1 Saudi Arabia Jordan Oman United Arab Emirates 0 10 14.3 United States (All Races) 26.2 6.9 36.6 3.5 6.4 4.1 16.3 28.0 5.0 Eastern Madinah 7.7 8.3 ASR* Regional Distribution of Colo-rectal Cancer in Saudi Arabia.1 12.0 35.3 12. 2006 40.Riyadh 12.0 Hail 11.3 2.3 20 30 40 50 60 70 Figure 3.1 Tabuk 5.9 2 4 6 8 10 12 14 Figure 3.7 Bahrain 8.6 6.9 0.1 8.4 9.2.7 Australia Wales 26.6 Makkah 6.6 15.2 Poland 52.7 7.0 41.2 Qassim 3.8 14.5 7.9 7.6 5.6 Najran 6.0 Jouf Jazan 6.7 0 5.000 ** Source for this information is summarized on page 64 39 .2.0 9.

ASR for males was 6.3/100. diffuse Follicular lymphoma.9 6.000 for females. NOS Marginal zone B-cell lymphoma.6 3.0 2. 2006 16. T cell and Null cell type Follicular lymphoma.9% Female All Figure 3. The five regions with the highest ASR were Riyadh region at 7.6 0.2 Stage Distribution of NHL Cancer.000 and Makkah regions at 5/100.1 2.3 5.1 4. diffuse.0 6.3.6% 32. It affected 351(60%) males and 234 (40%) females with a male to female ratio of 150:100. Tabuk region at 6.8/100. Madinah region at 6.9 2.9% Distant Localised Regional 16.0 2.2% Unknown .2/100. 2006 ICD-O-3 Code Morphology 9680 9590 9687 9591 9699 9670 9702 9700 9714 9690 9698 9675 9691 9729 9695 Malignant lymphoma.5% 15.7 0.8% 16.9 2.0 Table 3.3. NOS Mature T-cell lymphoma. The median age at diagnosis was 50 years among males (range 2-102 years) and 54 years among females (range 2-96 years).5% Male 40 17.7 8.7 2.000.000. This cancer ranked second among male population and fourth among female population.000) 70 male female 60 50 40 30 20 10 0 0- 5- 10- 15- 20- 25- 30- 35- 40- 45- 50- 55- 60- 65- 70- 75+ Age Groups Figure 3.Non-Hodgkin Lymphoma (C82-C85.7 1.1 Age-Specific Incidence Rate (AIR) for NHL in Saudi Arabia. non-Hodgkin.9% 35.1 7.0 6.9 1.3 2.1% 34.6/100. The overall ASR was 5.3 0.8 8.5% 16. large B-cell.0 0.1 Morphological Distribution of NHL in Saudi Arabia.000.6/100.5/100. grade 3 Malignant lymphoma. mixed small and large cell. NOS Malignant lymphoma.3 2.7/100. grade 1 Others Male % Female % 143 31 28 21 23 11 15 7 10 11 7 7 6 7 3 21 40.5 5.Eastern region at 6. grade 2 Precursor T-cell lymphoblastic lymphoma Follicular lymphoma.3.2 8. NOS Burkitt lymphoma. 2006 31.000. C96) There were 585 cases of Non-Hodgkin Lymphoma accounting for 7.0 1.000 and 4. 80 AIR (per 100. small B lymphocytic.6 4.000.0 108 20 12 17 12 10 6 11 4 2 6 2 3 2 5 14 46. NOS Malignant lymphoma.3% of all newly diagnosed cancers in year 2006.0% 32. NOS Mycosis fungoides Anaplastic large cell lymphoma.8 3.0% 34. NOS Follicular lymphoma.1 6.1 4. NOS Malignant lymphoma.

2 6.000 ** Source for this information is summarized on page 64 41 .8 0.8 Saudi Arabia 12.8 Najran 4.7 4.1 Jazan 0.6 5.0 3.4 Comparison of ASR for NHL Cancer among Saudis with ASR in Selected Countries** * ASR Per 100.5 2.6.9 7.0 Qassim 2.1 3.2 Australia 16.6 5.2 7.8 1.4 5. 2006 14.2 Asir 7.1 Norway 8.0 Northern 0 4.3.6 Poland 3.3 11.7 11.8 6.8 Jordan 0 2 4 10.9 1.8 1 2 3 4 5 6 7 8 9 Figure 3.0 Thailand.4 Qatar 6.3 1.2 4.4 United Arab Emirates 3.8 Tabuk 7.3.6 6 8 10 12 14 16 18 20 Figure 3. Bangkok 3.4 Hail 5.6 10.2 Jouf 4.5 3.7 5.3 ASR* Regional Distribution of NHL Cancer in Saudi Arabia.8 2.5 Oman 4.9 Riyadh 7.8 7.9 United States (All Races) 9.2 Bahrain 4.9 9.8 Makkah 6.1 2.5 6.9 Baha 4.1 Eastern Madinah 5.4 Canada 19.2 Wales 12.0 Kuwait 15.

4 8344 Papillary carcinoma. NOS 5 4.0% 29. There were 541 cases of thyroid cancer for year 2006.0% 6.1 34 8.7 232 54.1/100.8% Distant 39.4 8290 Oxyphilic adenocarcinoma 3 2.000 for females.000 for males and 6.3 8341 Papillary microcarcinoma 6 5.1 Morphological Distribution of Thyroid Cancer in Saudi Arabia.4.7 Others 5 4. columnar cell 1 0.0% Male 42 7.1% 18.2% 41. Eastern region at 5.0 8343 Papillary carcinoma. 24 22 male AIR (per 100.6 6 1.5% Female All Figure 3.7 14 3.9 7 1. 2006 Localised Regional Unknown .9 8510 Medullary carcinoma.9% 22.8% 33. Qassim region at 5/100.4. follicular variant 12 10.7/100.000.7 8340 Papillary carcinoma. 2006 ICD-O-3 Code Morphology Male % Female % 8260 Papillary adenocarcinoma. It affected 117(21.4% 30.3 8335 Follicular carcinoma.3 69 16. NOS 3 2.1 8000 Neoplasm.Thyroid (C 73) The five regions with the highest ASR were Riyadh region at 6/100.3 19 4. The overall ASR was 4.5/100. 2006 12.6 8 1.6 12 2. NOS 71 60. The median age at diagnosis was 47 years among males (range 12-84 years) and 39 years among females (range 9-109 years).4%) females with a male to female ratio of 28:100.1 Age-Specific Incidence Rate (AIR) for Thyroid Cancer in Saudi Arabia. malignant 3 2.4. encapsulated 2 1.000.2 Stage Distribution of Thyroid Cancer.6 6 1.3% 35.000.000.9% 23.000.000) 20 female 18 16 14 12 10 8 6 4 2 0 0- 5- 10- 15- 20- 25- 30- 35- 40- 45- 50- 55- 60- 65- 70- 75+ Age Groups Figure 3.3 9 2. NOS 3 2.8 8330 Follicular adenocarcinoma.6 8 1. ASR was 2.000 and Hail region at 4/100.3/100.5 Table 3.6%) males and 424 (78. Tabuk region at 5. minimally invasive 3 2. This cancer ranked second among female population and twelfth among male population. anaplastic.1/100.9 8021 Carcinoma.

1 0.5 2.4 Poland 5.1 Thailand. 2006 Canada 16.1 Kuwait 8.2 2.4 5.8 Jouf Baha 7.6 1.7 0.3 Bahrain 8.0 United States (All Races) 11.7 Norway 4.8 Eastern Qassim 7.1 Saudi Arabia 6.7 1.5 Asir 5.5 4.9 4 6 8 10 12 14 16 Figure 3.Riyadh 9.1 3.5 Tabuk 8.0 0 0.1 United Arab Emirates 6.0 Qatar 14.2 2.4 Oman 6.8 3.8 Australia 10.2 0 2 4.0 3.0 Najran 0.4.4 Comparison of ASR* for Thyroid Cancer among Saudis with ASR in Selected Countries** * ASR Per 100.9 2.2 2.3 ASR* Regional Distribution of Thyroid Cancer in Saudi Arabia.0 Jazan 1.4 3.8 1 2 3 4 5 6 7 8 9 10 18 20 Figure 3.000 ** Source for this information is summarized on page 64 43 .3 Madinah 4. Bangkok 1.2 Jordan 1.2 4.3 3.1 3.6 Makkah 4.8 Hail 3.8 3.3 Northern 1.7 5.5 2.3 0.4.6 3.5 2.9 1.2 0.

8 9837 Precursor T-cell lymphoblastic leukemia 7 2. NOS 35 11.000. NOS 31 10. NOS 54 18. Tabuk region at 4.000.9 9867 Acute myelomonocytic leukemia 4 1. 2006 44 . minimal differentiation 2 0. NOS 12 4. Eastern region at 4.1 Morphological Distribution of Leukemia in Saudi Arabia.2 9891 Acute monocytic leukemia 14 4.000 and 3.5 33 15.4 8 3.6/100.3 5 2. The median age at diagnosis is 25 years among males (range 0-99 years) and 28 years among females (range 0-88 years).4 9873 Acute myeloid leukemia without maturation 2 0.9 36 17. ASR for males was 4.2 9863 Chronic myeloid leukemia.000 and Asir region at 3.5 11 5.4 3 1.000.4 2 0.5 9826 Burkitt cell leukemia 2 0.9 9945 Chronic myelomonocytic leukemia.7 7 3.4 4 1.9 9874 Acute myeloid leukemia with maturation 8 2.1 4 1.9 Others 8 2.2 34 16.4 9872 Acute myeloid leukemia.4 9805 Acute biphenotypic leukemia 4 1.7%) females with a male to female ratio of 140:100.7 4 1.4/1000.000.000 for females.8/100. t(15.3%) males and 212 (41.8 Table 3.000) 35 male female 30 25 20 15 10 5 0 0- 5- 10- 15- 20- 25- 30- 35- 40- 45- 50- 55- 60- 65- 70- 75+ Age Groups Figure 3.8 30 14.7 8 3.8/100.3% of all newly diagnosed cancers in year 2006. q11-12) 11 3.7 7 3. 2006 ICD-O-3 Code Morphology Male % Female % 9836 Precursor B-cell lymphoblastic leukemia 53 17.3 9801 Acute leukemia.Leukemia (C91-C95) There were 508 cases of leukemia accounting for 6. The overall ASR was 4/100. Riyadh region at 5/100. NOS 10 3.0 2 0.4 1 0.0 9835 Precursor cell lymphoblastic leukemia. This cancer ranked third for males and fifth for females and affected 296(58. The five regions with the highest ASR were Northern region at 9.9 9940 Hairy cell leukemia 4 1.5.0 9861 Acute myeloid leukemia.5.7 3 1.3 9866 Acute promyelocytic leukemia.5/100.1 Age-Specific Incidence Rate (AIR) for Leukemia in Saudi Arabia.17) (q22.000.7 3 1.3 9800 Leukemia.7 7 3.6 9823 B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma 31 10. NOS 1 0.4 9910 Acute megakaryoblastic leukemia 3 1. 40 AIR (per 100.7/100.

5 9.5.4 Hail Jazan 3.4 Eastern Asir Makkah 2.6 Bahrain 8.8 2.6 1.9 2.0 6.3 Comparison of ASR for Leukemia among Saudis with ASR in Selected Countries** * ASR Per 100.2 3.0 6.2 ASR* Regional Distribution of Leukemia in Saudi Arabia.4 7.Northern 4.5 4.4 5.2 Jordan 2.8 4.3 0 5.5 Wales 10.2 5.4 9.2 1.5 1.6 4.1 Tabuk 3.6 6.4 Najran 2.8 Riyadh 3.1 4.3 Canada 14.4 Madinah 10.6 Thailand.0 United States (All Races) 11.000 ** Source for this information is summarized on page 64 45 . Bangkok 0 2 12.8 2.9 3.9 4. 2006 9.7 Australia 11.1 Baha 2.7 Qatar 7.0 4.3 2.7 Qassim 2.5 1 2 3 4 5 6 7 8 9 10 11 12 Figure 3.5.3 4.1 4.4 Saudi Arabia United Arab Emirates 2.4 Poland 4.6 Kuwait 6.5 5.0 4 6 8 10 12 14 16 Figure 3.5 0.7 4.7 Norway 7.1 Jouf 0.7 Oman 3.3 2.

7 2 1.0 17 13. Madinah region at 6.000 and Makkah region at 3. Riyadh region at 8/100. The median age at diagnosis was 67 years in males (range 0-105 years) and 64 years in female (range 0.3/100.4 4 3.5% All Figure 3.6/100.0% 17.2% 20.6.000 for males and 3.6.000. 2006 46 Unknown .2% 60.000.0% 62.2% 13.5/100. 2006 13.000) 100 female 80 60 40 20 0 0- 5- 10- 15- 20- 25- 30- 35- 40- 45- 50- 55- 60- 65- 70- 75+ Age Groups Figure 3.1 Age-Specific Incidence Rate (AIR) for Liver Cancer in Saudi Arabia.5 9 7.2% of all newly diagnosed cases in year 2006.000.0% 16.0 8140 Adenocarcinoma.3 79 63.7% 12.5 9 7. NOS 219 75.6. The over all ASR was 5.3% Distant Localised Regional 6.000. NOS 4 1.2 Table 3.2 8970 Hepatoblastoma 2 0.2 Stage Distribution of Liver Cancer.6 8160 Cholangiocarcinoma 13 4. 120 male AIR (per 100.000. The five regions with the highest ASR were Najran region at 10/100. NOS 5 1.2% Male 7.6 Others 13 4.93 years).5/100. ASR was 7.2 8010 Carcinoma. Eastern region at 5/100. malignant 35 12.7 5 4.9% 63.1 Morphological Distribution of Liver Cancer in Saudi Arabia.000 for females. and ninth in females and affected 291 (70%) males and 125 (30%) females with a male to female ratio of 233:100.2 8000 Neoplasm.1/100. This cancer ranked fourth in males.8% Female 7. 2006 ICD-O-3 Code Morphology Male % Female % 8170 Hepatocellular carcinoma.Liver (C 22) There were 416 cases of liver cancer accounting for 5.

4 1.6 Tabuk 4.4 1.7 Riyadh Madinah 9.5 Najran 17.3 0.6 1.1 Bahrain 5.0 5.2 United Arab Emirates 0.3 0.3 Thailand.5 Qassim 4.7 0 2 4 6 8 10 12 14 16 18 20 Figure 3.4 United States (All Races) 7.2.3 2 4 6 8 10 12 14 16 Figure 3.7 Oman 4.0 1.3 ASR* Regional Distribution of Liver Cancer in Saudi Arabia.000 ** Source for this information is summarized on page 64 47 .1 2.3 2.8 5.6.2 Kuwait 7.0 4.9 4.0 Australia 6.7 Canada 5.6 Jazan Northern 0.4 Comparison of ASR for Liver Cancer among Saudis with ASR in Selected Countries** * ASR Per 100. Bangkok 13.2 Eastern 1.6 Qatar 15.7 Poland 1.1 4.2 3.6 0.8 Norway 0 3.8 Makkah 4.1 3.1 Saudi Arabia 7.4 3.2 2.0 Hail 0.6.1 Asir Jouf 11.5 3.1 0.6 1.4 4.4 Baha 1.2 1.2 2.6 2.2 2. 2006 7.

0 8832 Dermatofibrosarcoma.000 for females.1 5 3.0 Others 9 4. 2006 2.1 Age-Specific Incidence Rate (AIR) for Skin Cancer in Saudi Arabia. This cancer ranked seventh for males and females.3 8 6.7 8410 Sebaceous adenocarcinoma 3 1.7.7/100. 2006 ICD-O-3 Code Morphology Male % Female % 8090 Basal cell carcinoma.000.5 3 2.8/100. keratinizing.6/100.2 8092 Infiltrating basal cell carcinoma.7 6 4.8/100.0% Female All Figure 3.8% 37.7% 35.7/100.2 Stage Distribution of Skin Cancer in Saudi Arabia.1% 1.7.2 8094 Basosquamous carcinoma 6 3.5 Table 3.6/100.1% 7.3% 7.0 8098 Adenoid basal carcinoma 3 1.0 8070 Squamous cell carcinoma. NOS 91 47.000. NOS 43 22. 2006 Unknown .2 10 7.6 8071 Squamous cell carcinoma.6 7 5. The median age at diagnosis was 68 years among males (range 12-101 years) and 62 years among female (range 14-109 years).Skin (Non-Melanoma) (C 44) There were 327 cases of skin cancer accounting for 4.7. The five regions with the highest ASR were Jouf region at 5.2 8091 Multifocal superficial basal cell carcinoma 1 0. NOS 18 9. 80 male AIR (per 100. nodular 5 2.1 Morphological Distribution of Skin Cancer in Saudi Arabia. NOS 4 2.5% 36.8% 6.000.000.000 and Riyadh region at 3.000) 70 female 60 50 40 30 20 10 0 0- 5- 10- 15- 20- 25- 30- 35- 40- 45- 50- 55- 60- 65- 70- 75+ Age Groups Figure 3.7% 54.000. NOS 10 5.5 8097 Basal cell carcinoma. It affected 193(59%) males and 134(41%) females with a male to female ratio of 144:100.6 4 3.6 3 2.3% Distant Localised Regional 52.1 0 0. The overall ASR was 3.6% 2.1% of all newly diagnosed cases in year 2006. Tabuk region at 5.2 55 41.4/100.000 for males and 3/100.3 33 24. Madinah region at 4. Asir region at 4.0% Male 48 56. ASR was 4.

9 1.1 4.5 Kuwait 1.6 6.4 1.3 Norway 15.8 1.4 2.1 Oman 3.0 1.4 3. Bangkok 2.9 3.8 2.2 4.6 Riyadh Najran 6.2 0.5 3.3 10.7 Baha 4.9 Bahrain 3.6 3.000 ** Source for this information is summarized on page 64 49 .2 Hail Qassim 2.8 Eastern Northern 0 3.4 Comparison of ASR for Skin Cancer among Saudis with ASR in Selected Countries** * ASR Per 100.6 2.4.0 Saudi Arabia 14.7 3.7.1 Asir 5.9 Madinah 2.0 Canada 0 2 4 6 8 10 12 14 16 Figure 3.0 6.4 Thailand.7 Jouf Tabuk 7.1 0.5 United Arab Emirates 1.5 0. 2006 10.6 4.6 5.3 Qatar 4.9 Poland 5.0 5.0 2.6 3.0 1 2 3 4 5 6 7 8 Figure 3.4 4.3 ASR* Regional Distribution of Skin Cancer in Saudi Arabia.9 Jazan 3.1 Makkah 2.7.

8 6.8 0.5/100.8% Male Female Unknown 13. malignant Small cell carcinoma.0 3.0 19.000. Riyadh region at 4. keratinizing.0 1.0 6.4/100. NOS Non-small cell carcinoma Carcinoma.8% 10.3% Regional 13.000.8.0 32 5 11 5 6 4 3 2 0 3 0 1 8 40.8 9.9% of all diagnosed cases in year 2006. NOS Large cell carcinoma.5% 24.2/100.9 6.9 3.9 12.2 Stage Distribution of Lung Cancer. 2006 ICD-O-3 Code 8140 8070 8000 8041 8046 8010 8012 8250 8071 8260 8013 8020 Morphology Adenocarcinoma.3 0.3/100.6 4. The median age at diagnosis was 67 years among males (range 23-100 years) and 63 years among females (range 17-91 years). Makkah and Jouf region at 4.000 for females. Northern region at 5. 70 male AIR (per 100. NOS Others Male % Female % 51 46 23 29 27 10 8 9 9 1 3 2 14 22. 2006 50 Localised All . 2006 28.4% 51.0% 13.0% Distant 36.3% Figure 3.8.4 3.8. The overall ASR was 4. NOS Papillary adenocarcinoma. ASR was 6. It affected 232 (74. undifferentiated. NOS Squamous cell carcinoma.6%) females with a male to female ratio of 290:100. NOS Large cell neuroendocrine carcinoma Carcinoma. NOS Squamouscell carcinoma.1/100.8% 10.6% 40.5 0.0/100.000 and.000) 60 female 50 40 30 20 10 0 0- 5- 10- 15- 20- 25- 30- 35- 40- 45- 50- 55- 60- 65- 70- 75+ Age Groups Figure 3.1 Morphological Distribution of Lung Cancer in Saudi Arabia.1 Age-Specific Incidence Rate (AIR) for Lung Cancer in Saudi Arabia.1/100.5 5.3 7.4 1.0 Table 3.3 13.000. Tabuk region at 4. The five regions with the highest ASR were Eastern region at 6.8 2.000.3 3. NOS Neoplasm.Lung (C33-C34) There were 312 cases of lung cancer accounting for 3.0 3.4%) males and 80 (25.3 10.3% 10.5 11.3% 47.9 0. NOS Bronchiolo-alveolar adenocarcinoma. Lung cancer ranked fifth among male population and thirteenth among female population.000 for males and 2/100.000.

4 15.7 27.4 5.2 Bahrain 31.7 20.0 Hail 0.6 United States (All Races) 47.4 Kuwait 3.9 21.4 Eastern 10.9 0.6 3.4 5.1 6.4 Madinah 1.5 1.2 23.2 1.0 Baha Najran 0.1 10 20 30 40 50 60 70 Figure 3.9 8.9 1.9 2.1 Tabuk 7.8 United Arab Emirates 2.6 8.0 2.0 0.6 Oman 2.4 0 1 2 3 4 5 6 7 8 9 10 11 Figure 3.5 Riyadh 6.7 Australia 41.3 ASR* Regional Distribution of Lung Cancer in Saudi Arabia.4 Comparison of ASR for Lung Cancer among Saudis with ASR in Selected Countries** * ASR Per 100. Bangkok 5.8 2.1 2.5 Thailand.0 Jordan 2.7 7.8.1 Canada 33.000 ** Source for this information is summarized on page 64 51 .5 Qatar 6.2.9 Norway 36.9 18. 2006 47.8.7 12.0 Jazan 0.8 Wales 43.0 Makkah 6.0 2.7 15.0 Saudi Arabia 0 67.5 Jouf 5.7 Asir 4.3 2.0 Northern 4.1 Poland 58.3 Qassim 0.

nodular sclerosis. nodular sclerosis. The overall ASR was 1.0 9665 Hodgkin lymphoma. The five regions with highest ASR were Qassim region at 3.9. It affected 173 (59%) males and 120 (41%) females with a male to female ratio of 144:100.000 for males and 1. nodular sclerosis.7 23 19.000 for females. grade 1 7 4.1/100. nodular sclerosis.0 9651 Hodgkin lymphoma. grade 2 7 4. 2006 52 Unknown .2% 29. mixed cellularity.3/100.9/100.9 6 5.1 Morphological Distribution of Hodgkin disease in Saudi Arabia.2% 31.7 9667 Hodgkin lymphoma.6/100.9/100.7 6 5.2 Stage Distribution of Hodgkin disease. This cancer ranked eighth among male and tenth in female population.2 9650 Hodgkin lymphoma.4% 32. NOS 34 19.7% 24.1 Age-Specific Incidence Rate (AIR) for Hodgkin disease in Saudi Arabia.2 2 1.7 18 15.9. lymphocyte-rich 12 6.4% Distant Localised Regional 12.000.5% 24.9.000) 10 female 8 6 4 2 0 0- 5- 10- 15- 20- 25- 30- 35- 40- 45- 50- 55- 60- 65- 70- 75+ Age Groups Figure 3.6% 24. Baha and Riyadh and Northern regions at 1. Tabuk region at 2. The median age at diagnosis was 24 years (range 3-85 years) in males and 22 year in females (range 4-80).2% 34.2 3 2.0 4 3.0 9659 Hodgkin lymphoma.000 for each.000.000.3 9664 Hodgkin lymphoma. 2006 ICD-O-3 Code Morphology Male % Female % 9663 Hodgkin lymphoma. Eastern region at 2.4/100. ASR was 2.000.1/100.6% of all newly diagnosed cases in year 2006.5 Table 3. NOS 22 12.0 5 4.9% Male 12.2 9653 Hodgkin lymphoma. cellular phase 2 1. 2006 31.6% All Figure 3.Hodgkin Disease (C 81) There were 293 cases of hodgkin disease cancer accounting for 3.2 9652 Hodgkin lymphoma. NOS 9 5.2% 30. 12 male AIR (per 100. NOS 65 37. lymphocyte depletion.2% Female 12. nodular lymphocyte predominance 15 8.6 53 44.

1 0.2 1. Bangkok 0 2.2 1.8 1.5 2.4 Najran 2.9 1.8 Bahrain 1.2.2 2.1 0.7 Qassim 3.2 0.6 Saudi Arabia 1.3 1.4 2.5 0.3 United States (All Races) Jordan 2.000 ** Source for this information is summarized on page 64 53 .8 1. 2006 2.2 2.9.5 1.3 Hail 2.4 Comparison of ASR for Hodgkin disease among Saudis with ASR in Selected Countries** * ASR Per 100.5 3.4 1 2 3 4 5 Figure 3.3 United Arab Emirates 0.8 Jouf Asir 0.8 2.0 3.4 Canada 3.8 Makkah 2.5 2.6 Qatar 2.7 Oman 1.0 0 1 2 3 4 Figure 3.1 1.8 2.8 0.1 Norway 1.2 Australia 2.9.0 1.8 Poland 0.2 Thailand.5 2.7 1.6 Baha Riyadh 1.7 2.6 Wales 3.1 2.8 Kuwait 4.2 Northern 3.0 Tabuk Eastern 2.3 ASR* Regional Distribution of Hodgkin disease in Saudi Arabia.6 0.6 Jazan 2.0 1.1 Madinah 2.

4 8000 Neoplasm.1 6 5.0 Others 13 8.000 for male and 2.Stomach (C 16) There were 275 cases of stomach cancer accounting for 3.8% 30. 2006 54 Unknown .6% 27.5 3 2.1 5 4.2% Female 18.0 Table 3.000 for females. NOS 74 45.9% 26.10.6 3 2.9 1 0.9 8260 Papillary adenocarcinoma.9/100.7 8490 Signet ring cell carcinoma 37 22.8% 21. The five regions with the highest ASR were Makkah region at 3.000) 50 female 40 30 20 10 0 0- 5- 10- 15- 20- 25- 30- 35- 40- 45- 50- 55- 60- 65- 70- 75+ Age Groups Figure 3.7 8145 Carcinoma.7/100. NOS 4 2. The over all ASR was 3.6/100.10.9%) males and 113 (41.2% Male 16. Hail and Eastern regions at 2.0 9 8.000.3/100.9/100. NOS 5 3.1 Age-Specific Incidence Rate (AIR) for Stomach Cancer in Saudi Arabia. malignant 3 1. It affected 162 (58.4/100.8 34 30. 2006 21.000.5 0 0. intestinal type 18 11.7 8070 Squamous cell carcinoma.The median age at diagnosis was 69 years among males (range 20-112 years) and 61 years among female (range 19-89 years).2 Stage Distribution of Stomach Cancer. This cancer ranked tenth among male population and eleventh among female population.1% 31.7% Distant Localised Regional 20. 2006 ICD-O-3 Code Morphology Male % Female % 8140 Adenocarcinoma. and. Asir and Jouf regions at 3.3 8010 Carcinoma. ASR was 3.1%) females with a male to female ratio of 143:100.7 46 40.000 for each.9 6 5. NOS 1 0.1 Morphological Distribution of Stomach Cancer in Saudi Arabia.2/100.3 8480 Mucinous adenocarcinoma 4 2.1 8144 Adenocarcinoma. Riyadh region at 3.000 for each. diffuse type 3 1.5% All Figure 3.000.10.9% 25.4% 30. 60 male AIR (per 100.4% of all newly diagnosed cases in year 2006.8% 28.

6 Bahrain 7.6 3.5 Makkah 4.9 Baha 1.2 Wales 9.8 12.0 13.9 4 6 8 10 12 14 Figure 3. Bangkok 2.0 Norway 7.6 0.7 3.5 Thailand.2 2.7 Jordan 0 2 6.1 10.4 5.2 4.5 0.2 Qatar 7.9 4.4 Australia 8.10.4 Tabuk 0.4 2. 2006 6.8 3.9 3.8 Riyadh 3.6 4.5 1.7 Saudi Arabia 2.6 1.0 2.2.6 United Arab Emirates 2.6 1.0 3.5 Oman Poland 4.000 ** Source for this information is summarized on page 64 55 .10.6 Asir 4.2 1.4 1 2 3 4 5 Figure 3.7 Jouf 4.9 Eastern Madinah 3.6 3.9 1.7 1.6 Jazan 0 1.6 2.5 3.8 Canada 4.2 Kuwait 2.7 2.3 ASR* Regional Distribution of Stomach Cancer in Saudi Arabia.6 0.0 Northern Qassim 3.4 Comparison of ASR for Stomach Cancer among Saudis with ASR in Selected Countries** * ASR Per 100.4 United States (All Races) 6.5 Najran 2.9 Hail 3.

4 8246 Neuroendocrine carcinoma. The ASR was 6.8/100. Tabuk region at 4. Makkah region at 6. NOS 7 3.4 8130 Papillary transitional cell carcinoma 1 0.3 8000 Neoplasm.2/100.000. The five regions with the highest ASR were Riyadh region at 7. NOS 1 0.000) 120 male 100 80 60 40 20 0 0- 5- 10- 15- 20- 25- 30- 35- 40- 45- 50- 55- 60- 65- 70- Age Groups Figure 3.11.3 8010 Carcinoma.11.000. anaplastic. NOS 1 0.1 Age-Specific Incidence Rate (AIR) for Prostate Cancer in Saudi Arabia. 2006 ICD-O-3 Code Morphology Male % 8140 Adenocarcinoma.4 Table 3.4% Distant Localised 10.3 8021 Carcinoma.2 Stage Distribution of Prostate Cancer. 2006 21.4 8480 Mucinous adenocarcinoma 1 0.0% Unknown Male Figure 3.1/100.8/100. malignant 12 5.Prostate (C 61) There were 228 cases of prostate cancer accounting for 5. NOS 1 0.1 Morphological Distribution of Prostate Cancer in Saudi Arabia.000 and Asir region at 3.6/100. 2006 56 75+ .11.000. Eastern region at 7.000 among male population. The median age at diagnosis was 71 years (range 1-101 years).7/100.4 8490 Signet ring cell carcinoma 1 0. NOS 199 87. AIR (per 100.5% 25.1 8550 Acinar cell carcinoma 3 1.4 8910 Embryonal rhabdomyosarcoma.8% of all newly diagnosed cases among males in year 2006.000.1% Regional 43.4 8320 Granular cell carcinoma 1 0. This cancer ranked sixth among males.

Bangkok 6.5 United States (All Races) 107.4 Australia 122.5 0 1 2 3 4 5 6 7 8 Figure 3.1 Jordan 4.2 Northern 1.2 Wales 69.2 Bahrain 13.6 Madinah 2.4 Najran 2.11.4 Comparison of ASR for Prostate Cancer among Saudi Males with ASR in Selected Countries** * ASR Per 100.6 0 20 40 60 80 100 120 140 Figure 3.8 Jouf 3.7 Makkah 6.2 United Arab Emirates 6.Riyadh 7.4 1.3 Qatar Oman 8.3 Kuwait 12. 2006 Canada 125.7 Baha 0.6 10.11.000 ** Source for this information is summarized on page 64 57 .3 ASR* Regional Distribution of Prostate Cancer in Saudi Arabia.8 Poland 27.7 Saudi Arabia 6.0 Norway 96.8 Qassim 2.3 Hail Jazan 0.8 Thailand.6 Tabuk 4.2 Asir 3.8 Eastern 7.

1/100.6% of all newly diagnosed cases in year 2006.000.0 1 2.6/100.4% 9.000.1 Morphological Distribution of Bladder Cancer in Saudi Arabia.Bladder (C 67) There were 211 cases of bladder cancer accounting for 2.8% 51.6/100. Northern region at 4/100. NOS 5 3.9 17 40.8% Female Regional 17. It affected 169 (80.4 8140 Adenocarcinoma. 50 AIR (per 100. The overall ASR was 2.9 11 26. Riyadh region at 2.5 Table 3.7/100.000 for females. 2006 9. 2006 58 Unknown .000 and Eastern region at 2.1% 52.7 8000 Neoplasm.2 8070 Squamous cell carcinoma. This cancer ranked ninth among male population and twentieth among female population.000 for males and 1/100. Makkah region at 2.4 1 2.5 8130 Papillary transitional cell carcinoma 64 37. NOS 5 3.9%) females with a male to female ratio of 403:100.4 Others 5 3.000.5% 21.000.1% All Figure 3. NOS 4 2.12.0 1 2. The five regions with the highest ASR were Tabuk region at 4.5% 21.5% Male 14.5% 21.3% 54.0 4 9. NOS 81 47.0 7 16.2 Stage Distribution of Bladder Cancer. ASR was 4.000) 45 male female 40 35 30 25 20 15 10 5 0 0- 5- 10- 15- 20- 25- 30- 35- 40- 45- 50- 55- 60- 65- 70- 75+ Age Groups Figure 3. 2006 ICD-O-3 Code Morphology Male % Female % 8120 Transitional cell carcinoma.12.1%) males and 42 (19. keratinizing. malignant 5 3.13.3% 9. The median age at diagnosis was 64 among males (range 24-110 years) and 69 among females (range 30-100 years).3% Distant Localised 17.9/100.1 Age-Specific Incidence Rate (AIR) for Bladder Cancer in Saudi Arabia.6/100.4 8071 Squamous cell carcinoma.000.

2.0 1.0 0. Bangkok 5.7 Kuwait 7.9 United Arab Emirates 5.8 Makkah Qassim 7.4 1.3 0.0 Poland 15.4 0 1 2 3 4 5 6 7 8 9 Figure 3.12.7 Jordan 1.2 0.4 5.1 Eastern Jazan 4.9 1.3 1.6 1.8 Asir 3.5 United States (All Races) 21.3 3.000 ** Source for this information is summarized on page 64 59 .2 0.8 Thailand.0 5.4 0.1 4.5 Canada 27.9 Baha Hail 4.9 0.1 5 10 15 20 25 30 Figure 3.9 Qatar 14.4 Riyadh Najran 6.4 1.7 Wales 11.3 3.1 0.3 Tabuk Northern 4.0 0.0 Bahrain 13.5 2.8 0.1 Australia 11.6 Madinah 3.1 3.9 1.9 Oman 7.9 0.2 1.1 Jouf 0.3 ASR* Regional Distribution of Bladder Cancer in Saudi Arabia.8 4.12.0 Saudi Arabia 0 6.6 0.4 Comparison of ASR for Bladder Cancer among Saudis with ASR in Selected Countries** * ASR Per 100.0 2. 2006 7.2 1.

Corpus uteri (C 54) There were 140 cases of corpus uteri cancer among females accounting for 3. This cancer ranked sixth among female population.13. 40 female AIR (per 100.1 Morphological Distribution of Corpus uteri Cancer in Saudi Arabia.1 Age-Specific Incidence Rate (AIR) for Corpus uteri Cancer in Saudi Arabia.2 Stage Distribution of Corpus uteri Cancer.13.9 8560 Adenosquamous carcinoma 4 2.8/100.9 8890 Leiomyosarcoma. NOS 4 2.7% 16. NOS 25 17.4% Distant Localised 16. The median age at diagnosis was 61 years (range 26-94 years).4 % of all newly diagnosed cases for females (4.7 8930 Endometrial stromal sarcoma.000) 35 30 25 20 15 10 5 0 0- 5- 10- 15- 20- 25- 30- 35- 40- 45- 50- 55- 60- 65- 70- 75+ Age Groups Figure 3.000.000 and Baha region at 2.6/100.000. 2006 10. Riyadh region at 3.156) in year 2006.4/100.2/100. Jouf region at 3.7 Table 3.4% Regional 56. 2006 60 .4% Unknown Female Figure 3.9 Endometrial stromal sarcoma.9 Others 15 10.6 8460 Papillary serous cystadenocarcinoma 4 2.9 8950 Mullerian mixed tumor 8 5.5/100.13. low grade 4 2.000.7 8140 Adenocarcinoma. The five regions with the highest ASR were Makkah region at 4. The ASR was 3. Eastern region at 4.000 for female population.8/100. 2006 ICD-O-3 Code Morphology Female % 8380 Endometrioid adenocarcinoma. NOS 5 3. NOS 71 50.000.

8 Jouf 3.7 Australia 12.5 Baha 2.0 Hail Jazan 0.Makkah 4.6 0 1 2 3 4 5 Figure 3.6 United Arab Emirates 2.000 ** Source for this information is summarized on page 64 61 .6 Bahrain 6.9 Saudi Arabia 3.9 0 5 10 15 20 25 Figure 3.9 Thailand.7 Oman 1.0 Qatar 9.4 Comparison of ASR for Corpus uteri Cancer among Saudi Females with ASR in Selected Countries** * ASR Per 100.4 Eastern 4. 2006 Canada 19.8 Najran 1.6 Kuwait 5.13.2 Northern 2.2 1.8 Asir 1.0 Norway 15.2 Riyadh 3.13.1 Qassim 1.8 Madinah 2.3 ASR* Regional Distribution of Corpus uteri Cancer in Saudi Arabia.5 United States (All Races) 17.8 Tabuk 1.5 Poland 13.1 Wales 16. Bangkok 3.

14. Eastern and Najran regions at 3.3% 13.9/100.000. The ASR was 2.5 1.1 3.0 3.5 9.5/100.0 1. NOS Neoplasm.000.1 Morphological Distribution of Ovarian Cancer in Saudi Arabia.2 Stage Distribution of Ovarian Cancer. NOS Serous surface papillary carcinoma Endometrioid adenocarcinoma.9 18. The median age at diagnosis was 54years (range 10-98 years).000.000) 16 14 12 10 8 6 4 2 0 0- 5- 10- 15- 20- 25- 30- 35- 40- 45- 50- 55- 60- 65- 70- 75+ Age Groups Figure 3.0 3.2% Distant 12. NOS Papillary serous cystadenocarcinoma Serous cystadenocarcinoma.6% Localised Regional Unknown Female Figure 3.6 6.156) in year 2006.14.2% of all newly diagnosed cases among females (4. 2006 62 .8 6.6/100.2 9.8/100. 2006 15.3 7.000 for females. NOS Carcinoma. and Riyadh region at 3. The five regions with the highest ASR were Jouf region at 5.1 Age-Specific Incidence Rate (AIR) for Ovarian Cancer in Saudi Arabia.1 Table 3.Ovarian Cancer (C 56) There were 132 cases of ovarian cancer among females accounting for 3.000. malignant.4/100. Tabuk region at 3.5 1.9% 58.14. This cancer ranked eighth among female population. NOS Mixed germ cell tumor Others Female % 25 24 13 11 10 9 8 4 4 4 2 2 2 2 12 18.8 8.5 1. 20 18 female AIR (per 100. 2006 ICD-O-3 Code 8140 8460 8441 8000 8470 8461 8380 8010 8480 9060 8980 9064 9080 9085 Morphology Adenocarcinoma. NOS Germinoma Teratoma. malignant Mucinous cystadenocarcinoma. NOS Mucinous adenocarcinoma Dysgerminoma Carcinosarcoma.

0 Qassim 2.7 Hail 0.5 Qatar 7.1 Kuwait 5.4 Comparison of ASR for Ovarian Cancer among Saudi Females with ASR in Selected Countries** * ASR Per 100.9 Jouf Tabuk 3.000 ** Source for this information is summarized on page 64 63 .14.8 0 2 4 6 8 10 12 14 Figure 3.0 Baha 1. 2006 Wales 13.9 Northern 1.3 ASR* Regional Distribution of Ovarian Cancer in Saudi Arabia.4 0 1 2 3 4 5 6 7 Figure 3.14.5 Jazan 0.3 Bahrain 8.2 Saudi Arabia 2.5 Najran 3.5 Riyadh 3.7 Canada 11.2 Madinah 2.1 Oman 4.5 Norway 11.2 Poland 10.1 Australia 12.8 United Arab Emirates 4.5 Asir 2.8 United States (All Races) 9.5.7 Thailand.6 Eastern 3. Bangkok 5.4 Makkah 2.

gov.cancer. Available from: http://www.gov.iarc.10.nci.nhs.au/publications/can/nbcspmr08/nbcspmr08_c04.au/publications/can/bca06/bca06.gov. Survival and Prevalence in Norway.uk/sites3/page.statcan.pdf 3 Surveillance Epidemiology and End Results (SEER Cancer Statistics Review 1975-2006).uk/sites3/page. Bowel Cancer Incidence and Mortality.aihw.pdf 15 Descriptive Epidemiology Group. Annual Incidence.au/cancer/data/acim_books/index. GLOBOCAN 2002. Available from: http://www. Mortality. Available from: http://www.hzjz.php?section=4&page=sect_04_table. Available from: http://www.au/publications/can/oca06/oca06.PDF 14 Cancer in Poland in 2006. Available from: http://www-dep.aihw.wales. 5 Cancer Incidence in Oman. IARC. Bangkok. Cancer in Norway. Available from: http://www.onkologia. Available from: http://www.org.cfm 12 Croatian National Cancer Registry. Second edition http://www.aihw.pdf 9 Breast Cancer in Australia: an overview.pdf 10 Australian Cancer Incidence and Mortality (ACIM).htm 13 Bangkok Cancer Registry.** References: 1 Cancer Incidence in Wales.cfm?orgid=242&pid=28752 2 Cancer Incidence in Canada. Available from: http://www. 2006.gov. 6 Cancer Incidence in Jordan. 7 Eight-Year Cancer Incidence among Nationals of the GCC States 1998-2005.pdf 11 Australian association of Cancer Registry. 2006. 2005 and 2006.fr/ 64 . 1998-2000.pl/doc/Biuletyn2006. 2006.gov/csr/1975_2006/browse_csr. 2007.aihw.cfm?orgid=242&pid=27758 and http://www. 2006.nhs.th/File_download/Cancer%20In%20Thailand%20IV/APP-G.ca/pub/82-231-x/82-231-x2008002-eng. 2002-2006 Available from: http://www.wales. Gulf Center for Cancer Registration. 8 Ovarian Cancer in Australia: An overview.hr/cancer/bilten06.go.html 4 Cancer Incidence.gc. Avaiable from: http://seer.

PART IV CANCER AMONG NON-SAUDIS 2006 .

.

4 1.6 2.3 1.2 4.5 1.6 2.7 1.9 100.6 10.9 Thyroid 96 4. approximately 5% of all cancers occurred before the age of 15.7 7. The median age at diagnosis was 50 years in males (range 0-100 years) and 45 years in females (range 0-90 years).7 7.0 408 250 246 187 146 98 92 82 69 59 57 50 44 40 39 39 34 33 33 32 31 29 24 28 174 2324 17. As a result. the total number of cases analyzed were 2.9 2.6 0. 2006 Nationality Male % Female % All % Yemen Sudan Egypt Philippines Pakistan India Syrian Arab Republic Bangladesh Jordan Indonesia Gaza Strip (Palestine) United States of America Eritrea Lebanon Afghanistan Nigeria Bahrain Occupied Palestinian Territory Somalia Ethiopia Chad United Kingdom Myanmar (formerly Burma) GCCR Nationalities Other Nationalities Total 231 149 131 76 70 63 53 72 44 7 30 29 20 23 16 25 13 15 11 13 8 22 16 9 88 1234 18. During 2006.5 2.7 Stomach 84 3.0 177 101 115 111 76 35 39 10 25 52 27 21 24 17 23 14 21 18 22 19 23 7 8 19 86 1090 16.6 10.4 1.5 1.6 Bladder 72 3.1 1.5 3.Those over 60 years represented 20% and the 20 to 54 agegroup represented 60% of non-Saudi population.7 5.9 1.9 1.2 1.2 1.0 2.8% were between the ages 41-64.090 (46.1 Ten Most common Cancers among non-Saudis. % Breast 390 16.3 2.7 12.7 1.0 1.6 6.0 1.1 Prostate 86 3.8 3.0 Table 4.2 7.0 6.1 1.2 0.2 Distribution of Cancer Cases among Different Nationalities in Order of Relative Frequency 67 . The male to female ratio was 113:100.9%) were females.8 10.7 1.9% occured after the age of 64.7 2.234 (53.0 NHL 153 6.395 cancer cases were reported among the NonSaudi population.3 10.8 Colo-rectal 232 10. out of this 1.9 1. Cancer No.1 0.4 1.3 5.2 5. 51.1 0.8 2.4 1.1%) were males and 1.6 0.3 0.9 2.0 3.3% occurred between the ages 15 to 40 years.6 1.6 8.6 Lung 119 5.Cancer Among Non-Saudi Population 2006 Between January and December 2006.1 4.7 2.7 1.6 Skin 129 5.2 3.0 3.1 10. a total of 2.4 2.3 4.5 100.9 1. Taking into consideration the population structure of non-Saudis and the fact that cancer is primarily a disease of the elderly. the pattern of cancer had some significant differences.3 1. Sixty three in situ cases and seven cases of ICD-10 were excluded from the analysis. and 14.324. 28.1 100.3 4.1 Other sites 848 36.2 1.0 1.8 1.2 7.5 2.1 Leukemia 115 4.6 1.6 0.2 9.5 Table 4.

2% Bladder 66 5.4% Cervix Uteri 46 4.7% Figure 4.0% Leukemia 48 4.5% Lung 90 7.0% NHL 104 8.1% Stomach 64 5.4% Colo-rectal 82 7.3% Corpus Uteri 45 4. 2006 700 AIR (per 100.6% Ovary 37 3.4% Thyroid 40 3.1% NHL 49 4.000) 600 male female 500 400 300 200 100 0 0- 5- 10- 15- 20- 25- 30- 35- 40- 45- 50- 55- 60- 65- 70- Age Groups Figure 4.2% Lung 29 2.4% Leukemia 67 5.8% Liver 57 4.5% Prostate 86 7.2 Age-Specific Incidence Rate (AIR) for All Cancers among non-Saudis in Saudi Arabia.2% Breast 382 35.1 Ten Most Common Cancer among non-Saudis. 2006 68 75+ .1% Skin 88 7.2% Skin 41 3.3% Thyroid 56 5.Male 1234 Female 1090 Colo-rectal 150 12.

PART V TABLES .

0% 0.8% 3.4% 0.8% 0.4% 0.9% 0.5% 0.0% 95.0% 2.1% 2.1 Age Distribution of Cancer Cases among Saudi Males.0% 0.1% 1.3% 1. C96 C88 C90 C91 C92-C94 C95 Other All Not C44 All Ages 6 37 30 14 0 0 95 9 3 55 162 18 232 182 8 291 46 93 10 62 232 14 64 11 193 8 22 57 18 1 228 38 3 111 5 1 169 0 26 149 117 19 5 173 351 0 48 155 115 26 186 3898 3705 Age Unk 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 1 0 4 3 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 3 0 0 2 0 0 1 1 0 0 0 0 7 0 0 1 1 0 9 0 0 0 0 16 19 0 11 0 1 6 0 0 39 11 4 7 140 140 0-4 Table 5.5% 1.0% 0.7% 0.7% 3. Multiple Myeloma Lymphoid Leukemia Myeloid Leukemia Leukemia unspecified Other & unspecified All sites Total All sites but C44 ICD (10th) C00 C01-C02 C03-C06 C07-C08 C09 C10 C11 C12-C13 C14 C15 C16 C17 C18 C19-C20 C21 C22 C23-C24 C25 C30-C31 C32 C33-C34 C37-C38 C40-C41 C43 C44 C45 C46 C47.0% 4.7% 4.0% 1.1% 4. C49 C50 C60 C61 C62 C63 C64 C65 C66 C67 C68 C69 C70-C72 C73 C74 C75 C81 C82-C85.1% 0.0% 0.70 Site Lip Tongue Mouth Salivary glands Tonsil Other Oropharynx Nasopharynx Hypopharynx Pharynx unspecified Oesophagus Stomach Small intestine Colon Rectum Anus Liver Gallbladder etc. Lung Other Thoracic organs Bone Melanoma of Skin Other Skin Mesothelioma Kaposi sarcoma Connective.0% 5.8% 0.0% 0.4% 4.6% 6.6% 1.2% 4.2% 0.4% 9.2% 0.0% 0.8% 1.5% 6. Soft tissue Breast Penis Prostate Testis Other male genital Kidney Renal Pelvis Ureter Bladder Other Urinary organs Eye Brain.3% 0.0% 4.0% 0. Nervous system Thyroid Adrenal gland Other Endocrine Hodgkin disease Non-Hodgkin lymphoma Immunoproliferative dis.2% 7.0% 0.8% 100.5% 0. Larynx Trachea.4% 1.2% 0. Pancreas Nose.4% 0.0% 3. Bronchus.1.2% 2.5% 0. 2006 0 0 0 1 0 0 1 0 0 0 0 0 0 0 0 1 0 0 0 0 0 1 7 0 0 0 0 2 0 0 0 0 0 5 0 0 0 0 1 16 0 0 0 8 21 0 0 19 6 3 1 93 93 0 0 0 0 0 0 3 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 15 0 2 0 0 2 0 0 0 0 0 0 0 0 0 0 1 11 2 1 3 24 11 0 0 15 3 0 0 94 92 0 0 0 0 0 0 7 0 0 0 0 1 0 1 0 2 0 0 1 0 0 2 18 0 1 0 0 6 0 0 0 2 0 0 0 0 0 0 0 6 5 0 1 24 12 0 1 15 9 4 7 125 124 0 0 1 3 0 0 2 0 0 0 1 0 1 0 0 2 0 0 0 1 1 1 10 0 5 0 0 3 0 0 0 6 0 2 0 0 1 0 1 4 6 2 0 31 22 0 0 6 11 2 2 127 122 0 0 1 0 0 0 8 0 0 0 1 1 3 2 0 1 0 2 0 0 1 1 2 0 5 0 0 2 0 0 0 8 0 1 0 0 0 0 0 10 9 0 0 17 7 0 1 8 15 0 2 108 103 5-9 10-14 15-19 20-24 25-29 0 2 0 0 0 0 3 0 0 0 7 0 5 5 0 2 0 1 1 1 2 2 2 0 5 1 0 4 0 0 0 4 0 4 0 0 4 0 2 3 10 1 0 12 19 0 0 3 8 1 4 118 113 0 4 2 0 0 0 11 0 0 0 0 1 13 6 0 3 0 2 0 1 1 0 1 0 4 0 0 4 4 0 0 5 0 4 0 0 3 0 0 7 11 1 0 13 25 0 2 2 4 0 8 142 138 0 1 0 3 0 0 10 0 0 1 5 2 13 12 0 4 1 5 0 3 6 0 1 3 5 0 3 2 1 0 1 2 0 4 0 0 10 0 0 8 7 0 0 11 27 0 0 2 8 0 3 164 159 0 4 3 0 0 0 8 0 0 3 13 0 27 20 1 12 2 4 1 4 16 2 1 2 12 1 1 2 1 0 5 6 0 14 0 0 15 0 0 4 18 1 1 8 21 0 5 7 4 0 7 256 244 0 3 0 1 0 0 12 4 0 2 11 2 22 13 1 18 2 10 0 6 15 0 1 1 11 1 1 3 0 0 10 2 0 15 0 0 18 0 1 6 10 1 0 8 24 0 4 4 2 0 19 264 253 0 6 0 2 0 0 5 0 0 3 9 0 30 18 1 28 5 8 0 7 24 1 0 0 9 0 6 2 3 0 15 0 0 7 1 0 13 0 1 13 6 0 0 2 23 0 3 2 5 0 16 274 265 0 3 3 0 0 0 5 1 0 8 16 4 28 28 1 34 4 13 0 11 30 0 2 0 24 0 2 5 4 0 22 0 1 12 2 0 21 0 0 9 7 0 0 4 22 0 6 5 3 0 21 361 337 0 4 7 0 0 0 6 1 0 5 21 3 26 29 3 55 9 21 0 11 47 0 2 1 24 2 3 2 0 1 42 0 2 17 0 0 25 0 1 9 8 1 0 0 27 0 8 9 5 1 25 463 439 2 2 5 2 0 0 7 0 0 7 33 1 34 16 0 44 7 18 0 6 43 1 0 2 25 2 1 4 0 0 39 2 0 8 2 1 22 0 2 12 12 0 0 2 27 0 10 7 8 4 25 445 420 30-34 35-39 40-44 45-49 50-54 55-59 60-64 65-69 70-74 4 8 8 2 0 0 6 3 3 26 45 3 30 32 1 82 16 9 5 11 46 1 1 2 60 1 5 7 4 0 93 0 0 9 0 0 37 0 0 12 6 0 0 7 57 0 8 12 13 6 39 720 660 0. sinuses etc.3% 5.6% 0.2% 0.0% 75+ % of Total .

8% 3. C96 C88 C90 C91 C92-C94 C95 Other All Not C44 All Ages 4 26 34 12 2 0 43 11 1 64 113 14 227 143 9 125 70 73 10 9 80 10 36 12 134 5 14 37 981 4 1 74 140 22 132 9 19 78 4 2 42 0 19 103 424 10 5 120 234 0 26 90 113 9 177 4156 4022 Age Unk 0 0 0 0 0 0 0 0 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 2 0 0 0 2 0 0 0 1 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 8 6 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 3 0 0 0 0 0 2 2 0 0 0 1 2 0 0 0 1 0 0 0 0 0 7 0 0 0 0 13 10 0 7 1 2 5 0 0 39 6 1 6 108 108 0-4 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 3 0 0 0 0 1 0 0 0 0 0 0 0 0 0 4 0 0 0 0 0 11 1 2 0 10 5 0 0 19 2 0 1 59 59 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 8 0 1 0 0 7 0 0 0 0 0 0 2 0 0 1 0 0 0 0 0 14 6 0 0 15 4 0 0 6 6 1 1 73 72 5-9 10-14 Table 5.8% 0.5% 2. 2006 0 0 0 0 0 0 4 0 0 0 1 0 0 0 0 0 0 0 1 1 1 0 6 0 3 0 0 2 1 0 0 0 0 0 5 0 2 1 0 0 0 0 0 6 12 0 0 18 11 0 0 3 8 1 3 90 87 0 0 0 2 0 0 1 1 0 1 4 0 5 0 0 0 0 0 1 0 0 0 2 0 1 0 0 3 7 0 0 0 0 0 6 0 0 1 0 0 0 0 0 4 32 0 0 24 9 0 0 2 6 1 0 113 112 0 0 0 0 0 0 1 0 0 0 3 1 7 2 0 0 0 2 0 1 4 0 7 0 2 0 0 1 37 0 0 1 3 1 4 1 6 4 0 0 0 0 0 6 60 0 1 13 8 0 1 1 10 0 2 190 188 0 1 2 1 1 0 6 0 0 3 3 1 11 2 0 3 0 0 0 0 1 1 2 0 6 0 1 1 75 0 0 2 6 0 5 0 1 2 0 0 2 0 0 6 56 0 0 8 11 0 1 2 4 0 4 231 225 0 1 2 0 0 0 3 1 0 2 6 0 10 5 0 4 4 2 1 1 1 1 0 1 8 0 0 5 126 0 0 7 3 2 3 1 3 3 0 0 2 0 0 5 63 1 0 3 15 0 1 0 8 1 11 316 308 0 1 4 2 0 0 2 2 0 2 8 0 19 15 0 4 4 6 1 1 6 0 3 0 5 1 1 4 163 0 0 15 8 0 14 0 3 8 1 0 2 0 0 7 43 0 0 6 16 0 1 1 8 0 14 401 396 15-19 20-24 25-29 30-34 35-39 40-44 0 3 2 1 0 0 6 1 0 3 7 1 23 20 2 8 6 5 0 1 8 0 0 1 13 0 1 2 182 1 0 11 8 0 14 0 3 9 1 0 1 0 1 2 51 0 0 2 16 0 2 2 13 0 13 446 433 0 2 3 0 0 0 7 5 0 5 11 2 23 18 1 10 8 11 0 1 5 1 0 1 10 0 2 4 105 0 0 7 15 2 17 1 0 9 0 0 2 0 0 7 15 0 0 1 17 0 3 1 6 1 11 350 340 0 3 3 1 0 0 1 1 0 2 6 4 24 21 4 9 8 3 0 1 6 1 0 1 12 0 1 2 86 1 0 4 22 4 13 1 0 8 1 0 3 0 0 3 21 0 0 3 21 0 5 2 5 0 13 330 318 1 6 6 1 0 0 6 0 0 8 11 2 38 15 0 27 10 9 0 1 13 0 0 3 6 1 4 0 78 1 0 5 26 2 15 2 0 4 0 0 5 0 2 10 25 0 0 1 26 0 1 0 10 0 22 403 397 1 2 2 0 0 0 0 0 1 10 19 2 31 21 1 9 6 11 2 1 11 2 0 1 13 1 1 2 43 0 0 9 27 1 14 0 0 6 0 0 4 0 1 6 16 0 3 8 17 0 4 5 8 2 24 348 335 45-49 50-54 55-59 60-64 65-69 0 4 4 1 0 0 2 0 0 12 16 0 19 4 1 21 9 13 0 0 11 0 1 1 14 2 1 0 38 0 0 4 8 5 9 2 0 6 0 0 8 0 0 4 10 0 0 4 25 0 4 1 7 1 19 291 277 70-74 2 3 6 3 1 0 3 0 0 15 17 1 17 20 0 27 15 11 4 0 13 2 2 3 38 0 1 1 39 1 1 8 13 5 11 1 1 5 1 2 12 0 2 2 14 0 0 2 28 0 3 6 6 0 33 401 363 0. Larynx Trachea.0% 1.2% 0. Soft tissue Breast Vulva Vagina Cervix Uteri Corpus Uteri Uterus unspecified.2% 1.9% 0. Multiple Myeloma Lymphoid Leukemia Myeloid Leukemia Leukemia unspecified Other & unspecified All sites Total All sites but C44 ICD (10th) C00 C01-C02 C03-C06 C07-C08 C09 C10 C11 C12-C13 C14 C15 C16 C17 C18 C19-C20 C21 C22 C23-C24 C25 C30-C31 C32 C33-C34 C37-C38 C40-C41 C43 C44 C45 C46 C47.5% 3.4% 0. Ovary Other Female Genital Placenta Kidney Renal Pelvis Ureter Bladder Other Urinary organs Eye Brain.0% 0.0% 1.0% 0.7% 0.9% 5.2% 0.2% 2.0% 0.4% 0.6% 0.8% 75+ % of Total .1% 2.2% 0.1. Pancreas Nose.3% 3.3% 0.1% 0.6% 0.6% 0.2% 3.5% 10.7% 1. Lung Other Thoracic organs Bone Melanoma of Skin Other Skin Mesothelioma Kaposi sarcoma Connective.2% 0.3% 100. Bronchus.2 Age Distribution of Cancer Cases among Saudi Females.6% 2.0% 1.8% 0.2% 0.1% 0.3% 0. sinuses etc.2% 0.5% 2. C49 C50 C51 C52 C53 C54 C55 C56 C57 C58 C64 C65 C66 C67 C68 C69 C70-C72 C73 C74 C75 C81 C82-C85.1% 0.0% 0.0% 1.5% 1.7% 0.9% 0.9% 23.0% 96.2% 0.0% 0.3% 0.9% 0.2% 4.1% 0.3% 5.0% 1.5% 3.71 Site Lip Tongue Mouth Salivary glands Tonsil Other Oropharynx Nasopharynx Hypopharynx Pharynx unspecified Oesophagus Stomach Small intestine Colon Rectum Anus Liver Gallbladder etc. Nervous system Thyroid Adrenal gland Other Endocrine Hodgkin disease Non-Hodgkin lymphoma Immunoproliferative dis.

0 0.9 0.0 0.1 0.6 0.0 0.2 0.3 0.0 0.0 0.7 0.0 17.5 0.0 0.0 0.0 0.0 3.0 0.2 15.2 0.6 68.0 0.6 0.7 32.0 0.0 0.7 0.4 1.2 0.1 0.3 0.0 0.5 44.0 1.8 0.0 0.0 0.0 0.3 0.0 2.0 0.4 19.0 2.0 0.1 0.0 0.1 0.8 3.0 0.0 0.7 0.0 0.2 2.0 0.8 7.0 0.9 0.0 0.1 0.2 51.7 0.9 7.3 2.4 0.0 613.2 72.1 3.1 0.0 0.5 1.0 0.6 3.9 8.6 0.5 0.4 0.8 0.0 1.0 0.0 0.0 0.9 15.0 0.0 0.9 8.2 1.1.0 0.1 0.0 0.9 8.3 2.0 0.0 4.9 8.0 0.1 0.4 0.8 0.1 0.0 0.0 1.2 14.0 0.2 1.2 0.7 10.0 1.4 0.0 0.0 0.0 0.0 0.0 0.0 1.5 1.2 13.8 2.0 9.4 5. Pancreas Nose.1 1.0 0.0 0.2 1. 2006 Crude Rate 0.0 0.0 12.0 0.2 0.4 0.0 75+ 0.4 0.7 5.0 0.1 98.0 0.1 3.4 0.3 5.4 8.1 30.6 0.8 3.6 0.3 0.0 0.8 3.0 0.0 0.0 12.0 0.7 15.6 19.4 1.0 0.0 0.1 4.0 3.0 0.0 111.9 0.0 0.7 0.0 0.6 47.2 0.0 0.0 1.0 1.1 0.0 0.6 8.0 0.1 0.7 0.0 1.6 2.6 0.0 0.0 0.0 0.0 0.0 0.0 0.4 4.3 0.0 0.1 5.0 0.8 0.0 0.6 0.5 2.0 9.0 0.0 0.0 1.0 0.0 0.4 0.7 1.0 0.1 45.8 0.9 34.0 0.8 0.0 0.0 0.3 4.3 0.1 1.3 0.0 1.2 0.3 0.2 4.0 1.7 1. Soft tissue Breast Penis Prostate Testis Other male genital Kidney Renal Pelvis Ureter Bladder Other Urinary organs Eye Brain.1 0.1 2.0 0.5 2.5 0.0 581.0 5-9 10-14 15-19 20-24 25-29 30-34 35-39 40-44 45-49 50-54 55-59 60-64 65-69 70-74 Table 5.5 1.1 0.0 0.0 0.0 0.0 2.6 0.4 4.6 8.0 0.3 0.1 0.8 0.1 6.0 0.8 99.9 0.2 0.7 10.8 0.2 0.4 0.0 0.7 0.1 0.6 2.0 0.0 0.0 0.0 1.0 1.8 0.3 15.0 0.6 0.3 0.0 0.2 0.0 0.1 1.1 1.5 14.1 0.0 0.0 18.1 2.0 0.7 0.0 0.6 0.0 0.0 4.0 1.0 1.0 4.0 0.0 0.1 3.8 8.0 2.6 5.0 147.1 0.0 0.2 0.0 0.9 0.0 0.2 2.8 1.0 7. Larynx Trachea.1 1.0 0.6 0.0 0.4 0.0 0.0 0.0 0.1 0.3 2.1 0.0 0.8 0.0 0.0 0.8 11.1 0.0 0.5 26.8 7.0 2.2 8.0 0.8 54.0 0.0 0.8 0.0 0.4 0.3 0.2 0.2 4.7 13.0 0.6 7.1 0.0 0.0 0.4 41.0 19.3 0.0 2.2 7.0 0.7 6.1 3.2 0.7 4.4 19. Bronchus.0 0.2 0.0 0.0 4.8 0.0 0.0 1.6 0.0 2.4 2.6 12.0 0.1 0.1 0.0 0.2 0.4 2.2 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.1 2.7 0.0 0.0 0.5 0.0 0.1 26.7 0.0 0.0 0.3 27.8 0.0 0.0 0.0 2.0 0.4 0.0 0.0 0.5 0.0 0.0 2.0 0.2 0.2 0.2 2.0 13.2 0.3 2.4 0.5 1.0 0.0 0.0 0.5 9.0 0.5 0.0 0.0 0.3 0.5 0.0 0.6 1.4 0.0 0.6 0.0 0.0 0.0 0.0 10.0 1.6 0.0 0.0 0.0 0.6 0.8 14.0 0.2 46.0 0.9 38.0 0.6 1.0 6.0 507.8 1.0 0.0 0.0 0.7 0.3 0.0 0.6 0.8 53.4 0.2 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.2 0.7 35.1 0.0 0.0 0.0 0.8 2.1 0.5 22.3 6.0 0.1 6.5 24.0 0.1 0.6 0.4 0.1 0.0 2.6 1.0 1.0 0. Multiple Myeloma Lymphoid Leukemia Myeloid Leukemia Leukemia unspecified Other & unspecified All sites Total All sites but C44 ICD (10th) C00 C01-C02 C03-C06 C07-C08 C09 C10 C11 C12-C13 C14 C15 C16 C17 C18 C19-C20 C21 C22 C23-C24 C25 C30-C31 C32 C33-C34 C37-C38 C40-C41 C43 C44 C45 C46 C47.5 0.5 1.72 Site Lip Tongue Mouth Salivary glands Tonsil Other Oropharynx Nasopharynx Hypopharynx Pharynx unspecified Oesophagus Stomach Small intestine Colon Rectum Anus Liver Gallbladder etc.0 0.9 0.1 0.8 39.0 0.6 0.5 0.4 3.1 5.4 1.0 792.0 0.0 3.5 7.3 0.0 0.2 6.1 0.1 0.1 1.0 0.1 2.0 0.0 0.0 0.2 0.0 1.2 0.6 13.7 2.0 0.0 .2 0.0 0.0 0.0 0.0 257.0 0.8 4.0 11.8 ASR World 0.3 3.0 0.0 3.0 0.1 9.2 72.0 0.6 6.0 240.0 0.0 0.0 1.0 0.0 0.0 13.1 0.0 0.0 0.6 0.0 0.0 0.0 0.3 0.0 1.0 0.0 5.0 0.0 0.2 1.0 0.0 537.7 1.0 0.3 0.4 0.2 0.0 0.0 0.2 0.0 0.2 1.0 0.1 0.8 2.0 1.2 5.0 2.0 0.0 0.0 13.0 0.0 0.0 0.8 15.2 6.0 4.0 0.0 0.6 0.0 0.0 0.0 0.0 0.8 0.0 0.3 83.1 0.0 0.0 0.0 33.3 2.0 0.0 36.3 0.0 0.0 0.8 0.3 38.5 0.0 0.0 0.0 0.1 5.3 2.1 0.0 0.4 14.9 0.0 0.8 4.8 21.0 36.4 62.0 864.7 0.0 0. Lung Other Thoracic organs Bone Melanoma of Skin Other Skin Mesothelioma Kaposi sarcoma Connective.1 0.0 0.1 0.4 0.0 0.0 0.0 0. sinuses etc.4 2.7 55.1 1.4 0.6 4.0 0.8 2.1 0.3 0.5 0.000).0 0.3 4.4 0.0 0.0 2.4 7.0 1.0 0.4 0.5 0.0 0.1 0.0 152.0 0.1 0.0 0.4 0.3 0.6 0.0 0.1 0.4 4.0 0.2 0.0 0.3 2.2 0.6 1.5 1.0 1.6 79.2 0.1 0.0 2.3 1.0 0.0 3.0 0.3 0.5 1.1 0.3 0.3 0.0 0.0 1.0 0.0 1.2 7.6 0.7 1.9 3.4 0.2 0.0 0.0 0.0 26.0 1.0 0.1 0.4 0.3 7.0 0.2 0.7 0.8 0.8 2.0 0.8 1.0 0.3 0.0 0.0 1.4 9.3 2.6 0.9 10.6 7.4 3.0 2.0 0.0 0.7 0.4 0.0 0.0 0.0 0.2 0.0 6.0 0.3 0.7 15.0 0.0 33.0 9.0 0.2 0.9 0.0 0.0 4.0 0.0 0.1 5.0 0.3 1.0 1.2 0.1 0.0 0.8 8.0 0.0 0.7 0.4 11.0 0.0 0.0 1.6 0.9 0.0 0.4 9.0 0.5 0.7 0.0 0.9 0.4 0.7 0.0 0.4 1.1 1.0 0.0 0.1 0.0 0.4 4.2 0.6 0.4 0.0 0.0 0.6 14.0 0.3 10.8 30.4 4.7 2.0 95.7 1.1 0.0 0.4 0.1 0.2 0.3 0.3 1.0 0.6 0.0 2.0 0.1 0.2 0.0 0.0 1.2 0.6 0.0 0.1 0.0 0.3 16.2 0.2 0.6 3.0 0.0 0.0 0.5 6.0 0.7 4.0 0.0 0.0 0-4 0.3 0.1 0.2 0.1 0.6 1.0 0.0 0.7 37.0 0.0 0.4 1.1 9.6 11.0 0.7 0.0 3.0 0.4 31.6 0.0 3.0 0.0 0.0 0.0 0.2 0.6 12.0 0.3 Cancer Incidence Cases among Saudi Males by Age Group (per 100.6 0.3 0.6 0.4 0.0 1.0 0.0 0.4 1.2 0.4 2.0 0.9 55.9 0.0 0. C49 C50 C60 C61 C62 C63 C64 C65 C66 C67 C68 C69 C70-C72 C73 C74 C75 C81 C82-C85.0 0.0 1.1 0.7 2.4 0.3 14.0 1.1 0.6 1.0 0.2 6.0 9.0 0.4 3.3 1.2 5.8 0.4 0.5 0.0 1.2 3.4 27.0 0.0 0.0 0.0 0.0 0.3 2.2 0.0 0.0 1.1 0.3 3.0 0.2 0.4 1.1 31.2 2.7 0.0 0.0 0.0 2.0 0.2 1.0 2.1 2.1 9.0 42.1 0.1 0.0 0.6 18.0 0.0 0.8 1.0 0.4 2.0 2.6 0.4 0.1 2.5 1.2 0.0 2.0 1.9 2.0 0.0 72.0 6.0 0.3 0.0 0.4 0.1 0.6 0.0 0.1 0.0 0.0 68.0 2. C96 C88 C90 C91 C92-C94 C95 Other All Not C44 All Ages 6 37 30 14 0 0 95 9 3 55 162 18 232 182 8 291 46 93 10 62 232 14 64 11 193 8 22 57 18 1 228 38 3 111 5 1 169 0 26 149 117 19 5 173 351 0 48 155 115 26 186 3898 3705 Age Unk 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 1 0 4 3 0.5 2.4 0.3 21.9 14.3 0.3 0.7 0.0 0.0 0.4 0.2 3.0 0.0 0. Nervous system Thyroid Adrenal gland Other Endocrine Hodgkin disease Non-Hodgkin lymphoma Immunoproliferative dis.0 0.7 2.4 9.0 0.6 9.0 1.4 0.3 1.

6 0.6 0.0 0. Multiple Myeloma Lymphoid Leukemia Myeloid Leukemia Leukemia unspecified.1 27.3 7.0 0.0 0.0 2.0 0.8 0.0 0.3 0.0 0.2 0.0 0.0 0.4 17.2 0.0 0.0 0.0 0.0 0.6 6.2 2.2 0.3 0.4 19.2 0.0 0.0 0.0 0.0 0.0 0.9 1.0 0.0 0.0 0.8 11.0 0.3 16.0 0.0 0.3 11.2 0.8 2.0 0.3 0.0 0.6 2.6 1.2 0.4 0.9 1.2 0.0 0.0 0.0 406.2 1.3 0.9 0.0 0.5 0.3 0.0 0-4 0.0 0.8 0.8 1.4 8.4 7.4 0.0 0.0 0.2 0.3 0.0 0.0 0.5 0.6 0.7 11.0 0.7 1.6 22.3 0.5 0.0 0.9 19.0 0.0 0.0 3.8 7.0 0.0 0.8 2.0 0.0 0.6 15.0 0.5 0.0 0.0 0. Other & unspecified All sites Total All sites but C44 ICD (10th) C00 C01-C02 C03-C06 C07-C08 C09 C10 C11 C12-C13 C14 C15 C16 C17 C18 C19-C20 C21 C22 C23-C24 C25 C30-C31 C32 C33-C34 C37-C38 C40-C41 C43 C44 C45 C46 C47.0 0.1 4.0 0.0 0.0 0.4 0.0 0.6 0.4 2.3 0.0 0.0 1.2 0.0 2.5 0.0 0.5 0.0 0.0 0.1 0.9 29.0 0.0 1.7 0.9 0.0 0.6 1.0 0.2 0.0 0.0 0.0 0.0 0.4 8.0 0.0 0.0 2.0 0.0 8.3 0.0 0.2 2.0 0.5 0.0 0.3 0.8 5.1 0.6 1.3 0.0 0.1 0.0 4.8 0.4 2.1 1.2 0.0 0.9 2.0 5-9 10-14 15-19 20-24 25-29 30-34 35-39 40-44 45-49 50-54 55-59 60-64 65-69 70-74 Table 5.0 0.0 0.3 13.0 1.6 0.7 1.0 0.4 3.2 0.1 3.8 2.6 2.1 0.6 0.0 0.2 9.3 48.8 ASR World 0.0 0.5 0.0 0.0 0.4 1.0 0.0 0. Pancreas Nose.0 0.6 2. C49 C50 C51 C52 C53 C54 C55 C56 C57 C58 C64 C65 C66 C67 C68 C69 C70-C72 C73 C74 C75 C81 C82-C85. 2006 Crude Rate 0.5 0.0 0.0 0.1 0.6 0.0 0.0 0.2 1.0 0.1 0.4 0.0 0.6 0.6 0.6 14.6 0.0 0.0 1.0 1.2 11.0 0.0 0.0 0.0 0.6 0.3 16.0 0.8 0.7 4.0 0.0 0.1 0.1 0.2 41.2 0.7 16.0 0.4 0.4 0.0 1.7 0.0 0.4 1.7 6. Lung Other Thoracic organs Bone Melanoma of Skin Other Skin Mesothelioma Kaposi sarcoma Connective.2 0.0 0.0 0.0 6.6 0.0 0.0 0.0 0.8 7.3 1.0 0.6 2.3 0.2 0.1 0.4 0.2 2.0 0.6 1.0 0.8 0.4 0.0 0.3 0.2 1.0 0.6 1.0 0.0 0.1 0.9 0.3 1.2 0.2 0.2 0.4 6.6 0.0 0.0 0. Oesophagus Stomach Small intestine Colon Rectum Anus Liver Gallbladder etc.2 0.0 0.1 48.3 0.0 0.0 1.0 3.0 0.0 0.0 0.4 0. Larynx Trachea. Ovary Other Female Genital Placenta Kidney Renal Pelvis Ureter Bladder Other Urinary organs Eye Brain.7 0.0 3.4 0.0 1.0 0.1 0.9 0.0 0.0 0.7 0.3 19.0 7.0 4.5 0.0 0.0 0.0 0.4 0.0 0.6 18.0 1.4 0.7 5.1 5.0 0.0 0.3 1.4 0.0 0.0 0.0 0.9 0.0 0.6 1.0 186.2 0.5 0.0 0.0 0.0 0.8 0.0 25.2 0.1 0.7 6.0 0.3 0.0 1.0 0.7 5.0 0.1 0.0 0.0 12.7 4.4 3.9 43.8 0.0 0.0 0.3 2.2 0.0 0.0 0.2 0.3 1.0 0.3 3.0 0.8 1.8 79.5 12.8 0.5 0.9 7.6 3.1 0.0 0.0 0.9 0.5 0.8 0.4 0.0 2.6 0.0 0.0 0.7 5.6 36.9 13.0 0.0 0.1 0.1 0.0 0.0 0.8 0.6 9.0 0.0 0.1 0.2 0.9 0.3 2.6 1.0 0.0 0.5 0.8 2.0 1.3 0.6 4.2 22.0 137.0 0.0 0.3 0.9 0.1 0.0 0.0 0.0 2.2 0.0 0.0 0.3 0.1 1.1 13.0 0.7 1.9 0.0 0.0 387.0 0.4 2.0 0.0 0.0 0.6 2.7 0.0 0.0 0.7 1.3 0.2 4.3 0.0 0.1 0.4 37.0 1.0 1.6 0.0 407.0 0.5 7.6 28.3 3.8 4.7 42.0 0.6 0.0 0.4 6.0 0.7 0.4 0.0 0.0 0.0 0.2 1.0 0.0 294.0 0.0 0.7 0.1 0.1 1.0 0.1 26.0 0.0 2.0 0.6 12.0 0.4 9.0 0.5 4.0 0.4 0.4 0.8 31.2 25.0 0.5 34.6 1.0 0.4 1.0 0.0 1.6 1.5 0.0 0.0 0.3 14.0 0.4 0.0 0.4 1.9 11.0 0.5 2.0 1.3 9.4 3.2 0.3 0.0 1.0 0.0 461.5 0.6 1.0 0.2 1.0 0.7 10.4 0.0 0.3 31.0 1.0 1.0 0.2 0.0 0.0 0.0 0.0 0.4 0.0 0.2 0.4 3.0 0.3 0.2 3.0 0.1 0.0 0.0 0.0 0.5 1.3 0.0 0.5 0.3 0.0 0.0 0.0 0.3 11.0 35.6 3.0 0.6 0.0 0.0 1.6 0.2 11.0 1.7 1.7 1.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.0 0.1 6.1 7.9 23.1 0.0 0.0 0.6 57.4 1.0 1.2 0.0 0.0 1.1 4.8 1.2 4.4 5.1 0.0 0.1 0.2 0.5 0.6 2.0 0.0 0.0 0.6 5.6 0.0 0.7 5.0 5.0 0.0 0.0 0.8 3.0 8.0 0.0 0.0 0.9 0.1 82.0 91.0 0.0 52.0 0.1 0.0 0.6 0.1 0.6 0.9 0.0 0.0 12.4 0.5 2.8 4.1 14.2 0.5 0.0 132.6 0.0 0.0 0.6 0.0 0.0 2.7 0.0 0.0 0.0 0.0 0.3 1.8 3.0 0.0 0.0 0. Bronchus.4 0.0 0.0 0.0 10.7 0.0 0.6 6. Nervous system Thyroid Adrenal gland Other Endocrine Hodgkin disease Non-Hodgkin lymphoma Immunoproliferative dis.3 0.0 0.4 6.8 2.7 7.1 1.3 0.2 0.0 128.0 0.4 2.0 0. C96 C88 C90 C91 C92-C94 C95 Other All Not C44 All Ages 4 26 34 12 2 0 43 11 1 64 113 14 227 143 9 125 70 73 10 9 80 10 36 12 134 5 14 37 981 4 1 74 140 22 132 9 19 78 4 2 42 0 19 103 425 10 5 120 234 0 26 90 113 9 177 4156 4022 Age Unk 0 0 0 0 0 0 0 0 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 2 0 0 0 2 0 0 0 1 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 8 6 0.8 1.3 35.1 0.0 0.0 0.3 25.8 2.0 0.2 0.0 0.2 1.1 0.0 0.7 0.0 0.0 0.0 0.2 0.0 75+ 0.1 0.0 0.1 4.9 0.7 0.2 19.4 2.8 0.5 0.3 0.0 0.1 2.0 0. sinuses etc.1 0.0 0.1 0.6 4.0 0.0 0.0 299.0 92.2 0.0 6.3 1.0 0.7 4.0 0.0 0.1 20.7 1.2 0.8 0.9 18.9 0.3 0.1 6.0 1.0 0.1 0.0 0.5 21.0 58.0 1.9 0.8 1.1 18.0 0.0 0.9 .0 11.0 2.8 0.9 0.2 2.9 5.4 0.7 14.5 0.2 0.7 3.0 0.0 2.1 0.2 3.0 0.0 0.3 3.9 1.6 0.0 0.8 0.0 0.4 2.6 0.9 2.0 0.3 5.6 0.6 0.7 0.0 0.4 5.2 0.0 0.6 0.0 0.0 0.3 0.0 0.8 0.8 1.0 0.7 3.0 0.0 0.1 0.0 0.0 0.0 0.1 0.0 0.5 3.3 0.0 0.2 0.4 11.7 0.0 0.7 6.4 0.1 0.0 6.7 0.0 0.8 0.5 3.3 1.8 0.0 57.1 1.0 0.0 9.1 0.1 0.0 0.0 0.0 0.0 0.1 37.0 5.8 4.5 1.0 0.6 3.8 0.6 0.4 0.4 0.1 0.0 0.6 0.8 57.0 0.4 4.0 0.4 10.3 5.2 1.4 0.6 0.4 1.8 2.0 12.0 0.0 1.73 Site Lip Tongue Mouth Salivary glands Tonsil Other Oropharynx Nasopharynx Hypopharynx Pharynx unspecified.1 0.3 22.0 0.1 0.0 0.0 0.1 0.2 0.2 0.3 0.5 1.2 0.2 0.0 1.4 8.4 3.2 1.0 0.0 0.7 0.1 6.1 0.0 0.0 0.5 0.0 0.0 1.0 0.0 0.7 0.0 0.0 0.1 0.2 30.5 0.0 0.8 3.9 15. Soft tissue Breast Vulva Vagina Cervix Uteri Corpus Uteri Uterus unspecified.0 11.4 0.0 0.9 15.6 9.0 0.6 3.2 4.1 0.5 0.0 0.5 0.0 0.0 2.0 0.0 0.0 0.0 0.3 0.4 0.3 0.0 0.7 0.9 0.5 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.8 0.7 0.0 0.4 2.0 0.0 0.0 0.0 0.4 0.0 0.0 0.2 0.0 0.2 13.2 3.5 42.2 0.2 0.0 0.0 0.0 0.1 0.1 0.0 0.7 0.1 1.1 0.1 3.4 0.9 0.0 449.0 0.0 141.8 7.4 19.4 53.0 0.0 0.1 1.0 0.3 0.1.0 0.000).2 0.1 0.0 0.1 0.3 0.2 0.2 2.3 0.2 0.0 0.0 0.1 3.1 1.8 11.7 0.0 1.6 0.0 0.8 2.7 1.0 0.0 0.3 0.0 0.2 0.0 0.6 0.4 2.0 0.0 0.0 0.3 0.6 4.0 12.4 1.6 18.0 0.5 16.0 0.0 0.7 0.0 1.9 8.9 11.0 0.6 0.3 1.0 0.0 0.0 0.2 2.8 9.5 10.0 0.0 0.4 0.0 5.8 26.0 1.0 0.1 12.0 0.0 2.1 0.0 0.2 4.0 0.0 180.2 0.1 0.0 0.0 444.0 0.6 0.0 0.0 1.0 0.0 0.0 0.0 0.0 0.1 0.4 0.4 Cancer Incidence Cases among Saudi Females by Age Group (per 100.4 46.0 0.0 0.3 0.

3% 0.0 0.8% 1.0 0.0% 1.1 0.C96 C88 C90 C91 C92-C94 C95 Other All Not C44 2 6 2 2 0 0 7 0 0 3 22 3 15 11 1 23 7 5 1 2 9 1 6 1 28 0 6 6 1 0 21 3 0 6 0 0 17 0 0 9 4 0 1 6 24 0 3 16 10 2 13 ----305 277 0.0% 0.0% 0.6% 4.9% 0.0 0.3 3.0 0.0 0.0 0.0 0.4 0.1 0.6% 0.2 0.6 2.1 0.0% 91.3% ----100.0% 1.2% 11.0 0.0 0.3 0.0% 1.0 0.0% 9.0 0.0 0.2 0.0% 1.4 0.0 2.4% 0.2 1.0 0.0 0.2 0.2 0.0 0.8 0.0 1.0 2.0 0.0% 2.9 0.0 2.6% 0.0 3.3 0.0% 1.4 0.9 0.2 0.0 0.0% 7. 2006 .0% 2.0 0.0% 7.9 1.6% 0.2 0.6 0.0% 0.6% ----100.6 0.0 0.0% 0.3% 0.0 0.7% 0.4 0.0 0.1 0.3% 6.0 0.6% 1.7 0.0 0.0 0.0 0.3% 8.4 0.5 1.0 0.0% 6.0% 1.3% 0.0 0.6 0.0 3.1 0.0% 0.2 0.0 2.9 ----55.4 0.0% 0.2 1.0% 1.0% 1.0 0.0 1. sinuses etc. Pancreas Nose.0 0.2 0.3 1.5 0.8 0.4 1.0 2.0 4.0 0.8 0.0% 0.0 0.1 38.0 0.7 4.0 0.6 0.0 0.3% 0.Lung Other Thoracic organs Bone Melanoma of Skin Other Skin Mesothelioma Kaposi sarcoma Connective.0% 0.2 0.0 0.6% 0.6 0.5 0.0% 0.8 0.6% 6.0 0.0% 1. Other & unspecified All sites Total All sites but C44 ICD (10th) C00 C01-C02 C03-C06 C07-C08 C09 C10 C11 C12-C13 C14 C15 C16 C17 C18 C19-C20 C21 C22 C23-C24 C25 C30-C31 C32 C33-C34 C37-C38 C40-C41 C43 C44 C45 C46 C47.5 35.7 0.0% 1.2 0.7 3.0% 8.0 0.0 0.6% 0.0 1.Soft tissue Breast Penis Prostate Testis Other male genital Kidney Renal Pelvis Ureter Bladder Other Urinary organs Eye Brain.8 3.C49 C50 C60 C61 C62 C63 C64 C65 C66 C67 C68 C69 C70-C72 C73 C74 C75 C81 C82-C85.0% 3.0 0.0% 0.3% 0.0% 3.0 1.3 0.4% 5.3 0.2 2.0 0.6 ----38.7% 4.8 0.0 1.7 1.0 0.3 0.0% 1.0% 0.7% 3.0 0.0 0.0 0.2 0.0 0.5 0.0 0.0 0.0 1.0% 1.8% 0.0 0.0 3.4 0.3 0.0 0.1 0.3 All Ages % of Total Crude Rate ASR World Asir 0 1 0 0 0 0 1 0 0 4 3 0 2 5 1 3 1 1 0 0 4 0 2 2 5 0 0 0 0 0 1 0 0 1 0 0 2 0 1 0 0 1 0 5 7 0 0 5 2 0 1 ----61 56 0.0% 0.8 0.3% 0. Multiple Myeloma Lymphoid Leukaemia Myeloid Leukaemia Leukaemia unspec.9 0.6 0.0 1.3% 0.3% 0.0% 91.6 0.6% 0.0% 6.0 0.6 0.6 0.0 0.2 0.0% 6.0% 2.6 0.0 0.9% 1.1 1.0 0.2 0.0 0.3 1.0 1.0 0.0 0.2 0.0 1.1 1.0 0.0 0. Oesophagus Stomach Small intestine Colon Rectum Anus Liver Gallbladder etc.3% 3.8 50.0% 4.2 0.1 Number.0 2.0 1.0 0.2 0.5 4.7 0.3% 0.0% 0.6 0.8% 0.0 0.2% 1.0 0.0% 1.1% 0.3 0.0% 5.8 0.6 1.0 0.2 4.1 0.0% 0.0 0.5% 2.8 ----42.3% 1.0 0.8 ----43.3% 0.0 1.3 1.3 38.3% 2.0 1.0% 0.2 1.5 2.0 0. Larynx Trachea.0 0.6% 0.6% 0.3 1.0 0.0% 0.3 1.2 0.2 13.3 3.2 1.0 0.0 0.0% 0.0 0.9% 0.0 0.3% 1.0 0.2 0.0 0.0 0.2.7 0.3% 0.0% 0.1 3.8 0.8 0.3 0.3 0.4 0.4 2.0% 1.3 0.6% 0.3% 0.5 0.0 1.1 0.0 0.0% 3.3% 6.0 0.7% 0.8 4.6% 0.0% 0.1 0.0 1.4 0.0% 0.4 2.8 0.5 0.5% 0.8 18.0 2.0% 1.0 0.2 0.4 0.6% 0.2 0.4 0.8 0.1 0.0 0.0 0.3% 1.0% 0.0 3.9 All Ages % of Total Crude Rate ASR World Baha 1 5 4 1 0 0 3 0 0 2 5 0 2 4 0 3 1 1 1 0 5 0 1 0 7 0 0 1 1 0 2 0 0 1 0 0 1 0 0 6 0 1 1 5 9 0 0 1 1 0 2 ----78 71 1.0% 6.7 1.2 0.0 0.4 ----15.0% 0.5 ----20.0% 3.0% 90.0 0.0% 0.0 0.0% 2.7 0.3 0.4 1.1% 1.8 0.0 1.0% 0.6 0.0 0.7% 0.1 0.0% 0.0 2.0% 0.4% 0.0 0.3% 7.0% 0.9% 3.3 0.2 6.3% 1.4 0.0 0.0% 0.0% 7.0 0.0 0.2 0.0% 0.0% 1.9 0.6 0.0 0.9% 1.0% 2.4 0.8 0.0% 0.74 Site Lip Tongue Mouth Salivary glands Tonsil Other Oropharynx Nasopharynx Hypopharynx Pharynx unspec.0% 2.2 0.0% 0.0 0.6% 0.3% 9.0 0.2 0.0 0.5% 0.3% 0.0 0.3% 1.0 1.2 1.4% 11.Bronchus.2% 0.2% 0.0% 0.7% 2.2% 3.8 0.0 0.0 3.6 0.0% 2.9 0.0% 8.2 0.3 0.0 0.8 0.0 0.6% ----100.0 1.3% 8.0 0.4 3.8 0.4 0.2 5.0% 3.3 0.0 0.2% 3.4 1.3% 0.6% 4.2 0.8 0.1 0.2 1.0 0.0% 0.3% 2.3 0.2 0.3% 1.3 0.5 0.0 0.2 2.0 0.0% 2.2 0.0 1.6% 5.0% 5.6 0.0% 3.2% 1.8% 0.0 0.0 1.1 1.8 All Ages % of Total Crude Rate ASR World Jazan Table 5.0 0.2 4. Age Standardized and Crude Rates for All Cancer Cases Among Saudi Males by Site and Administrative Region.0 2. Nervous system Thyroid Adrenal gland Other Endocrine Hodgkin disease Non-Hodgkin lymphoma Immunoproliferative dis. Relative Frequencies.2 0.4 0.8 0.0 0.3 0.5 1.1 3.4 1.

9 0.0% 3.7% 2.0 0.8 0.9 0.4 All Ages % of Total Crude Rate ASR World Hail 0 0 1 1 0 0 8 2 0 5 2 0 10 7 0 11 0 2 1 1 5 2 3 0 8 0 0 1 0 0 7 3 0 2 0 0 4 0 3 7 9 1 0 14 14 0 0 9 4 1 11 ----159 151 0.3 0.5% 0.9 0.0 0.5 0.0 3.0 2.7% 0.0 0.0 2.1 0.3% 3.9 0.2 Number.9% 3.0% 1.1% 0.5% 0.8 0.0% 3.9% 9.7 0.9 4.9 0.4 0.0 0.0 0.0% 0.4 0.0 2.4% 4.0 0.7% 0.2 67.3 1.0% 0.2 0.0 0.2 2.3 0.0 0.5% 0. Lung Other Thoracic organs Bone Melanoma of Skin Other Skin Mesothelioma Kaposi sarcoma Connective.0% 11.4 0.8% 0.2 0.3 0.2 38.4 0.6 2.0 0.0% 0.1 ----42.3% 1.7 0.0 0.9% 10.0 0.3% 0.7% 0.3 0.3 0.0 0.5% 0.0% 0.0% 1.1 5.0 3.6 2.0% 8.0 9.0% 0.9% 0.5% 1.1% 0.1 0.0 3. Age Standardized and Crude Rates for All Cancer Cases among Saudi Males by Site and Administrative Region.3% 0.4 0.0 0.6% 0.0% 0.7 0.7% 5.0% 4.8 0.4 0.0 0.0% 0.0 0.0% 0.4% 0.0 1.4% 0.75 Site Lip Tongue Mouth Salivary glands Tonsil Other Oropharynx Nasopharynx Hypopharynx Pharynx unspecified.0 0.9 0.3 ----73.2% 0.8% 0.0 0.0 0.0% 0.0 0.6% 0.8% 8.0% 2.0% 0.3% 0.8 5.0 0.0% 0.5% 0.9% 4.0% 0.9 0.0% 0.0 0.0 0.0% 89.0 0.0% 5.8% 0.0 0.4 3.6 0.0% 0.6 1. Nervous system Thyroid Adrenal gland Other Endocrine Hodgkin disease Non-Hodgkin lymphoma Immunoproliferative dis.2 0.0 0.0% 0.0 0.0 3.1 43.6 0. Relative Frequencies.5% 0.4 0.2 1.Soft tissue Breast Penis Prostate Testis Other male genital Kidney Renal Pelvis Ureter Bladder Other Urinary organs Eye Brain.0 0.9% 0.0% 2.2 0.9 0.0 2.3 6.4 0.0% 3.0 0.3 0. 2006 .5 0.0 0.0% 93.2 3.0 1.0 0.0 0.5 0.4 0.6 1.4% 5.9 1.4 0.0% 3.3% 0.0 0.0 0.0 2.7% 0.0% 5.8 0.8 2.8% 0.3% 4.0 0.0 0.2 2.9 0.0 0.0 0.4 1.0 0.0 3.0 3.5 0.0 2.2 1.6% 0.7% 0.0% 1.3% 3.4 1.6% 0.8% 8.9 0.9 1.0 0.0% 0.0% 0.0 1.0% 1.0 0.0% 6.0 0.4 0.9 0.0 0.3% 8.3 0.0% 0.4 0.0 0.9% ----100.3 2.3 5.7% 0.0 2.0 0.6% 0.0 1.0 2.0 0.0% 6.4% 6. Bronchus.0 1.0 5.0 0.8% 0.4 0.0 0.0 2.0 0.0 0.5 0.9 0.2 3.0 3.3 ----34.8% 0.0 0.9 ----47.0% 1.7 0.1 0.3 0.2 0.0% 0.0 0.0% 0.0 2.6 ----37.0 2.3% 3.0 0.1 0.6 0.2 1.0 0.5 0.0 0.0 0.0% 0.2 0.9 0.3% 8.7% 1.0% 0.9 0.0 0.4 0.0 0.2 0.0 4.9% 2.0% 1.0% 0.0 0.6 1. C96 C88 C90 C91 C92-C94 C95 Other All Not C44 0 2 2 1 0 0 10 0 2 1 6 1 13 14 0 32 2 5 2 3 16 0 2 1 19 0 0 2 0 0 9 2 0 11 0 0 13 0 1 11 11 1 0 11 25 0 2 11 7 5 23 ----279 260 0.9% 1.5 0.3 48.0% 0.6% 3.0 1.3 0.0% 0.3 0.0 0.0 0.2% 0.6 3.4% 3.9 2.2 1.9% 0.9% 0.0 0.4 3.4 1.0 0.1% 1.0 0.9 0.4 3.6 4.0 2.0 0.3 1.7 1.9 0.2.0% 0.0% 0.0 0.6 1.9 ----51.5 0.3% 1.7% 0.6 3.4 1.7 0.0 1.1% 2.0% 0.9% 0.0 0.7 0.5 0.1% 5.0% 1.0 2.8 0.4 0.0% 0.7% 1.0 0.2 0.0 0.3% 0.2 4.2 0. Multiple Myeloma Lymphoid Leukemia Myeloid Leukemia Leukemia unspecified Other & unspecified All sites Total All sites but C44 ICD (10th) C00 C01-C02 C03-C06 C07-C08 C09 C10 C11 C12-C13 C14 C15 C16 C17 C18 C19-C20 C21 C22 C23-C24 C25 C30-C31 C32 C33-C34 C37-C38 C40-C41 C43 C44 C45 C46 C47.3 0.2 0.0 1. Larynx Trachea.3 0.2 1.6 0.5 2.4 1.5 0.0 1.5 0.4 1.4 0.3 0.6 0.5 0.1 0.4 0.5 0.2 0.7 0.5 All Ages % of Total Crude Rate ASR World Qassim Table 5.3 2.0 0.0 0.3 0.6% 6.7 0.0 1.2% ----100.5 1.0 0.0 0.0 0.5 0.0% 2. C49 C50 C60 C61 C62 C63 C64 C65 C66 C67 C68 C69 C70-C72 C73 C74 C75 C81 C82-C85.8 All Ages % of Total Crude Rate ASR World Madinah 1 0 0 2 0 0 0 0 0 1 7 1 7 8 0 0 0 1 1 3 0 0 1 1 8 0 0 3 0 0 2 0 0 3 0 0 1 0 1 3 6 0 0 5 3 0 1 4 2 0 3 ----79 71 1.0% 3.0% 5.0 0.4% 1.8% ----100.5 0.9 0.0% 95.6 0.3% 0. Oesophagus Stomach Small intestine Colon Rectum Anus Liver Gallbladder etc.9 0.3% 10.0% 1.8% 0.3 1.2 0.3% 5.4 35.6 3.9% 0.3 3.0% 0.0% 3.0 0.5 0.0 0.0 1.0% 3. sinuses etc.0 1.7% 0.0 0.9 0.4 30.5 0.2 0.0 0.0% 1.2 2.0 0.2% 0.7% 3.0% 0.0 0.0% 0.0 0.2 0.0% 0.0% 4.4% 0.6% 0.0% 3.3% 1.6 0.8% 7.0 1.4% 2.5 0.8 3.7 1.0 0.7% 0.4 1.4 0.3 0.1% 1.9 0.8 0.0 2.2 0.0 0.0 1.0 1.7 0.3 0.0 0.0 0. Pancreas Nose.0 0.3 2.0% 0.0 0.0 2.5 0.8 4.2 0.0% 0.0 0.2 0.0% 1.1 3.6% 0.0% 6.0 0.8 0.6 0.0 0.

0 0.8 7.76 Site Lip Tongue Mouth Salivary glands Tonsil Other Oropharynx Nasopharynx Hypopharynx Pharynx unspecified Oesophagus Stomach Small intestine Colon Rectum Anus Liver Gallbladder etc.0 3.0% 34.0 0.9 2 0.0 0 0.0 0.6 3 0.0% 0.9 0.3 2 0.0 1 6.6 0.5 0.7 4.0 3.0 4.0 0.0% 0.0% 0.4 3 0.0 0.4 4.5 --------100.1 0.0 0 0.0 1.2% 1. Nervous system Thyroid Adrenal gland Other Endocrine Hodgkin disease Non-Hodgkin lymphoma Immunoproliferative dis.9% 1.4 0.0 3.0 0 0.0% 0.3% 2.8 0 1.0% 0.8 ASR All Ages World 0.0% 0.0% 0.0% 0.6% 1.0% 0.5 2 0.0 0.9% 40.1 0 7.6 52 Northern Region % of Crude Total Rate 0.0 3.0 0.0 0 17.0 0.0% 0.8 2 0.0 9.7% 2.0 6 1.8% 1. Age Standardized and Crude Rates for All Cancer Cases among Saudi Males by Site and Administrative Region.1 0 0.6% 0.1 0.2% 1.0 4.6 5 1.4% 0.0% 0.0 0.0 0.0 0.0 0 2.9% 1.0 0.0% 0.9% 1.0 0.9 0 1.2 1.2 0.5 0.9 1 1.0% 0.0% 0.2 2.6% 0.5 1.0% 0.0 70 55.0 0 0.8 1.2 4 0.1 0.1 0.6 0.0% 3.2 0 0.0 0 0.1 0.0 0. 2006 ASR World 0.1 1.0 0 2.0% 0.8 3.2 1.0 2.7% 0.0 2.9% 0.0 1.0 0 0.0% 0.8 3.0 0.5% 3.8 0 0.5 2.6 0.8 0.0 0 4.3 3.2% 1.9 2 0.8% 2.0% 0.0 0 0.3 4 0.6 1.0% 0.0% 0.6% 0.0 0.0% 0.6% 0.0 0.3 2.0 0.0 3 0.1 1.5 0.6 138 62.0 0.0 9.7% 3.0% 0.6 4 0.9 0.2 1.4% 0.1 0.0 0 0.0 0.0 3.0% 0.0 0.5 65 Jouf Crude % of Rate Total 0.6 6.3 11 3.0 0.8 4 7.6 4.0 0 2.9 1 7.0% 0.4 1 0.2 0 1.3 2 0.8% 2.4% 0.4% 0.5 2 1.0 1 2.0 2.1 0.4% 0.1 4 1.0% 0.0 0.7% 2.3% 1.4 5 1. C96 C88 C90 C91 C92-C94 C95 Other All Not C44 0 0 0 0 0 0 2 1 0 1 2 0 4 0 0 15 1 1 0 0 2 0 0 0 6 1 0 1 0 0 2 0 0 2 0 0 2 0 2 1 0 1 0 4 8 0 0 2 2 0 0 ----63 57 All Ages Najran Crude % of Rate Total 0.8% 1. sinuses etc.0 0.6 2.0 0 0.0 1 1.3 1.7% 2.0% 0.6 1.0% 0.0 0 0.0 1.0 0.5 0.1 1.6 2 0.6 Table 5.0 0.7% 0.8 0.0 3.0 0.2 2.0 0.0% 0.0% 0.9% 0.0% 0.4% 0.0 0 0.0% 0.2 11.2% 1.0% 0.6 3.4 3.0 0.3% 1.8% 1.0 0 2.0 2.0 0.0 0 0.2 1.8 53 88.0 0.0% 0.1 3 --------95.0% 0.9 0.2 4.0% 0.0 0 1.8% 1.0% 0.9 0 2.0% 0.0 4.5% 3.7% 2.0 4 0.7% 2.0 1.0% 0.0% 0.3% 2.7 4.5 0.0% 0.0% 0.0 0 0.0% 0.7 6.3% 1.0% 0.8 0.0 0.0% 0.2 0.0 0.0 1.0% 0.2 0.8 5 0.0 0.0 4.0% 0.7 4 3.6 .0 0 0.0 4.8 5.9% 0.0 1.0 0.0% 0.9% 1.5% 3.5 0.0 0.1% 3.1 1 3.2 1 7.0% 0.0 1 2.0 4.0 10 4.0% 0.2% 1.0 0.0% 0.4% 4. Lung Other Thoracic organs Bone Melanoma of Skin Other Skin Mesothelioma Kaposi sarcoma Connective.1 2 0.6% 0.6 1.0 0.1 ASR All Ages World 0.7 --------100.0% 0.0 0 0.9 2 0.0 5.8 1.0 0 2.0% 0.7 0.0% 0.0% 0.5% 30.5 1 0.5 1.3 0.9 4 2.0 0.6 94.0 0.8 9 0.1 2 2.7% 0.0 0.0 0 1.2.0% 0.0 3.0 0.8 12 0.3% 1. Larynx Trachea.0% 0.0 0 1.6% 0.0% 0.0% 0.9% 0.8 0.0 2 1.0 92.8 7. Pancreas Nose.6 0.5 0.3% 1.5 3.6 0 1.0 2.4% 0.0% 0.8% 8.1 3.2 0.3 8.0 4 --------62.8 1 0.2% 0.8 7.4% 0.0 0.3 ----75.0 5 0.0 0.4% 0.0% 0.7 2 1.0 2 0.2 1.4% 0.0 2 4.2% 0.8 0.0% 42.0 3.8 5.7 2.0 1.3 4.1 3 0.6 5.0 1 3.5 0.2 3 0.6 3 4.8 0 1.0% 0.0% 0.0 --------100.6 0.0% 0.6 0.6 8 0.2 12.3 1 0.9% 0.7% 0.5 1.0% 0.0% 0.1 0 0.0% 0.2 1 0.9% 0.2% 0.0 0.9 130 Tabuk % of Crude Total Rate 0.1 0.0 0.5 0.0% 0.0% 0.0 0 4.0 0.0 2.3 1 8.0 5.0 0.3% 1.8 1. Multiple Myeloma Lymphoid Leukemia Myeloid Leukemia Leukemia unspecified Other & unspecified All sites Total All sites but C44 ICD (10th) C00 C01-C02 C03-C06 C07-C08 C09 C10 C11 C12-C13 C14 C15 C16 C17 C18 C19-C20 C21 C22 C23-C24 C25 C30-C31 C32 C33-C34 C37-C38 C40-C41 C43 C44 C45 C46 C47.9% 0.0 1.0% 42.0 0 0.0% 0.0 0 0.0% 0.0 0 0.9% 0.0 0.0% 0.5% 3.7 3.8 5.0% 0.4% 0.0 2.6 1.9% 1.7% 4.0 0 3.0 0 0.2% 1.6 0.3 3 0.8 74.0% 0.9 0.0 0.9 3 0.1 8.6% 0.0 3 0.7 3 2.0 0.0 1.0 23.0 0 6.6% 0.0 1.0 2 5.2% 1.9% 5.0% 43.0 3.7% 0.9 0.0 3.0 1 1.0 2.8 12.0 0 0.9% 0.0 0 3.3% 1.6 3 0.0 7.9 0 1.2 0 0.9 0.3% 1.0 3.8% 1.4% 0.0 0 0.3 5.8 1.2 0.0 0 1.0 3.0 0 1.5 2.0% 0.0 0 1.0 7.0% 0.0% 0.0 0.0 0 0.3 Number.4 0. C49 C50 C60 C61 C62 C63 C64 C65 C66 C67 C68 C69 C70-C72 C73 C74 C75 C81 C82-C85.7% 2.8 0.0 0 0.0% 0.9% 1.0 0 1.0% 0.5 0.6 8.7% 3.0% 0.0% 0.0% 0.0 2 0.0 0 0.0% 0.0 6.2 5.9% 0.0 1.3% 1.4% 0.0 0 1.4 8 0.0 0.2 1 3.3 0.4 3 1.0% 0.0 0 0.8 0.8 0.6 1.2 0.0 2 5.0% 0.0 1.6 2.0 2.9% 1.0% 0.0 1.0% 0.0% 0.1 90.0 ASR All Ages World 0.0 0.0 0 0.0 2 0.5 0.0 0 0.0% 0.0 0.0 1.0 0 1.0% 0.2% 3.0 1.6 0.0% 0.0 4.3 2 4.0 0 1.0 0 6.9 0 0.0% 0.0% 0.0 0.2% 1.0 0 2.0 1 5.0 0.0 1.2% 40. Bronchus.5% 2.4% 0.0 0.0 0.0 0.1% 41.9% 1.0 0 2.0 1.8 0.3 0.4% 0.6 2 1.0% 0.9 1.0 5.3% 4.4 98.0 0 2.0 6.0 0.0 0 0.6 0.0 1.3% 1.0 0 0.2% 1.0% 0.0 0 2.0 0.4 --------100.0 1.9% 1.0 4 0.5 0.1 9 0.0 1 0. Relative Frequencies.7 2 0.0 1 1.0 0.0% 0.0 4.9% 0.0 3 0.0 2.6 0.0 7.0 0.0 0 0.0% 0.2 1 0.Soft tissue Breast Penis Prostate Testis Other male genital Kidney Renal Pelvis Ureter Bladder Other Urinary organs Eye Brain.0% 0.4% 0.2 0.0 0.8 0.3 0.0 0.2 12 --------69.5 6 0.0 0 2.0% 0.6% 1.0% 0.0% 0.6 0.6 0.9% 1.5 3 0.0 1.

5 0.9% 0.9 3.0% 0.3% 5. Bronchus.7 6.6 44.4 2.9% 0.5 0.0% 2.4% 0.2% 6.8% 3.9% 0.4 0 7.9 0.4 2.1 0 0.3% 0 0.9% 0.3% 0.8% 0.0% 0.2% 5.1% 0.2% 0.2 0.5% 1.0% 1.1% 0.6 0.0% 0.0% 9.2% 0.2 0.8 0.2 1. Pancreas Nose.1% 0.5 ----95.8 0.6 0.6 3.8 All Ages % of Total Crude Rate ASR World Eastern Province Table 5.2 0.1 0.1 4.4 5.6 0.2% 3.5 0.3 0. Nervous system Thyroid Adrenal gland Other Endocrine Hodgkin disease Non-Hodgkin lymphoma Immunoproliferative dis.2 3.1 1.6 0 2.8 0 0 0 1.5 1.5 0 4.9% 5.1 0.1 0.0% 0.4% 0.2 0.2 0 0 0.8% ----100.4 0.8% 0.3 0 3.2 0 1.0% 3.4 0.1% 0 0.5 0 1.1 2 0.2% 1.3 0.1 2 0.1 1.9 0 0 0.6% 8.3 2 ----50 47.0% 0.2 1. C49 C50 C60 C61 C62 C63 C64 C65 C66 C67 C68 C69 C70-C72 C73 C74 C75 C81 C82-C85.0% 1.2% 5.1 0.4 5.8 0.4% 2.3% 0.2% 0.1 2.7% 0.2 3.1 2 10.2 3.8% 5.8 4.9% 3.3 0 1.9 0.1 0.8 1.5% 7.3 0 1.8 0.6 0.0% 1.0% 96. Multiple Myeloma Lymphoid Leukemia Myeloid Leukemia Leukemia unspecified Other & unspecified All sites Total All sites but C44 ICD (10th) C00 C01-C02 C03-C06 C07-C08 C09 C10 C11 C12-C13 C14 C15 C16 C17 C18 C19-C20 C21 C22 C23-C24 C25 C30-C31 C32 C33-C34 C37-C38 C40-C41 C43 C44 C45 C46 C47.5 0 2.6 ----45.2 0.7 2.1% 0.2 5.5 0 2.1% 1.5% 0.9 0.1 1.3 0.0% 0.6 0.3 0.0% 4.6% 0.1 0.0% 1.6% 0.6% 1.9 0.6% 1. sinuses etc.4 75 All Ages % of Total Crude Rate ASR World Makkah 0 3 3 2 0 0 20 2 0 6 20 1 32 32 1 37 7 15 1 7 51 3 6 1 17 3 4 9 3 0 35 12 1 22 1 0 24 0 5 24 19 5 0 29 61 0 7 30 19 5 36 ----621 604 0.0% 97.5% 0.2% 0.5% 6.1 6.2% 0.1 1.4% 7.3 0.0% 5.4 0.1 2.8% 3.2 1.1 49.2 0.8% 1.1 1.5% 0.4 1.7 2.0% 1.0% 0.1 2.3% 0.9% 0.1% 0.3 0 0.1 0.2 3.9 0.3 0 2.2% 3.1 4.2 0.4 1.7% 0.1 0 0.1 0.5 1.3 0.9% 5.3 0 0 1.5 0.9% 0.4 0.7 0.2 All Ages % of Total Crude Rate ASR World Riyadh 1 7 8 1 0 0 21 3 0 18 53 5 58 46 3 57 7 35 1 23 69 4 14 2 41 2 6 10 6 1 70 4 1 25 3 1 48 0 8 29 17 5 0 39 80 0 13 22 20 5 37 ----929 888 0.2% 2.9 0.6% 2.5 1.5 7.6 92. Larynx Trachea.7 0.1% 2.4 0.2% 0.1 0.0% 0.8% 3.3% 0.7 0.6 0.4 90.8 1 0.2 0.6 0.1 5.3 5.4% 0.2% 0.4 0.0% 95.3% 6.2% 3.8 7.8 0.5 0. C96 C88 C90 C91 C92-C94 C95 Other All Not C44 1 9 6 4 0 0 19 1 0 10 32 4 75 51 0 96 16 20 2 19 55 4 22 2 40 2 5 17 7 0 69 10 0 30 1 0 42 0 2 40 37 2 2 37 91 0 19 43 33 5 40 ----1022 982 0.2% 0.7% 0.8 0.0% 0.2 2.9 2.4 0.0% 3.0% 6.3 0.8 ----94.2 0.4 2.7 0.7 0.2 0.1% 4.9 2.2 3.4% 0.2 0.2 ----78.2 0.5 0.3 0.5 0 0.4 1.5% 3.2 0.5% 0.2.1% 0.4 1.5 0 0.5% 0.5% 1.1% 0.8 0.1 2.0% 1.2 0.9% 4.1% 0.6% 0.4 0.0% 1.1 0.7% 9.8 0.5% 4.7 0.3 3.6% 0.1 0 1.1 5.0% 3.7 0.9% 3.2% 0.9 2.1 0.9% 0.5% 0.5 0.4 0.2 0.1 0.3 0 2.1 0 0 1.2% 8.5 0.9% ----100.1 6.6 4.7 1.1 2.2 0 2.1 3. 2006 .5 0.1% 2.1 2.0% ----100.1 6.8 0.9 0.8 0.1 0 0.5 1.8 0 0.3 0.2% 3.5 0.4% 0. Relative Frequencies.4% 2.2% 5.3 0.8 2.1 1.4 2.1 0 1.2 2 ----51.1 0.77 Site Lip Tongue Mouth Salivary glands Tonsil Other Oropharynx Nasopharynx Hypopharynx Pharynx unspecified Oesophagus Stomach Small intestine Colon Rectum Anus Liver Gallbladder etc.8 0.6 0 0.4 0 0.2 0 11. Soft tissue Breast Penis Prostate Testis Other male genital Kidney Renal Pelvis Ureter Bladder Other Urinary organs Eye Brain.2 0.2 0 1 2.1% 5.9% 3. Lung Other Thoracic organs Bone Melanoma of Skin Other Skin Mesothelioma Kaposi sarcoma Connective.0% 2.8 0 1.3 4.2% 0.2 0.2 0.1 0.7% 0.5% 0.1 0 0 1.4 3.5% 0.9% 0.6 0 7.0% 0.1 4.5 2.1 1.2% 0.1 0.1% 0.4 0 2.1 4.5 0 0 2.4 Number.4% 1.4% 2.1% 8.1% 0.7 0.2 0.4 0.0% 0.0% 0.0% 4.0% 3.4 0.4 3.2 1.1 0.6 1.2% 1.1 2 1.4 0.7 0.2% 3.5 3.3 3 0.1 1.0% 4.4 0 0.1 0 4.1 0.1% 7.2% 4.2% 0.9 0.1 2.1 3.4% 1.8% 0.6 0.2 0.4% 0.6 0 0.6% 0.1 0.3 0.8% 0.1% 2.4% 0.1% 0.2 1.8% 0.1 6.2 0.8 1.7 0.5 0.1 0 0 2.2 1.6% 1.3 3.0% 1.4 0 2 7.6 0.7% 0. Age Standardized and Crude Rates for All Cancer Cases among Saudi Males by Site and Administrative Region.1 2.3% 0.2 3.2 0 4.

2 0.0 0.3 0.9 0.7 0.0 1.3 0.6 0.0% 3.0 0.0 0.5 0.6 0.0 0.0 0.0% ----100.0 0.6 0.0% 1.0 0.7 0.0 0.9 0.0% 2.7% 0.0 3.0 0.0% 0.4 2.0 1.0 0.0% 0.0 0.7 0.7 0.1 0.6 0.0 0.0 0.0 0. Larynx Trachea.0 1.0% 0.1 0.0 0.0% 4.6 0.7 0.0 0.0 0.9 2.0 0.4% 0.0% 2.0% 98.0% 0.0 1.1 0.7% 1.0 0.0% 0.2 0.4 0.1% 0.0 1.0% 0.7 0.3 0.1 2.6 0.0 0.0 0.6 1.0% 3.0% 0.6 0.0 0.0% 0.0 0.0% 2.4 0.0 0.5 18.0% 3.2 0.0 1.0 0.0% 0.0% 6.0% 94.9 0.0% 92.0% 1.8% 1.0% 0. Bronchus.0% 0.0 0.0 0.0% 0.6 0.6 1.3 0.0 0.0 0.0 2.2 0.1% 1.3% 0.0 0.0% 2.8 0.0% 0.0% 0.8% 0.3 0.9 0.0% 2.0 0.0 1.7% 4.2 0.8 0.0% 0.4 0.0 0.3 0.0% 4.5 0. Multiple Myeloma Lymphoid Leukemia Myeloid Leukemia Leukemia unspecified Other & unspecified All sites Total All sites but C44 ICD (10th) C00 C01-C02 C03-C06 C07-C08 C09 C10 C11 C12-C13 C14 C15 C16 C17 C18 C19-C20 C21 C22 C23-C24 C25 C30-C31 C32 C33-C34 C37-C38 C40-C41 C43 C44 C45 C46 C47.0 0.0% 5.7% 0.0% 2.6 0.1 1.0 0.0% 0.0% 1.0% ----100.5 0.0 1.0% 0.0% 6.0% 2.6 1.4% 5.0 0.5 2.4% 11.2 1.9 0.0 0.3% 0.7% 1.5% 4.5 4.0 0.0% 9.0 0.4 35.0% 0.8 0.0 0. Lung Other Thoracic organs Bone Melanoma of Skin Other Skin Mesothelioma Kaposi sarcoma Connective.0% 3.9 0. sinuses etc.0% 0.4 2.1% 0.7 0.0% 0.0 0.0 2.7 0.0 0.2 0.8 1.2 2.8 Jazan All Ages % of Total Crude Rate ASR World Table 5.0% 0.0 0.2 1.0% 2.9 0.4 0. Nervous system Thyroid Adrenal gland Other Endocrine Hodgkin disease Non-Hodgkin lymphoma Immunoproliferative dis.0 1.3 0.0% 0.6 1.0 0.0% 0.0% 2.0% 4.3 0.0 0.6 9.7 0.2 34.0% 0.7 0.1% 0.1 0.0% 0.0 0.6 1.0% 2.9 0.4 0.0 0.2 0.0% 0.0 0.7 29.0 0.0% 2.2 0.5 0.7 0.1% 0.5 0.0 1.6 0.0 1.0% 3.0 0.0 0. C49 C50 C51 C52 C53 C54 C55 C56 C57 C58 C64 C65 C66 C67 C68 C69 C70-C72 C73 C74 C75 C81 C82-C85.0% 0.4 0.0% 0.1 3.0 0.0 0.1 ----36.0% 0.0% 4.0% 0. C96 C88 C90 C91 C92-C94 C95 Other All Not C44 0 3 0 0 0 0 2 1 0 2 12 1 16 12 0 10 2 2 2 2 3 1 2 3 21 0 0 4 48 0 0 6 9 2 11 0 2 4 0 0 5 0 0 4 34 1 0 10 15 0 1 9 11 3 16 ----292 271 0.0 0.7 0.2 0.0% 0.1 0.6 0.0 0.0 0.4 0.0 0.0 0.0% 0.1 0.0% 2.6 1.2 26.78 Site Lip Tongue Mouth Salivary glands Tonsil Other Oropharynx Nasopharynx Hypopharynx Pharynx unspecified Oesophagus Stomach Small intestine Colon Rectum Anus Liver Gallbladder etc.4 3.0% 2.0% 0.0% 0.0% 1.3 1.0% 2.5 0.0 4.0 0.6 ----18.9 0.0 0.0% 3.0 1.0% 1.5 2.0 0.0 0.0 0.0 0.4% 0.0 0.4 0.1 0.9 0.2 0.4 0.1 0.7 0.0 0.0% 2.2 0.0 5.0 1.0 0.6 0.2 0.0 3.3 0.0 1.6 1.7 2.9 0.0% 2.7 0.6 0.4 Asir All Ages % of Total Crude Rate ASR World 0 0 0 0 1 0 1 1 0 0 1 0 1 3 0 1 2 1 0 0 0 0 0 0 3 0 1 0 7 0 0 1 3 0 2 0 2 1 0 0 1 0 0 1 6 0 0 1 3 0 0 3 1 0 2 ----50 47 0.0 0.0% 0.0% 1.4 0.0% 0.5 Baha All Ages % of Total Crude Rate ASR World 0 9 14 0 1 0 1 0 0 4 2 1 3 0 0 3 4 3 0 0 0 0 2 1 2 0 2 1 9 0 0 1 2 0 1 0 0 2 0 0 2 0 2 2 5 1 0 3 6 0 0 2 4 1 3 ----99 97 0.0% 1.1 ----28.0 0.2% 0.1% 0.0% 2.0% 0.2 0.0% 0.6 0.0% 1.0% 2.0 0.0% 2.0 0.1 Number.0 0.5 4.0 0.0 0.7% 0.4 5.9 0.0% 0.2 0.4 0.0 0.0 0.1 0.1 ----38.6 0.4 0.1% 3. 2006 .0 0.1 0.0 0.8 0.3 0.2 0.6 0. Pancreas Nose.0 0.0 0.0 0.4 0. Soft tissue Breast Vulva Vagina Cervix Uteri Corpus Uteri Uterus unspecified Ovary Other Female Genital Placenta Kidney Renal Pelvis Ureter Bladder Other Urinary organs Eye Brain.1 1.2 0.4 0.0 1.0 0.5 4.0% 0.6 0.0% 0.0 0.0% 1.0 1.0 0.0% 5.0 1.2 1.0 0.0% 2.0 0.0 0.2 0.0 0.0 0.0% 12.0% 2.0% 4.0% 0.0% 0.0% 0.0 0.3 0.0 0.6% 0.0% 6.0% 6.0 0.5 0.0% 0.4 0.3 0.0% 0.0 0.0% 4.5 0.5% ----100.1 1.4 0.4 1.0% 0.7 ----55.4% 16.6 0.7% 3.0% 2.0% 0.0% 0.0 1.0 0.6 3.0 0.0 0.6 0.0% 0.0 0.0% 2.2 2.0 0.4 0.2 1.4% 0.6 0.5 51.6 0.0 0.0% 0.0% 0.0 0.0% 2.0% 0.0% 14.3 0.9 0.0% 0.4 0.0 0.1 0.0 0.5 0.0 0.0% 0.1% 0.0 0.0% 0.0% 3.0 0.2 0.3% 5.0% 1.0 0.8 3.0% 0.0% 0.1% 0.0 0.0 0.1% 3.3% 3.1% 14.0 0.0% 0.0 0.3 1.7% 1.1 0.0% 2.2 0.3% 0.0 0.2 1.7% 0.0% 0.8 0.0% 9.3 0.7 0.6 0.0 0.0 0.0 0.0 0.5 6.7 0.6 0.0 0.0% 1.3 2.0% 6.0% 7.9 0.6 0.1 0.4 0.2 0.0% 4.0 0. Age Standardized and Crude Rates for All Cancer Cases Among Saudi Females by Site and Region.0 0.3.6 0.7 0.3 0.0 0. Relative Frequencies.6 0.0% 0.0% 1.3 1.6 2.7% 0.2 0.8% 0.0% 0.6 ----30.0% 6.0 1.3 0.0% 0.0 0.0 0.0 0.

7% 1.6 0.0 1.0% 0.7% 0.6% 6.0 0. Pancreas Nose.0 0.0 49.0% 0.8 1.0 0.0 0.2 ----81.4 0.7 2.6% 1.0% 7.0 0.4 0.0% 0.7% 1.6 0.2 0.0 0.1 0.4 0.0 0.0% 0.0 0.2% 0.0 1.0% 0.0 2.0 2.7% 4.0% 0.0% 0.4 0.4% 1.6% 5.9 0.3 1.5% 0.0 0.1% 3.3% 0.4 0.0% 0.3 0.0% 2.0% 1.7 1.0 0.0 1.2 1.0 0.4 0.1% 0. 2006 .0% 0.0 1.4 All Ages % of Total Crude Rate ASR World Madinah 1 0 0 0 0 0 5 0 0 0 3 0 2 3 0 1 3 0 0 0 0 0 1 0 4 0 0 1 27 0 0 1 2 1 1 0 1 2 0 0 0 0 0 6 9 1 0 4 1 0 0 0 1 0 3 ----84 80 1.0% 2.0% 95.2% 0.8 0.2% 32. C49 C50 C51 C52 C53 C54 C55 C56 C57 C58 C64 C65 C66 C67 C68 C69 C70-C72 C73 C74 C75 C81 C82-C85.0% 2.0% 0.2 0.8 0.8 0.0% 2.0% 0.8% 1.3% 2.0 0.3% 0.2 0.3 0.0% 3. Age Standardized and Crude Rates for All Cancer Cases Among Saudi Females by Site and Region.2 0.0 2.0 0.2 0.0% 1.8 0.2 0.4 1.0 0.0 0.2 0.0 0.4% 0.6 1.3% 3.8 0.6% 0.0% 2.0 0.3 0.1 56.0% 1.9 33.0 0.0 0.0 0.9 0.1 0.3% 1.7 0.0 0.7 0.1 0.4 11.0% 0.0 0.0 0.0 0.2 ----34.8% ----100.6% 0.0% 4.0% 0.0 2.2% 0.0% 4.79 Site Lip Tongue Mouth Salivary glands Tonsil Other Oropharynx Nasopharynx Hypopharynx Pharynx unspecified Oesophagus Stomach Small intestine Colon Rectum Anus Liver Gallbladder etc.4 3.0 0.0 0.3% 2.0 0.4 1.0 0.0% 0.5 0.0 0.0% 0.6% 0.0% 2.6 0.7 0.2 11.3 2.0 0.2 1.9 0.0% 5.0% 0.0% 0.2% 3.0 0.6 0.0 0.3% 0.8% 1.0 0.3 1.2 0.0% 0.0% 1.5 0.3% 0.6% 1.7 6.5 0.0 1.0 0.0 0.0 0.0% 0.3 0.7 0.6 0.2% 0.4 0.2 77.9 0.4 ----40.5% 0.4 0.7 2.0 0.0 0.7 0.0 0.0 0.3% 1.0 0.0% 0. C96 C88 C90 C91 C92-C94 C95 Other All Not C44 0 0 1 1 0 0 6 1 0 13 10 2 21 13 2 11 5 4 2 0 8 1 2 4 14 0 0 3 66 1 0 4 7 1 8 0 1 5 1 0 2 0 2 17 21 1 0 7 24 0 2 2 6 0 12 ----314 300 0.8% 0.2 0.0 0.0 0.0% 0.8 0.0 1.1% 10. sinuses etc.7 2.2% 0.7 0.0 0.0 0.7 0.5 0.3% 0.0% 0.6 16.3 0.3 0. Larynx Trachea.2 All Ages % of Total Crude Rate ASR World Table 5.0 1.3% 0.0 0.0% 0.4% 3.2% 2.2 0.0 0.3% 0.6% 0.0% 0.0 0.2 Number.9% 0.6% 0.0 0.3 0.0 1.0% 0.2 1.5 ----59.0 0.0 0.4 0.0 0.4% 0.0% 0.0 3.3 0.0 0.0 0.0 1.1 2.0 0.7 0.0% 0.2% 1.0 0.7% 15.3 0.0% 1.2 0.0 2.5 10.4% 6.2 0.0 0.0 2.2 1.9 0.9 0.0 0.0 3.0 3.0 1.0 0.0% 0.0 0.0 0.5 1.7 0.0 0.9% 0.0% 2.2 4.0 0.0 1.0 0.0% 1.3 0.4 0.2 0.2 0.0% 3.9 0.6% 1.6% 0.2 0.0% 0.7% 1.0% 1.7 4.0 ----52.9 0.0 0.0% 0.0 2.1% 0.5 3.6% 0.6% ----100.6 0.0 0.0 0.3 3.0 0.0 2.3 0.3 1.0% 1.3% 4.9 0.0 0.4 2.8 3.0 ----45.0 0.1 3.3 0.0 2.0% 1.7% 0.3% 0.0% 0.5% ----100.0 1.0 0.3 1.0 1.6 38.0 0.0 0.4 0.7 3.0 0.7 0.0% 95.0 0.0 0.0 0.0 0.4 0.0 0.6% 1.2 0.0 2.2% 7.0% 21.0 1.0% 0.2 0.8 0.1 0.0 0.3 16.5 5.0% 1.2 0. Relative Frequencies.0 0.0 0.4 0.6 0.0% 0.4% 2.6% 0.2% 0.0 0.0% 0.1 0.0 0.0% 0.4 1.2% 0.3% 0.3 14.2% 0.2 0.2% 0. Bronchus.3% 0.0 1.0 1.9% 0.0% 6.4 0.9 1.0 0.8 0.4 0.0% 0.0 1.0 3.2% 0.1 0.0 0.0 0.0 0.5 0.4 0.6% 0.6% 3.0 0.3 1.2 1.6% 1.2% 0.0 0. Multiple Myeloma Lymphoid Leukemia Myeloid Leukemia Leukemia unspecified Other & unspecified All sites Total All sites but C44 ICD (10th) C00 C01-C02 C03-C06 C07-C08 C09 C10 C11 C12-C13 C14 C15 C16 C17 C18 C19-C20 C21 C22 C23-C24 C25 C30-C31 C32 C33-C34 C37-C38 C40-C41 C43 C44 C45 C46 C47.0% 3.2% 2.7 0.0 1.0 0.0 0.0% 0.0 0.0 0.5% 0.6% 27.3% 2.3.9 0.0 0.0 1.3 0.3 0.1 0.7 3.8 0.7 0.2% 0.4 0.4 0.0 1.2 0.0% 4.0 0.3 1.0 0.0 0.7 0.0 0.0% 0.2% 0.0 2.2 0.5 All Ages % of Total Crude Rate ASR World Hail Qassim 0 0 1 2 0 0 2 0 0 4 6 0 10 3 0 3 3 2 0 0 4 1 3 0 8 0 0 1 47 0 0 0 4 0 5 0 2 1 0 0 0 0 0 3 26 1 0 11 4 0 4 4 2 0 6 ----173 165 0.9 1.0 0.2 0.7% 0.6 0.0% 0.0% 6.0% 4.0 0.0 0.0 2.9 0.0 0.0 1.0 2.7 43. Lung Other Thoracic organs Bone Melanoma of Skin Other Skin Mesothelioma Kaposi sarcoma Connective.2 0.4 0.0 0.2 0.6 7.6% 0.0% 3.0 0.0 0. Nervous system Thyroid Adrenal gland Other Endocrine Hodgkin disease Non-Hodgkin lymphoma Immunoproliferative dis.5 0.5 2.3% 0.0% 1.0 0.0 0.0 0.0% 95.0% 2.0 2.0% 0.0% 1.0% 1.2 0. Soft tissue Breast Vulva Vagina Cervix Uteri Corpus Uteri Uterus unspecified.3 0.2 0.2 0.8 0.8 0.0 1.2 0.0 0.5 0.5% 0.0% 0.2% 0.3 0.8 4.0 0.0 0.5% 0.0% 0.3 0.0 0.5% 1.4 0.0 4.1 6. Ovary Other Female Genital Placenta Kidney Renal Pelvis Ureter Bladder Other Urinary organs Eye Brain.2% 0.0 0.6% 0.0 0.7 1.2 0.

6 0.1 0 0.0% 0.1 0.7 3 1.8 0.0 4 0.0 1 0.0 0 4.7% 0.0% 0.0 0 0.0 0 0.4% 1.5 3 0.0 6.0 1.3 38 79.0% 0.0 0 0.9% 0.0 0.4% 1.8 0 4.0 0.0 0 0.3 0.0% 0.6 130 Tabuk % of Crude Total Rate 0.5 10 0.9% 0.0% 0.7 0.5 1 0.3 0.7 0.3 5.0% 0.0 0 1.3 2.7% 0.0 0.0 0 0.8 1 1.6% 42.1 0 0.7 0 0.1 1 0.0% 0.5 13.0% 0. Pancreas Nose.0 0.0 54 38.0% 0.7% 0.0 0.2% 0.0 2.0 0.6 0.0% 0.1 0 1.7% 0.0 4 0.5 92.2 8 0.4% 1.0 0.0 0.0% 0.0 4 0.0% 0.0 1.6 .0% 0.0 0.0% 0.7% 0.0 0 0.8 17 0.0 0.0 1.7% 0.0 0.0% 0.0% 0.7% 0.0 0.8 0 0.0 1 0.0 0.0 0.0% 0.2% 0.0% 0.6% 1.2% 1.2 0.4% 2.3% 3.6 0 0.0% 0.4% 2.8 0.3 0.8 4 5.0% 0.0% 0.0% 0.6 3.0 0 4.6 0.0% 24.0 1.0 50 Jouf % of Crude Total Rate 0.6 0.0 0 0.0% 0.3 2.8 0.0 2.6 0 0.0 2.0% 0.0 8.5 3 1.4% 1.3 ASR All Ages World 1.4 0.0 0 0.6 1.0 0.0 0 4.0 0 0.0 0.0 5.0 0.0 0.2% 0.5% 0.0% 0.0 0 0.0 0.5% 0.0 0.0% 0.0 1 0. C49 C50 C51 C52 C53 C54 C55 C56 C57 C58 C64 C65 C66 C67 C68 C69 C70-C72 C73 C74 C75 C81 C82-C85.0 0 2.4 2 1.0 0 2.9% 0.2 0 0.2% 0.7% 0.0 0.1% 2.0 1 9.2 0 1.7 5.0 2.0% 0.0 0 0.0 0.0 0.0% 0.0% 0.1 ASR All Ages World 0.0 2.0% 0.0 0 0.0% 0.4% 1.9% 0.0 0 5.0% 0. Soft tissue Breast Vulva Vagina Cervix Uteri Corpus Uteri Uterus unspecified.2 --------100.0 1.7 2.3 0.0 0 1.0 0 1.0% 0.9% 0.0% 0.0 0.0 2 0.0 1 0.0% 0.6 0.3 95.6 0.2% 0.0 12.5 0.7 0.0 1 0.0 2.5 2 0.0 0.0 0.3 0.0% 0.3 0 0.0% 0.3 5.4 0 1.3 0 1.0 0.7% 0. Lung Other Thoracic organs Bone Melanoma of Skin Other Skin Mesothelioma Kaposi sarcoma Connective.6 --------100.1 0.0 0.0 0.0 1 0.8 0 0.5 1 1.4% 1.0 2 0.4 0.1 0.8 8.0 0.0% 0.0 0.0% 0.0 0.0% 0.7% 1.0% 0.0 1 0.0% 0.0 1.0 --------100.0 1 0.0 0 0.4 0.7 6 1.0% 0.0 1 1.0 0.0% 0.6% 31.0 0.0 4.0 0 0.7% 1.4% 2.8 2 0.3 0.0 0 5.0% 0.0 4.0% 0.0 0.0 1 1.0 0 0.0 2.4 136 61.9% 1.0 3.3 0.7% 1.0 0.0 0.7 0.0 4.8 30 0.0% 0.3 4.5 4.1 1 0.9% 1.0% 0.6% 28.0% 0.0 0 0.0 0 1.0% 0.0 0 0.0 0.0% 0.7 0.0 1.2 0.1 0.0 0.4% 2.7% 0.4% 1.2 0 16.0 1 0.1 3.0 6 0.5 2.3 4.7 0.0 0.4% 2.6 1.0 2.0% 0.4% 2.0% 0.0% 0.4 0 0.0 0.0 1 1.4% 1.5 0.1% 2.1 0.0 2. C96 C88 C90 C91 C92-C94 C95 Other All Not C44 0 0 0 0 0 0 0 0 0 0 2 0 2 1 0 3 1 2 0 0 0 0 0 0 0 0 0 1 6 0 0 4 1 1 3 0 1 2 1 0 0 0 0 3 2 0 0 1 2 0 1 1 2 0 2 ----45 45 All Ages Najran % of Crude Total Rate 0.0 0.0% 0.0 2 0.0 0.5 2.8 0.5 0.0 18.0% 0.0 0 0.0 13.1 3.3 0.0 1.0 2.6 1 0.7% 0.2 94.0 1 3.0 0.0 3.2% 1.7% 0.0% 0.0 0.1 0 3.3% 3.5 4.0 0.9% 0.8 0 0.0% 33.0 0 0.0 0.7% 0.2% 0.9% 5.2 2 0.1 0 0.5 0 0.0% 0.0% 24.4 0 1.0 0 0.0 0.0% 0.7% 0.0 0.8 0.0 2 0.0 0.0 0. Ovary Other Female Genital Placenta Kidney Renal Pelvis Ureter Bladder Other Urinary organs Eye Brain.0 5.0% 0.0 1 1.0 3.1 ASR All Ages World 0.6 2.0 2 4.9% 0.9% 0.0 0.0 0.3 0 0.0 0 0.4% 1.4 36 Table 5.0% 0.0% 0.3 Number.3 2 --------38.5% 0.0% 0.5% 0.0 0.0% 0.1 2 0.1 2 0.0% 0.0 2.8 5.0 0 1.0 0.9% 0.0 0 3.0 0 0.2 1.0 0.0% 0.5% 0.6 0 3.8 0.7% 1.4% 1.0 0.0 1.2% 0.0 0.0 0 1.6 0 1.7% 0.0% 0.9 1 0.0% 0.6 0.8 0.0 1.0 3 2.0 0.0% 0.0 1.4% 1.0% 0.4 7 0.0% 0.5 6.1 --------100.2 4.0 0 0.0 1 0.0 0 3.0 0 2.0 7.4% 1.0 0.0 5.0 0.0 1 2.0% 0.0 1 5.0% 30.2 0.6 0 0.9 1.0 0.0 2.0 1.8 0 0.0 0.6 1 0.0% 0.0 1.0 0 1.6 4.5% 0.6 2.0% 0.4% 1.0 4.0 3.2 0.0% 0.8 5 0.0 0 0.2 0.3 1.0 2 0.0 2.0 1.0 1 0.0 0.6 0.0 0.8 5.4 6 2.4 1 2.0 1.6 2.0 0 0.0% 0.2 9.0% 0.1 0.5 0.0% 0.0 3.0 2 2.0 0 1.0% 0.3 22.1 0.9% 1.0 0.0 1.0% 0.6 ASR World 0.7% 0.5 1.5 3 0.8 5.0 0.0% 0.0% 0.5 0.0 1 1.7% 0.7% 1.0 5.0% 0.9 5 0.0 0 2.6 0.2 0.0 3.0% 0.0 0.0 2 0.0% 0.0 1.4% 1.0% 0.0 0.8 0 2.6 0.0 0.0 0.0% 0.0 0.7% 0.0 0.5% 5.6 1 0.7% 0. 2006 Northern Region % of Crude Total Rate 0.6 60.0 2.2% 0.0 1.0 0 0.9 2 --------83.0 0.0 0.0 0 0.0 0 1.0% 0.5 4.3 4. Age Standardized and Crude Rates for All Cancer Cases Among Saudi Females by Site and Region.0 0 0.0 18.0 0.0% 0.7% 1.6 0.5% 0.0% 0.0% 0.2 0.9% 2.6 3.6 4.6 0.0 0.7 0.0% 0. sinuses etc.0 0 3.0 0.0% 44.2% 0.0 0.1% 9.8 2 0.1 100.9% 0.0 0.0 1 0.0% 0.0 6 --------66.9% 2.4 2.0 0.0 0.8 0.0 0 0.5 2 0.7% 1.0% 0.0% 0.0 0.7% 1.1 2.1 2.0 2.0% 0.8 0 0.2% 0.6 0.4 1 2.8 5. Multiple Myeloma Lymphoid Leukemia Myeloid Leukemia Leukemia unspecified Other & unspecified All sites Total All sites but C44 ICD (10th) C00 C01-C02 C03-C06 C07-C08 C09 C10 C11 C12-C13 C14 C15 C16 C17 C18 C19-C20 C21 C22 C23-C24 C25 C30-C31 C32 C33-C34 C37-C38 C40-C41 C43 C44 C45 C46 C47.7% 1.5% 6.7 7 0.0 0.0% 0.0% 0.0% 0.0 0 5.6 0.0 0.7 2 0.0 0.0 3.7% 0.9% 0.0 4.0% 0.0% 0.0 1.7% 0.7 0.0 7.0 0.3 0.5 1 0.0 0.6 0.8 2 0.4 2 1.9% 0.0% 0.6 3.0 0 0.0% 0.1 2.6 1 8.9 ----63.0% 0. Bronchus.0 6. Nervous system Thyroid Adrenal gland Other Endocrine Hodgkin disease Non-Hodgkin lymphoma Immunoproliferative dis.0 1 2.8 2.80 Site Lip Tongue Mouth Salivary glands Tonsil Other Oropharynx Nasopharynx Hypopharynx Pharynx unspecified Oesophagus Stomach Small intestine Colon Rectum Anus Liver Gallbladder etc.0% 0.0 0 0.5% 0.0 0.0% 0.0% 0.0 0.0 0 0.0 0.6 2.7% 0.7% 1.7% 0.0% 0.3 4 0.6 0 2.7 0.0% 0.0% 0.0% 0.5 4.2 1. Larynx Trachea.0 4.4% 2.2 0.2 0.0 1 0.5 2 0.0% 0.0 1.5 1.0% 0.3.0 0.7% 1.1 0 0.0 2. Relative Frequencies.0% 0.0% 0.0 0.0 0 1.0% 0.7% 1.7% 0.0% 0.0 0.

7 0.7% 1.5 0.4% 0.1 0.1 0. C49 C50 C51 C52 C53 C54 C55 C56 C57 C58 C64 C65 C66 C67 C68 C69 C70-C72 C73 C74 C75 C81 C82-C85.0% 97.0 0.5 0.0 2.1 1.1 1. 2006 .0% 0.4 0.1 0.8 1.8% 3.1 0.2 0.5 0.8 0.1 0.0 2.9 99.6 0.3 0.1% 5.1% 3.4% 0.1 0.4% 0.0 0.2% 2.1 2.2 3.1 0.3 0.3 0.2 5.3 0.1% 0.6 0.5 0.6 0.3 5.0 1.6 0.0% 0.8 4.0 0.2 2.1 2.1 1.0% 0.2 0.1 0.4 1.2 0.8% 0.0% 0.9 59.0% 1.0 0. Pancreas Nose.3 7.0 0.1% 0.2 2.2 0.5% ----100.0 0.2% 2.0 0.9 0.0% 0.1 1.0 2.5 0.3 All Ages % of Total Crude Rate ASR World Riyadh 2 8 5 2 0 0 11 2 1 16 28 3 56 32 2 19 13 17 1 4 22 3 12 1 23 0 1 9 240 3 0 27 45 12 28 5 2 17 0 1 10 0 8 21 83 1 1 13 51 0 4 14 23 3 53 ----958 935 0.3% 2.1 1.3% 3.6 18.4 0.8% 0.7 0.6% 0.8% 0.4% 0.3 5.3% 0.2 0.6 0.0 0.0 1.6% 0.1 0.2 0.4 0.0% 0.2 2.1 0.2 0.4 1.8% 0.6 0.0% 0.0 1.2% 1.5 0.6 1.1 0.1 0.7 0.2 0.4 89.8 ----76.0% 1.3% 0.2% 0.4% 0.3% 5.7 2.0 0.1 0.4 0.3% 0.0 2.0% 23.3% 2.1% 5.1% 0.4% 1.0 0.3% 5.8 3.0 2.3 0.3 0.6 2.2 3.0 2.2 0.3% 2.8 3.2 2.0 2.0 0.1 0.6 1.3% 2.3% 0. Larynx Trachea.4 Number.2 0.0 4.1% 2.0 0.3% 2.2 1.0 0.3 3.5 1.0% 0.5% 0.6 0.3% 1.8 All Ages % of Total Crude Rate ASR World Makkah 0 1 3 1 0 0 4 2 0 12 13 1 39 23 1 25 16 8 2 2 14 1 3 1 17 2 5 5 204 0 0 13 24 2 27 0 3 12 2 0 6 0 2 14 73 1 4 29 39 0 5 16 21 0 18 ----716 699 0.7 0.9 1.3 0.0 0.4 0.6 14.2 1.3 0.1 0.2% 8.2 3.8 0.1 0.6% 0.8% 4.2 2.3% 0.2 0.2% 0.0 0.9 ----51.2 4.0 0.1 1.6 0.0 0.2 4.4 0.0% 0.3 1.2 0.9 0.1% 2.1% 1.7 0.2 1.0 0.8 All Ages % of Total Crude Rate ASR World Eastern Province Table 5.0 0.2% 0.4 3.2 0.2 0.4 0.0 0.1 0.0 0. Age Standardized and Crude Rates for All Cancer Cases Among Saudi Females by Site and Region.4% 0.5 1.5 0.0 0.0 0.0 0.0% 0.4% 3.1 0.0 0.0% 0.9 1.9 0.0 0.0 0.5% 0. Soft tissue Breast Vulva Vagina Cervix Uteri Corpus Uteri Uterus unspecified Ovary Other Female Genital Placenta Kidney Renal Pelvis Ureter Bladder Other Urinary organs Eye Brain.8% 0.2 1.4% 1.0 0.9 0.5% 0.0% 4.4 0.1 1.5 0.6 ----60.0% 10.8 9.5% 0.6 0. C96 C88 C90 C91 C92-C94 C95 Other All Not C44 0 4 6 5 0 0 9 3 0 9 29 4 65 51 4 43 19 23 2 1 23 2 6 2 30 1 4 11 275 0 0 16 36 3 37 3 3 28 0 1 13 0 3 25 141 0 0 34 75 0 7 32 32 0 50 ----1170 1140 0.6% 4.4% 0.1 4.8 1.2% 0.2 0.3 7.2 0.1 1.1% 1.3 0.4 0.3% 3.3% 0.0 0.7% 2.0 0.4% 0.1% 0.6 0.3% 0.0 1.6% 2.9% 25.0% 0.8 0.0% 2.5% 0.5% 0.3 25.5 12.6 0.2 0.0 0.0% 0.4 15.8 0.5 3.7% 0.1% 1.9 0.0 1.0% 1.7 0.1 0.4% 0.4 0.8% 3.0 0.1 5.7 0.1 0.8 0.9 6.2 1.0 0.2 0.0 1.8 0.7 0.0 0.2 0.1 0.0 1.9 0.1% 0.1 0.8 3.8 1.2 1.0 0.0% 2.0 0.9 0.0% 0.1 1. Bronchus.3% 0.5 2.4 0.0 0.4% 3.1% 12.7 0.3% 0.0 2.4% 0.1% 0.2 0.2 0.0% 0.7 1.3 0.0 0.8 0.3 2.4% 0.7 2.0% 0.1 4.3.0% 0.7% 0.6 0.3% 0.3 0.8% 2.2 0.1 0.2 1.1% 0.3 2.2% 0. Nervous system Thyroid Adrenal gland Other Endocrine Hodgkin disease Non-Hodgkin lymphoma Immunoproliferative dis.0 0.4 6.0 0.5 0.2% 1.6 0. Multiple Myeloma Lymphoid Leukemia Myeloid Leukemia Leukemia unspecified Other & unspecified All sites Total All sites but C44 ICD (10th) C00 C01-C02 C03-C06 C07-C08 C09 C10 C11 C12-C13 C14 C15 C16 C17 C18 C19-C20 C21 C22 C23-C24 C25 C30-C31 C32 C33-C34 C37-C38 C40-C41 C43 C44 C45 C46 C47.9 1.6% 2.9 1.5 0.1 0.7% 28.1 0.0 0.7% 0.7 0.9% 6.9 0.0 0.1% 1.0% 0.2 0.4% 2.9 1.9% 0.0 1.1 0.4 0.0% 0.2 0.1% 0.7% 2.2 5.2 0.5 0.1 1.4% 1.81 Site Lip Tongue Mouth Salivary glands Tonsil Other Oropharynx Nasopharynx Hypopharynx Pharynx unspecified Oesophagus Stomach Small intestine Colon Rectum Anus Liver Gallbladder etc.0 1.1% 0.3 0.0 1. Lung Other Thoracic organs Bone Melanoma of Skin Other Skin Mesothelioma Kaposi sarcoma Connective.2 3.8 1.1 3.7 50.4 1. sinuses etc.3% 5.0 0.2% 0.5 4.8 0.0 1.0 1.3% 0.8% 2.1 0.2 1.2 0.4 1.1 0.1 0.4 ----55.7% 0.0% 0.2 0.3% 0.6% 0.5 0.0% 2.0 0.0% 0.1% 0.0 0.2% 0.5% 2.3% 3.4 0.2 0.0 0.4 2.3 0.5 2.8% 0.1% 0.0 0.6 0.8 0.1 0.1% 0.2% 0.0% 0.5 0.6% 4.5% 0.7% 1.2 1.5% 2.0% 97.8 0. Relative Frequencies.5 0.9% 0.3 0.2 0.2 0.0 1.0% 1.8 22.1% 2.1 0.7% 2.9 0.2 2.4 0.5 0.0% 97.1 0.0% 0.2% 2.0 0.8% 0.0% 0.1 1.0% 0.0 0.0 0.3 0.2 2.3% 1.2 1.3 0.4% 5.0 53.4% 0.7 ----92.0 0.0% 1.5% ----100.5 0.2 0.3 0.2 0.3 0.0% 0.7 0.9 74.1 2.3% ----100.2 1.8 ----101.0 0.4 0.5 0.1% 0.7% 1.0% 0.9% 0.9 5.0 2.0 0.

82

Site

Lip
Tongue
Mouth
Salivary glands
Tonsil
Other Oropharynx
Nasopharynx
Hypopharynx
Pharynx unspecified.
Oesophagus
Stomach
Small intestine
Colon
Rectum
Anus
Liver
Gallbladder etc.
Pancreas
Nose, sinuses etc.
Larynx
Trachea, Bronchus, Lung
Other Thoracic organs
Bone
Melanoma of Skin
Other Skin
Mesothelioma
Kaposi sarcoma
Connective, Soft tissue
Breast
Penis
Prostate
Testis
Other male genital
Kidney
Renal Pelvis
Ureter
Bladder
Other Urinary organs
Eye
Brain, Nervous system
Thyroid
Adrenal gland
Other Endocrine
Hodgkin disease
Non-Hodgkin lymphoma
Immunoproliferative dis.
Multiple Myeloma
Lymphoid Leukemia
Myeloid Leukemia
Leukemia unspecified
Other & unspecified
All sites Total
All sites but C44

ICD (10th)

C00
C01-C02
C03-C06
C07-C08
C09
C10
C11
C12-C13
C14
C15
C16
C17
C18
C19-C20
C21
C22
C23-C24
C25
C30-C31
C32
C33-C34
C37-C38
C40-C41
C43
C44
C45
C46
C47; C49
C50
C60
C61
C62
C63
C64
C65
C66
C67
C68
C69
C70-C72
C73
C74
C75
C81
C82-C85; C96
C88
C90
C91
C92-C94
C95
Other
All
Not C44

All
Ages
4
5
7
5
1
1
21
5
0
13
64
7
87
63
8
57
14
21
3
23
90
6
13
7
88
7
5
30
8
0
86
18
0
29
4
1
66
0
6
30
40
3
1
28
104
0
18
29
29
9
70
1234
1146

Age
Unk
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1
0
0
0
0
0
1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2
2
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1
0
0
0
0
0
0
0
0
0
0
0
2
0
0
0
1
0
3
0
0
0
0
4
4
0
0
0
0
4
0
0
8
3
0
1
31
31

0-4
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1
1
0
0
1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
3
0
1
0
2
2
0
0
5
0
0
0
16
15

0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
3
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2
0
1
1
0
0
0
0
1
2
1
0
11
11

5-9 10-14

Table 5.4.1 Age Distribution of Cancer Cases among non-Saudi Males, 2006

0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
3
0
0
0
0
2
0
0
0
2
0
0
0
0
0
0
0
0
0
0
0
2
3
0
0
2
0
0
0
14
14

15-19
0
0
0
0
0
0
1
0
0
0
1
0
2
0
0
1
0
0
0
0
0
0
3
0
1
0
1
4
0
0
0
2
0
0
0
0
0
0
0
0
2
0
0
5
4
0
0
4
0
0
0
31
30

20-24
0
0
0
2
0
0
0
0
0
0
0
0
1
2
0
0
0
0
0
1
0
1
1
0
3
0
0
3
0
0
0
2
0
0
0
0
1
0
1
2
3
1
0
4
6
0
0
1
4
1
4
44
41

25-29
0
0
0
0
0
0
3
0
0
1
1
0
4
6
0
1
0
1
1
1
3
1
0
1
4
0
1
2
1
0
0
2
0
0
0
0
2
0
0
2
4
0
0
1
6
0
0
0
3
1
6
59
55

30-34
0
1
0
0
0
0
1
1
0
0
3
1
10
5
1
0
0
0
0
0
2
2
0
1
7
1
0
3
1
0
0
3
0
1
0
0
3
0
0
2
7
0
0
2
11
0
1
0
3
1
8
82
75

35-39
0
2
2
2
0
0
3
0
0
2
8
2
11
8
0
5
2
3
0
2
8
0
2
1
6
0
0
3
0
0
1
1
0
6
1
0
7
0
0
3
5
0
0
5
12
0
1
2
2
0
3
121
115

40-44
0
2
2
0
0
0
7
1
0
3
9
0
11
8
0
9
0
3
1
5
10
0
1
0
14
3
0
1
2
0
3
1
0
1
0
1
12
0
0
2
7
0
0
3
12
0
4
2
6
1
9
156
142

45-49
0
0
2
0
1
0
0
0
0
0
12
2
15
10
4
10
3
2
1
1
15
0
0
2
17
1
0
4
0
0
14
2
0
7
1
0
6
0
0
5
6
0
0
1
11
0
4
0
3
2
13
177
160

50-54
3
0
1
0
0
1
5
1
0
1
8
0
11
6
2
6
1
2
0
5
11
1
0
0
11
0
2
2
1
0
23
0
0
2
0
0
9
0
0
1
5
0
0
3
13
0
4
1
1
1
7
151
140

55-59
1
0
0
1
0
0
0
2
0
2
10
0
10
9
1
8
2
2
0
2
16
0
0
0
10
2
0
2
2
0
17
2
0
7
0
0
8
0
1
1
0
0
0
0
11
0
3
1
1
0
3
137
127

60-64
0
0
0
0
0
0
1
0
0
1
4
1
3
5
0
8
1
3
0
4
12
0
0
1
5
0
0
0
0
0
9
0
0
1
0
0
7
0
0
0
1
0
0
0
3
0
1
0
0
0
2
73
68

65-69
0
0
0
0
0
0
0
0
0
1
3
0
4
3
0
5
3
2
0
1
7
0
0
0
5
0
0
1
0
0
7
0
0
0
1
0
5
0
0
3
0
0
0
0
1
0
0
2
0
0
7
61
56

70-74
0
0
0
0
0
0
0
0
0
2
5
1
5
1
0
3
2
3
0
1
5
0
0
1
4
0
1
1
1
0
11
0
0
1
1
0
5
0
0
0
0
0
0
0
5
0
0
0
1
1
7
68
64

75+

% of
Total
0.3%
0.4%
0.6%
0.4%
0.1%
0.1%
1.7%
0.4%
0.0%
1.1%
5.2%
0.6%
7.1%
5.1%
0.6%
4.6%
1.1%
1.7%
0.2%
1.9%
7.3%
0.5%
1.1%
0.6%
7.1%
0.6%
0.4%
2.4%
0.6%
0.0%
7.0%
1.5%
0.0%
2.4%
0.3%
0.1%
5.3%
0.0%
0.5%
2.4%
3.2%
0.2%
0.1%
2.3%
8.4%
0.0%
1.5%
2.4%
2.4%
0.7%
5.7%
100.0%
92.9%

83

Site

Lip
Tongue
Mouth
Salivary glands
Tonsil
Other Oropharynx
Nasopharynx
Hypopharynx
Pharynx unspecified
Oesophagus
Stomach
Small intestine
Colon
Rectum
Anus
Liver
Gallbladder etc.
Pancreas
Nose, sinuses etc.
Larynx
Trachea,Bronchus,Lung
Other Thoracic organs
Bone
Melanoma of Skin
Other Skin
Mesothelioma
Kaposi sarcoma
Connective, Soft tissue
Breast
Vulva
Vagina
Cervix Uteri
Corpus Uteri
Uterus unspecified
Ovary
Other Female Genital
Placenta
Kidney
Renal Pelvis
Ureter
Bladder
Other Urinary organs
Eye
Brain, Nervous system
Thyroid
Adrenal gland
Other Endocrine
Hodgkin disease
Non-Hodgkin lymphoma
Immunoproliferative dis.
Multiple Myeloma
Lymphoid Leukemia
Myeloid Leukemia
Leukemia unspecified
Other & unspecified
All sites Total
All sites but C44

ICD (10th)

C00
C01-C02
C03-C06
C07-C08
C09
C10
C11
C12-C13
C14
C15
C16
C17
C18
C19-C20
C21
C22
C23-C24
C25
C30-C31
C32
C33-C34
C37-C38
C40-C41
C43
C44
C45
C46
C47; C49
C50
C51
C52
C53
C54
C55
C56
C57
C58
C64
C65
C66
C67
C68
C69
C70-C72
C73
C74
C75
C81
C82-C85; C96
C88
C90
C91
C92-C94
C95
Other
All
Not C44

All
Ages
1
6
1
10
0
1
7
1
0
16
20
1
48
34
4
14
9
9
1
4
29
4
7
2
41
0
1
12
382
2
1
46
45
10
37
3
2
23
0
0
6
0
4
11
56
3
0
16
49
0
8
19
19
10
55
1090
1049

Age
Unk
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
3
0
0
0
0
0
0
0
0
0
3
0
0
0
0
3
2
0
2
0
0
3
0
0
9
1
3
0
29
29

0-4
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1
0
0
0
0
0
0
0
0
0
0
0
1
0
0
2
0
0
0
0
0
2
0
1
0
1
0
0
0
2
1
1
0
12
12

5-9
0
0
1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1
0
0
0
0
1
0
0
0
1
0
1
0
7
7

10-14

Table 5.4.2 Age Distribution of Cancer Cases among non-Saudi Females, 2006

0
0
0
0
0
0
1
0
0
0
1
0
0
0
0
0
0
1
0
0
0
0
2
0
1
0
0
2
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2
0
0
2
2
0
0
2
2
0
1
19
18

15-19
0
0
0
0
0
0
1
0
0
0
1
0
0
2
1
0
0
0
0
0
0
0
1
0
0
0
0
0
3
0
0
0
1
0
0
0
0
0
0
0
0
0
0
0
8
0
0
3
3
0
0
0
3
1
1
29
29

20-24
0
0
0
2
0
0
0
0
0
0
0
0
1
4
0
0
0
0
0
0
0
1
0
0
0
0
0
0
13
0
0
1
2
0
0
0
0
1
0
0
0
0
0
2
8
0
0
2
2
0
0
2
1
0
3
45
45

25-29
0
0
0
0
0
0
2
0
0
0
2
0
4
1
0
1
1
0
0
0
5
0
0
1
2
0
1
2
43
0
0
6
4
0
5
0
0
0
0
0
1
0
0
0
5
0
0
1
3
0
2
1
2
1
6
102
100

30-34
0
1
0
2
0
0
0
0
0
1
2
0
3
8
0
1
0
1
1
1
1
0
1
0
4
0
0
0
72
0
0
6
1
0
4
0
0
3
0
0
2
0
0
0
8
0
0
2
8
0
0
0
1
0
4
138
134

35-39
0
1
0
4
0
0
1
0
0
0
1
0
7
3
0
0
1
0
0
0
6
2
0
0
1
0
0
1
68
1
0
6
6
2
9
0
1
3
0
0
0
0
0
1
8
0
0
1
2
0
1
0
4
0
4
145
144

40-44
0
0
0
1
0
0
1
0
0
4
2
0
6
2
1
1
1
3
0
1
2
0
0
0
5
0
0
0
74
0
0
11
6
1
4
1
0
2
0
0
1
0
0
0
9
0
0
0
3
0
1
0
2
0
8
153
148

45-49
0
1
0
0
0
0
0
0
0
4
5
1
4
4
0
1
2
0
0
0
1
0
0
0
5
0
0
2
49
0
1
5
8
3
5
0
1
2
0
0
0
0
0
1
4
0
0
1
5
0
0
0
0
1
9
125
120

50-54
1
1
0
0
0
1
0
0
0
1
1
0
6
4
2
4
1
2
0
1
3
0
0
0
9
0
0
0
24
0
0
5
6
2
1
1
0
2
0
0
1
0
0
1
0
0
0
1
4
0
1
1
1
0
7
95
86

55-59
0
0
0
1
0
0
0
0
0
3
0
0
3
4
0
2
0
0
0
0
5
1
0
1
9
0
0
0
14
0
0
3
3
0
3
0
0
4
0
0
0
0
0
1
2
0
0
0
6
0
1
0
0
1
5
72
63

60-64
0
2
0
0
0
0
1
0
0
1
2
0
4
1
0
0
1
1
0
1
3
0
0
0
1
0
0
2
8
1
0
1
4
1
2
1
0
1
0
0
0
0
0
1
1
0
0
1
5
0
2
1
1
1
1
53
52

65-69
0
0
0
0
0
0
0
1
0
1
2
0
5
1
0
2
1
0
0
0
3
0
0
0
1
0
0
0
7
0
0
1
3
0
0
0
0
0
0
0
0
0
0
0
1
0
0
0
1
0
0
0
0
0
1
31
30

70-74
0
0
0
0
0
0
0
0
0
1
1
0
5
0
0
2
1
1
0
0
0
0
0
0
3
0
0
0
7
0
0
1
1
1
3
0
0
0
0
0
1
0
0
0
0
0
0
0
2
0
0
0
0
0
5
35
32

0.1%
0.6%
0.1%
0.9%
0.0%
0.1%
0.6%
0.1%
0.0%
1.5%
1.8%
0.1%
4.4%
3.1%
0.4%
1.3%
0.8%
0.8%
0.1%
0.4%
2.7%
0.4%
0.6%
0.2%
3.8%
0.0%
0.1%
1.1%
35.0%
0.2%
0.1%
4.2%
4.1%
0.9%
3.4%
0.3%
0.2%
2.1%
0.0%
0.0%
0.6%
0.0%
0.4%
1.0%
5.1%
0.3%
0.0%
1.5%
4.5%
0.0%
0.7%
1.7%
1.7%
0.9%
5.0%
100.0%
96.2%

75+ % of Total

84

Site

Lip
Tongue
Mouth
Salivary glands
Tonsil
Other Oropharynx
Nasopharynx
Hypopharynx
Pharynx unspecified
Oesophagus
Stomach
Small intestine
Colon
Rectum
Anus
Liver
Gallbladder etc.
Pancreas
Nose, sinuses etc.
Larynx
Trachea, Bronchus, Lung
Other Thoracic organs
Bone
Melanoma of Skin
Other Skin
Mesothelioma
Kaposi sarcoma
Connective, Soft tissue
Breast
Penis
Prostate
Testis
Other male genital
Kidney
Renal Pelvis
Ureter
Bladder
Other Urinary organs
Eye
Brain, Nervous system
Thyroid
Adrenal gland
Other Endocrine
Hodgkin disease
Non-Hodgkin lymphoma
Immunoproliferative dis.
Multiple Myeloma
Lymphoid Leukemia
Myeloid Leukemia
Leukemia unspecified
Other & unspecified
All sites Total
All sites but C44

ICD (10th)

C00
C01-C02
C03-C06
C07-C08
C09
C10
C11
C12-C13
C14
C15
C16
C17
C18
C19-C20
C21
C22
C23-C24
C25
C30-C31
C32
C33-C34
C37-C38
C40-C41
C43
C44
C45
C46
C47; C49
C50
C60
C61
C62
C63
C64
C65
C66
C67
C68
C69
C70-C72
C73
C74
C75
C81
C82-C85; C96
C88
C90
C91
C92-C94
C95
Other
All
Not C44

4
5
7
5
1
1
21
5
0
13
64
7
87
63
8
57
14
21
3
23
90
6
13
7
88
7
5
30
8
0
86
18
0
29
4
1
66
0
6
30
40
3
1
28
104
0
18
29
29
9
70
1234
1146

All
Ages
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1
0
0
0
0
0
1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2
2

Age
Unk
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.4
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.9
0.0
0.0
0.0
0.4
0.0
1.3
0.0
0.0
0.0
0.0
1.7
1.7
0.0
0.0
0.0
0.0
1.7
0.0
0.0
3.4
1.3
0.0
0.4
13.0
13.0

0-4
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.4
0.4
0.0
0.0
0.4
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
1.3
0.0
0.4
0.0
0.9
0.9
0.0
0.0
2.2
0.0
0.0
0.0
7.0
7.0

0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
1.6
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
1.1
0.0
0.5
0.5
0.0
0.0
0.0
0.0
0.5
1.1
0.5
0.0
6.0
6.0

0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
2.1
0.0
0.0
0.0
0.0
1.4
0.0
0.0
0.0
1.4
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
1.4
2.1
0.0
0.0
1.4
0.0
0.0
0.0
10.0
10.0

0.0
0.0
0.0
0.0
0.0
0.0
0.5
0.0
0.0
0.0
0.5
0.0
1.0
0.0
0.0
0.5
0.0
0.0
0.0
0.0
0.0
0.0
1.5
0.0
0.5
0.0
0.5
1.9
0.0
0.0
0.0
1.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
1.0
0.0
0.0
2.4
1.9
0.0
0.0
1.9
0.0
0.0
0.0
15.0
15.0

0.0
0.0
0.0
0.4
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.2
0.4
0.0
0.0
0.0
0.0
0.0
0.2
0.0
0.2
0.2
0.0
0.5
0.0
0.0
0.5
0.0
0.0
0.0
0.4
0.0
0.0
0.0
0.0
0.2
0.0
0.2
0.4
0.5
0.2
0.0
0.7
1.1
0.0
0.0
0.2
0.7
0.2
0.7
8.0
8.0

0.0
0.0
0.0
0.0
0.0
0.0
0.4
0.0
0.0
0.1
0.1
0.0
0.5
0.8
0.0
0.1
0.0
0.1
0.1
0.1
0.4
0.1
0.0
0.1
0.5
0.0
0.1
0.3
0.1
0.0
0.0
0.3
0.0
0.0
0.0
0.0
0.3
0.0
0.0
0.3
0.5
0.0
0.0
0.1
0.8
0.0
0.0
0.0
0.4
0.1
0.8
8.0
7.0

0.0
0.1
0.0
0.0
0.0
0.0
0.1
0.1
0.0
0.0
0.4
0.1
1.3
0.6
0.1
0.0
0.0
0.0
0.0
0.0
0.3
0.3
0.0
0.1
0.9
0.1
0.0
0.4
0.1
0.0
0.0
0.4
0.0
0.1
0.0
0.0
0.4
0.0
0.0
0.3
0.9
0.0
0.0
0.3
1.4
0.0
0.1
0.0
0.4
0.1
1.0
11.0
10.0

0.0
0.4
0.4
0.4
0.0
0.0
0.5
0.0
0.0
0.4
1.4
0.4
2.0
1.4
0.0
0.9
0.4
0.5
0.0
0.4
1.4
0.0
0.4
0.2
1.1
0.0
0.0
0.5
0.0
0.0
0.2
0.2
0.0
1.1
0.2
0.0
1.3
0.0
0.0
0.5
0.9
0.0
0.0
0.9
2.1
0.0
0.2
0.4
0.4
0.0
0.5
22.0
21.0

0.0
0.5
0.5
0.0
0.0
0.0
1.9
0.3
0.0
0.8
2.4
0.0
3.0
2.1
0.0
2.4
0.0
0.8
0.3
1.3
2.7
0.0
0.3
0.0
3.8
0.8
0.0
0.3
0.5
0.0
0.8
0.3
0.0
0.3
0.0
0.3
3.2
0.0
0.0
0.5
1.9
0.0
0.0
0.8
3.2
0.0
1.1
0.5
1.6
0.3
2.4
42.0
38.0

75+

0.0
2.8
2.4
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.9
0.9
0.0
0.0
0.0
0.0
0.0
0.0
2.4
0.0
0.0
0.0
0.5
0.0
0.0
0.0
0.0
0.0
0.0
0.9
0.0
0.0
0.0
0.0
0.0
4.7
0.0
5.8
0.0
0.0
0.0
0.9
4.7
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.9
4.7
5.8
9.3 16.1
5.4
7.5 23.6 23.1 28.0 40.3
0.9
0.0
0.0
5.8
0.0
8.1
6.8 10.3 23.6 17.4 37.3 40.3
4.5
5.6 21.3 28.9 28.0
8.1
1.8
1.9
2.4
0.0
0.0
0.0
4.5
5.6 18.9 46.3 46.7 24.2
1.4
0.9
4.7
5.8 28.0 16.1
0.9
1.9
4.7 17.4 18.7 24.2
0.5
0.0
0.0
0.0
0.0
0.0
0.5
4.7
4.7 23.1
9.3
8.1
6.8 10.3 37.8 69.4 65.4 40.3
0.0
0.9
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.9
0.0
0.0
5.8
0.0
8.1
7.7 10.3 23.6 28.9 46.7 32.2
0.5
0.0
4.7
0.0
0.0
0.0
0.0
1.9
0.0
0.0
0.0
8.1
1.8
1.9
4.7
0.0
9.3
8.1
0.0
0.9
4.7
0.0
0.0
8.1
0.0
0.0
0.0
0.0
0.0
0.0
6.3 21.5 40.2 52.1 65.4 88.7
0.9
0.0
4.7
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
3.2
1.9 16.5
5.8
0.0
8.1
0.5
0.0
0.0
0.0
9.3
8.1
0.0
0.0
0.0
0.0
0.0
0.0
2.7
8.4 18.9 40.5 46.7 40.3
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
2.4
0.0
0.0
0.0
2.3
0.9
2.4
0.0 28.0
0.0
2.7
4.7
0.0
5.8
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.5
2.8
0.0
0.0
0.0
0.0
5.0 12.1 26.0 17.4
9.3 40.3
0.0
0.0
0.0
0.0
0.0
0.0
1.8
3.7
7.1
5.8
0.0
0.0
0.0
0.9
2.4
0.0 18.7
0.0
1.4
0.9
2.4
0.0
0.0
8.1
0.9
0.9
0.0
0.0
0.0
8.1
5.9
6.5
7.1 11.6 65.4 56.4
80.0 141.0 324.0 422.0 570.0 548.0
72.0 131.0 300.0 393.0 523.0 516.0

5-9 10-14 15-19 20-24 25-29 30-34 35-39 40-44 45-49 50-54 55-59 60-64 65-69 70-74

Table 5.4.3 Incidence Rates for Cancer Cases among non-Saudi Males by Age Group (per 100,000), 2006

0.1
0.1
0.2
0.1
0.0
0.0
0.5
0.1
0.0
0.3
1.4
0.2
2.0
1.4
0.2
1.3
0.3
0.5
0.1
0.5
2.0
0.1
0.3
0.2
2.0
0.2
0.1
0.7
0.2
0.0
1.9
0.4
0.0
0.7
0.1
0.0
1.5
0.0
0.1
0.7
0.9
0.1
0.0
0.6
2.4
0.0
0.4
0.7
0.7
0.2
1.6
27.9
25.9

Crude
Rate

0.2
0.1
0.1
0.1
0.0
0.0
0.6
0.3
0.0
1.0
3.9
0.4
4.3
3.2
0.3
4.3
1.4
1.8
0.0
1.6
6.8
0.1
0.5
0.4
4.7
0.3
0.3
1.2
0.4
0.0
7.6
0.6
0.0
1.5
0.4
0.0
4.6
0.0
0.3
1.4
0.9
0.1
0.0
0.7
4.5
0.0
0.8
1.5
0.8
0.3
4.0
68.2
63.5

ASR
World

0 0.0 1.0 0.85 Site Lip Tongue Mouth Salivary glands Tonsil Other Oropharynx Nasopharynx Hypopharynx Pharynx unspecified.0 0.0 0.0 1.0 0.0 0.0 0.0 0.0 20.0 0.6 0.0 0.0 3.0 0.0 0.0 0.0 0.0 1.0 0.0 1.0 0.0 0.0 0.4 7.7 14.7 0.0 1.0 0.0 0.5 6. Ovary Other Female Genital Placenta Kidney Renal Pelvis Ureter Bladder Other Urinary organs Eye Brain.0 0.5 0.1 0.0 0.7 0.0 0.0 0.9 12.0 0.0 11.0 0.0 0.0 1.0 0.0 6.0 0.0 ASR World 0.0 0.0 0.0 41.0 2.0 6.0 0.0 0.9 0.0 19.3 0.3 0.3 8.0 0.0 0.0 0.0 0.0 0.6 0.5 8.0 0.0 0.0 0.0 0.0 4.0 0.0 0.0 0.0 1.8 0.4 0.0 0.0 11.0 0.0 4.8 7.0 0.0 0.7 0.9 38.0 0.8 0.9 369.0 0.6 0.0 0.5 1.0 34.4 1.0 4.2 0.0 0.0 3.2 17.7 0.0 13.5 0.0 0.7 3.0 0.0 0.1 1.8 1.3 0.5 11.0 0.0 0.8 0.9 10.0 2.1 10.0 0.0 0.2 4.1 2.8 3.3 1.3 0.0 0.2 0.0 0.2 1.2 44.0 0.0 0.8 0.0 0.0 11.0 0.0 0.0 0.0 582.3 0.0 109.0 3.0 260.2 2.4 0.8 3.0 0.4 0.0 0.0 0.5 210.7 0.0 11.4 Incidence Rates for Cancer Cases among non-Saudi Females by Age Group (per 100.3 0.5 0.9 0.0 11.7 0.0 5.9 0.3 31.0 0.8 3.0 0.4 0.3 6.3 0.0 0.0 0.0 0.2 1.0 3.0 0.0 0.7 0.0 0.0 0.0 34.8 55.0 0.0 0.0 6.0 0.0 0.0 0.7 0.2 1.0 0.0 0.4 11.0 0.0 0.7 14.6 0.7 8.1 15.4 0.0 0.0 0.4 1.0 0.0 0.0 0.5 0.0 0.0 0.0 0.0 0.6 0.0 0.0 0.0 0.0 0.2 12.0 0.4 1.3 0.0 0.0 3.0 0.0 34.7 0.9 0.0 0.0 0.0 0.4 0.0 55.9 1.0 0.0 13.4 1.8 0.0 0.0 0.0 1.0 0.0 0.8 3.0 2.0 0.0 0.0 0.0 0.0 11.0 0.0 0.9 0.0 0.0 0.2 0.9 12.9 0.9 0.0 0.2 0.0 0.4 0.0 1.0 0.0 0.0 0.6 0.4 0.0 437.7 0.0 0.0 0.0 0.4 0.5 0.0 0.0 0.0 0.0 3.0 0.0 0.0 0.5 1.0 0.0 20.0 0.8 27.0 0.7 0.0 0.3 2.0 0.0 0.0 0.0 0.4 0.4 11.0 38.0 0.9 0.0 0.0 0.5 1.8 0.0 0.0 11.7 0.9 107.0 0.0 414.0 0.1 2.0 0.3 101.0 0.2 11.0 0.0 12.7 0.2 0.4 .1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 1.0 0.0 0.2 3.9 12.9 0.2 0.0 5-9 10-14 15-19 20-24 25-29 30-34 35-39 40-44 45-49 50-54 55-59 60-64 65-69 70-74 Table 5.0 0.0 0.9 0.0 0.3 0.0 0.3 0.0 0.0 0.0 0.0 1.5 0.0 0.0 1.6 0.5 0.0 3.2 0.9 366.2 0.0 0.1 0.8 0.0 0.0 4.0 0.0 1.9 0.4 3.4 4.0 1.0 0.0 0.0 0.0 0.0 0.5 4.0 0.0 0.0 2.0 0.0 0.0 0.0 0.5 0.2 11.8 3.0 0.7 0.0 23.6 452.9 34.0 2.0 0.0 0.1 2.9 12.4 1.0 0.0 0.9 0.0 0.0 0.0 0.0 0. Bronchus.6 2.0 0.1 0.2 0.0 0.0 0.0 0.0 0.0 11.0 0.0 0.0 0.0 11.5 1.0 0.0 0.8 0.9 0.000).0 20.0 0.0 23.0 0.0 0.5 0.3 0.2 0.0 0.0 0.0 0.0 5.0 0.5 0.0 0.0 0.2 0.0 0.0 11.4 0.0 0.2 8.0 3.1 4.7 0.5 1.4 0.4 0.0 1. sinuses etc.0 1.4 89.0 0.0 0.8 2.0 0.8 6.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 83.0 0.0 0.2 0.8 0.8 0.0 1.0 0.5 0.0 0.4 0.0 0.0 1.8 0.0 1.0 0.9 0.8 0.0 0.2 11.0 0.0 0.0 0.8 0. Oesophagus Stomach Small intestine Colon Rectum Anus Liver Gallbladder etc.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.3 4.5 0.0 0.1 10.0 3.3 20.0 0.0 0.0 2.0 0.0 0.5 0.1 0.8 0.0 3. Pancreas Nose.0 0.0 26.0 11.0 0.0 0.0 0-4 0.8 1.3 0.0 0.0 0.2 0.3 2.0 0.5 0.6 0.7 2.0 0.0 0.3 1.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.8 3.0 0.3 0.0 0.0 0.5 2.0 0.0 0.0 0.8 51.0 0.7 0.0 3.0 0.0 0.0 4.0 0.0 0.0 0.0 0.2 0.0 0.0 1.0 0.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.9 0.0 0.0 0.0 0.0 20.3 1.0 59.0 0.0 6.0 0.0 75+ Crude Rate 0.7 11.0 11.6 0.0 0.0 7.8 0.0 0.8 0.4 4.0 0.0 0.0 0.0 0.5 10.0 0.0 0.2 0.0 0.0 0.0 0.7 500.4 0.6 0.0 1.0 0.2 15.0 0.5 0.0 0.0 0.7 0.0 1.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 11.0 0.2 11.4 0.7 10.0 13.0 12.5 0.8 20.0 0.2 55.0 25.0 1.0 0.4 0.0 0.8 0.0 0.0 0. Other & unspecified All sites Total All sites but C44 ICD (10th) C00 C01-C02 C03-C06 C07-C08 C09 C10 C11 C12-C13 C14 C15 C16 C17 C18 C19-C20 C21 C22 C23-C24 C25 C30-C31 C32 C33-C34 C37-C38 C40-C41 C43 C44 C45 C46 C47.0 0.0 0.9 3.3 0.0 109.0 0.0 0.0 0.9 0.0 6.0 0.5 0.0 0.0 0.0 2.0 1.0 0.4 0.0 0.4 0.1 0.0 0.3 0.0 0.6 113.0 0.0 0.0 0.2 593.4 0.0 1.0 22.0 2.0 0.0 0.0 0.0 0.0 0.0 0.3 0.2 11.7 0. Nervous system Thyroid Adrenal gland Other Endocrine Hodgkin disease Non-Hodgkin lymphoma Immunoproliferative dis.0 64.5 0.0 0.1 0.7 1.9 0.0 6.0 0.7 0.0 0.0 0.9 0.0 0.0 0.5 0.8 0.0 0.0 1.0 97.0 0.8 0.0 0.3 0.5 0.0 29.6 0.8 0.4 0.0 92.0 0.2 8.4.0 0.0 3.6 0.0 0.0 0.7 0.0 0.0 0.0 0.5 5.2 3.0 0.0 0.0 0.0 0.6 0.8 11.0 0.0 0.7 6.0 0.0 331.0 0.0 13. 2006 0.0 1.0 357.0 0.3 0.0 1.0 20.0 0.0 0.0 0.5 0.0 0.2 2.3 0.0 0.C96 C88 C90 C91 C92-C94 C95 Other All Not C44 All Ages 1 6 1 10 0 1 7 1 0 16 20 1 48 34 4 14 9 9 1 4 29 4 7 2 41 0 1 12 382 2 1 46 45 10 37 3 2 23 0 0 6 0 4 11 56 3 0 16 49 0 8 19 19 10 55 1090 1049 Age Unk 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0.0 0.0 0.6 0.0 0.0 0.8 0.0 0.8 0.4 6.0 0.0 35.0 6.3 0.0 0.0 0.4 106.8 0.4 0.6 0.0 0.9 0.0 0.0 0.0 0.0 3.0 0.0 0.0 2.7 0.8 11.0 2.C49 C50 C51 C52 C53 C54 C55 C56 C57 C58 C64 C65 C66 C67 C68 C69 C70-C72 C73 C74 C75 C81 C82-C85.0 19.0 12.0 0.0 0.6 4.0 0.0 0.0 11.0 1.8 0.0 0.0 0.0 0.0 0.0 0.4 0. Soft tissue Breast Vulva Vagina Cervix Uteri Corpus Uteri Uterus unspecified.0 0.9 0.0 0.0 0.1 7.4 1.0 0.0 34.0 2.0 0.0 0.0 0.0 0.0 0.0 2.8 0.0 0.0 0.0 0. Larynx Trachea.0 0.9 0.8 15.0 20.9 23.0 2.4 0.7 0.0 0.3 0.4 1.7 0.0 1.0 0.0 0.0 0.0 0.0 0.0 0.0 1.0 0.0 1.9 0.0 0.0 0.4 0.0 1.0 0.0 1.0 5.0 0.5 0.0 0.0 0.0 11.0 0.0 0.0 0.0 0.9 0.1 0.9 0.0 2.0 0.0 90.0 0.0 0.0 0.0 0.0 0.8 0.0 0.0 0.9 0.6 2.0 5.0 0.7 11.2 0.0 0.0 0.8 2.0 0.0 0.0 0.0 6.0 0.5 0.0 0.0 0.0 0.1 0.2 22.6 19.2 1.0 0.2 22.8 0.2 11.0 0.0 0.0 0.8 8.0 0.4 0. Lung Other Thoracic organs Bone Melanoma of Skin Other Skin Mesothelioma Kaposi sarcoma Connective.0 0.2 0.3 0.7 15.7 0.0 25.0 0.0 11.0 0.0 0.0 0.0 0.0 22.4 0.2 0.7 2.0 27.0 0.4 0.0 0.0 44.8 0.0 0.0 0.4 0.5 0.8 1.0 0.0 0.3 0.9 35.9 62.0 0.0 0.7 20.0 0.0 0.4 0.0 0.7 4.8 0.0 271.0 3.2 0.0 0.0 0.9 13.0 64.0 53.5 11.3 0.0 0.0 0.0 0.0 0.4 2.0 0.6 0.7 0.7 0.0 0.0 0.0 0.0 0.0 0.0 203.2 0.3 0.0 0.1 6.2 23.0 0.2 33.0 0.1 7.0 0.1 0.5 5.7 0.0 0.0 0.0 0.5 0.0 1.3 2.0 0.1 0.0 0.6 57.0 0. Multiple Myeloma Lymphoid Leukemia Myeloid Leukemia Leukemia unspecified.8 0.2 6.4 0.0 22.8 0.4 0.0 0.2 0.0 0.0 0.0 0.0 0.4 2.0 0.0 2.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 1.9 12.5 0.8 0.8 0.0 0.0 0.7 2.

C96 Non-Hodgkin lymphoma 275 216 233 226 285 270 269 245 273 328 355 361 C88 Immunoproliferative dis.C49 Connective.Table 5. 0 0 0 1 0 1 0 0 0 1 2 0 0 C90 Multiple Myeloma 60 41 30 36 47 37 46 36 28 39 45 60 48 C91 Lymphoid Leukemia 152 118 148 144 156 137 152 158 142 164 149 160 155 C92-C94 Myeloid Leukemia 95 91 83 107 94 110 93 127 112 89 112 105 115 C95 Leukemia unspecified 10 5 5 5 9 8 14 13 12 13 16 15 26 122 100 133 147 141 126 136 152 145 151 183 186 Other Other & unspecified 149 All Not C44 All sites Total All sites but C44 2963 2718 2668 2687 3054 2962 3045 3095 3243 3520 3782 3990 3898 2859 2597 2555 2576 2954 2841 2931 2938 3094 3354 3640 3836 3705 86 . Lung 189 186 190 164 223 206 196 190 194 203 254 280 232 C37-C38 Other Thoracic organs 7 11 13 13 8 17 7 6 5 12 13 22 14 64 C40-C41 Bone 48 50 34 46 51 56 52 67 50 46 67 55 C43 Melanoma of Skin 21 8 8 8 6 7 11 9 12 10 13 13 11 C44 Other Skin 104 121 113 111 100 121 114 157 149 166 142 154 193 C45 Mesothelioma 5 4 5 5 7 2 7 5 3 5 6 8 8 C46 Kaposi sarcoma 15 10 14 14 12 11 19 20 21 26 27 23 22 C47.5. Nervous system 132 99 127 125 103 121 142 120 121 147 154 140 149 C73 Thyroid 73 63 60 73 85 85 75 74 93 89 95 93 117 C74 Adrenal gland 8 9 8 8 4 9 11 7 7 15 6 10 19 C75 Other Endocrine 2 3 5 1 2 2 1 4 1 5 3 6 5 C81 Hodgkin disease 105 107 108 99 137 119 129 137 120 144 182 167 173 351 C82-C85. sinuses etc.1 Number of Cases by Primary Site and Years among Saudi Males. Bronchus. 1994-2006 ICD-10 Site 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 C00 Lip 9 2 4 5 4 1 6 1 5 5 8 6 6 C01-C02 Tongue 32 15 22 24 13 26 29 14 24 29 35 40 37 C03-C06 Mouth 24 24 30 25 26 27 25 27 26 26 40 31 30 C07-C08 Salivary glands 4 10 6 11 7 12 8 16 14 13 15 17 14 C09 Tonsil 4 9 2 4 6 2 1 3 6 5 2 3 0 C10 Other Oropharynx 2 3 3 2 1 3 0 3 3 0 2 3 0 95 C11 Nasopharynx 78 61 87 100 109 99 89 122 85 89 104 118 C12-C13 Hypopharynx 11 9 18 7 7 6 5 8 6 8 7 12 9 C14 Pharynx unspecified 0 2 0 0 1 1 0 2 1 4 4 4 3 C15 Oesophagus 77 71 67 64 79 58 69 63 70 68 55 57 55 C16 Stomach 131 128 133 109 124 104 125 125 148 180 151 163 162 C17 Small intestine 11 8 11 10 15 13 16 13 17 14 22 24 18 C18 Colon 62 88 74 86 108 100 117 119 153 179 201 259 232 C19-C20 Rectum 83 66 67 66 66 89 84 108 123 143 176 191 182 C21 Anus 10 8 6 8 6 5 10 12 14 11 17 17 8 C22 Liver 301 298 279 269 329 296 289 274 287 285 276 282 291 C23-C24 Gallbladder etc. 5 6 10 5 10 13 6 9 14 10 10 15 10 C32 Larynx 49 48 44 41 47 43 44 51 33 60 53 53 62 C33-C34 Trachea. Soft tissue 85 68 50 60 50 70 55 47 63 69 60 77 57 C50 Breast 11 16 6 12 20 11 16 12 15 16 14 15 18 C60 Penis 3 4 1 8 0 1 1 1 3 1 3 6 1 C61 Prostate 150 148 155 125 163 147 185 170 199 193 245 269 228 38 C62 Testis 32 22 25 29 39 31 34 36 44 38 46 46 C63 Other male genital 1 2 0 3 1 2 3 3 3 4 3 2 3 C64 Kidney 70 82 57 65 72 79 75 85 90 85 125 103 111 C65 Renal Pelvis 5 5 0 0 10 2 6 2 1 7 8 3 5 C66 Ureter 1 3 1 0 3 0 4 1 0 6 3 3 1 169 C67 Bladder 165 155 129 128 156 152 159 143 160 180 174 164 C68 Other Urinary organs 1 1 1 0 1 1 0 0 1 1 1 0 0 C69 Eye 22 12 18 35 17 24 25 22 24 21 21 17 26 C70-C72 Brain. 24 31 25 22 28 25 27 39 42 39 27 36 46 C25 Pancreas 50 49 53 45 60 59 68 53 74 84 82 99 93 C30-C31 Nose.

Table 5. C49 Connective. Nervous system 78 75 76 93 88 78 89 84 85 93 110 106 103 C73 Thyroid 206 221 201 217 271 281 265 258 277 367 348 398 424 C74 Adrenal gland 10 6 10 11 9 10 13 8 8 13 17 10 10 C75 Other Endocrine 2 1 2 1 2 3 1 0 0 1 2 5 5 C81 Hodgkin disease 59 70 59 62 74 76 90 77 76 112 109 105 120 234 C82-C85. 1994-2006 ICD-10 Site 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 C00 Lip 3 3 4 2 1 6 4 3 7 5 8 6 4 C01-C02 Tongue 23 20 28 28 29 31 23 19 30 30 27 21 26 C03-C06 Mouth 23 40 37 22 33 40 26 27 29 29 23 43 34 C07-C08 Salivary glands 8 7 6 3 12 9 14 8 6 10 12 14 12 C09 Tonsil 0 3 3 3 1 1 3 1 5 4 1 1 2 C10 Other Oropharynx 0 1 0 0 1 0 0 0 2 0 2 2 0 C11 Nasopharynx 39 28 39 34 38 35 24 41 41 39 46 35 43 C12-C13 Hypopharynx 19 11 15 15 19 16 10 12 12 2 16 17 11 C14 Pharynx unspecified 2 3 1 1 1 1 2 0 3 1 3 0 1 C15 Oesophagus 75 54 69 54 47 49 55 37 58 53 52 69 64 C16 Stomach 67 74 64 59 67 71 62 73 77 76 78 75 113 C17 Small intestine 9 11 9 10 16 8 10 15 8 10 13 13 14 C18 Colon 64 80 86 75 74 107 108 143 135 146 183 200 227 C19-C20 Rectum 44 51 52 59 57 86 74 88 106 109 119 146 143 C21 Anus 6 4 2 3 5 2 4 2 5 9 6 9 9 C22 Liver 110 89 100 87 125 93 121 101 117 128 119 113 125 C23-C24 Gallbladder etc.2 Number of Cases by Primary Site and Years among Saudi Females. C96 Non-Hodgkin lymphoma 145 149 141 148 190 179 188 201 203 238 246 262 C88 Immunoproliferative dis. 6 9 5 4 8 8 6 6 8 2 6 10 10 C32 Larynx 10 2 7 10 9 10 10 3 7 4 8 6 9 C33-C34 Trachea.Bronchus. 52 38 25 32 51 60 47 54 41 59 55 67 70 C25 Pancreas 28 30 24 25 50 42 35 35 54 40 36 53 73 C30-C31 Nose. Soft tissue 42 57 42 46 61 50 49 43 39 53 75 51 37 C50 Breast 434 435 469 487 534 521 611 564 671 714 831 964 981 C51 Vulva 8 6 7 3 3 3 8 7 6 6 11 1 4 C52 Vagina 5 6 2 6 2 3 1 5 5 1 5 7 1 C53 Cervix Uteri 79 74 84 77 98 78 84 87 87 92 95 98 74 C54 Corpus Uteri 59 47 39 50 61 58 92 81 89 113 122 152 140 C55 Uterus unspecified 4 2 11 10 17 13 6 15 14 14 12 15 22 C56 Ovary 96 98 97 114 111 100 103 109 110 128 117 140 132 C57 Other Female Genital 1 1 0 2 2 4 3 5 4 5 10 6 9 C58 Placenta 16 10 11 7 9 12 9 14 15 6 8 14 19 78 C64 Kidney 61 37 50 57 53 64 49 69 68 67 85 63 C65 Renal Pelvis 0 1 0 2 3 3 2 1 1 2 1 4 4 C66 Ureter 0 1 1 0 1 1 0 1 1 1 2 4 2 C67 Bladder 29 40 23 31 41 37 40 52 41 45 44 37 42 C68 Other Urinary organs 0 0 0 0 0 1 1 0 0 0 1 1 0 C69 Eye 15 16 18 14 11 26 25 18 20 16 19 21 19 C70-C72 Brain. 0 0 0 1 0 1 1 1 0 1 0 0 0 C90 Multiple Myeloma 20 33 20 13 24 27 26 18 19 16 26 26 26 C91 Lymphoid Leukemia 77 89 80 80 75 95 112 85 102 92 83 83 90 C92-C94 Myeloid Leukemia 79 80 74 90 83 92 93 103 104 96 122 101 113 C95 Leukemia unspecified 6 6 0 5 7 11 9 4 5 11 11 15 9 Other Other & unspecified 105 96 94 96 143 129 126 116 120 165 183 151 177 All Not C44 All sites Total All sites but C44 2400 2380 2375 2403 2815 2818 2927 2916 3120 3481 3785 4039 4156 2321 2325 2288 2344 2733 2741 2846 2813 3024 3358 3653 3906 4022 87 .5.Lung 52 55 49 53 51 49 54 56 52 64 72 89 80 C37-C38 Other Thoracic organs 7 6 6 6 5 5 8 5 3 10 10 12 10 C40-C41 Bone 26 38 38 25 45 36 39 43 35 39 41 40 36 C43 Melanoma of Skin 11 8 7 2 8 8 6 8 7 8 12 9 12 C44 Other Skin 79 55 87 59 82 77 81 103 96 123 132 133 134 C45 Mesothelioma 1 0 1 1 0 4 1 1 3 7 5 7 5 C46 Kaposi sarcoma 0 3 0 8 7 8 4 5 3 6 5 9 14 C47. sinuses etc.

3 0.0 0.3 6.6 0.5 2.4 1.3 4.1 2.3 0.4 0.2 5.5 64.0 1.1 0.2 0.3 0.4 7. 0.6 0.2 0.2 1.2 0.1 4.2 0.2 0.2 3.2 2.3 0.4 0.4 0.8 69.4 3.1 1.1 C37-C38 Other Thoracic organs 0.1 0.2 0.7 C43 Melanoma of Skin 0.5 0.1 2.6 6.1 0.2 1.3 0.1 67.9 1.5 2.0 0.1 C62 Testis 0.1 2.4 2.1 0.1 0.0 2.1 4. 0. C96 Non-Hodgkin lymphoma 6.4 C60 Penis 0.5 4.0 88 .0 0.5 6.3 1.2 0.6 64.0 0.2 C44 Other Skin 2.5 C47.0 0.2 C22 Liver 8.1 0.1 0.8 1.8 73.4 0.2 0.0 0.9 6.4 Other Other & unspecified 4. 0.1 0.5 0.7 1.3 1.7 0.2 5.2 1.4 0.2 0.7 0.3 0.6 0.6 2.6 3.4 4.5 1.2 1.1 0.1 0.1 1.5 0.2 0.6 0.6 0.0 1.1 5.3 0.1 0.6 79.1 0.9 4.5 1.6 7.1 0.1 4.0 0.3 0.1 0.3 0.0 0.4 0.9 C17 Small intestine 0.5 83.0 0.1 0.7 0.1 0.9 C50 Breast 0.1 3.2 0.9 0.0 0.3 0.1 0.1 0.1 C01-C02 Tongue 0.0 6.7 0.1 0.7 1.3 0.6 67.1 62.0 0.7 2.3 6.5 1.4 C65 Renal Pelvis 0.1 63.8 5.1 0.7 1.1 2.0 0.0 0.1 0.7 1.9 1.3 1.4 2.2 0.7 1.6 1. Nervous system 2.2 0.2 0.0 0.2 C25 Pancreas 1.6 1.1 0.4 1.1 0.2 0.8 1.3 0.4 3.0 1.1 0.1 0.6 1.3 0.0 3. Soft tissue 1.5 3.1 0.3 C70-C72 Brain.0 1.2 0.7 2.6 0.9 5.9 1.2 0.6 0.2 0.0 1.2 0.0 0.2 0.0 0.0 4.3 0.1 0.8 C03-C06 Mouth 0.4 C30-C31 Nose.8 2.9 61.7 0.5 1.0 0.2 C91 Lymphoid Leukemia 2.5 1.5 3.0 0.3 3.4 0.9 3.2 0.5 0.1 0.7 4.0 1.4 63.1 0.4 1.9 2.0 C69 Eye 0.0 0.7 0.4 C18 Colon 1.1 C82-C85.3 0.0 0.3 1.0 0.0 2.4 2.0 0.7 2.4 0.2 0. sinuses etc.4 0.3 0.8 C95 Leukemia unspecified 0.2 7.0 0.7 3.5 C63 Other male genital 0.6 0.6 0.7 0. Lung 5.3 3.0 0.2 0.6 63.1 0.1 65.0 2.3 0.8 0.1 0.3 0.3 0.5 4.3 All Not C44 All sites Total All sites but C44 76.2 0.6 2.9 1.1 0.7 0.1 0.0 2.1 0.2 3.1 0.0 0.6 0.8 1.0 67.2 70.8 76.7 58.3 0.8 1.1 2.2 0.2 4.4 2.3 0.1 0.0 0.2 0.2 2.5 7.7 0.5 0.6 0.1 0.1 0.2 0.2 1.1 0.7 1.1 0.7 2.0 0.9 0.3 4.0 0.3 2.5 1.4 1.6 1.5 4.3 0.0 3.7 3.3 0.1 0.5 0.2 0.0 0.4 2.9 1.5 C23-C24 Gallbladder etc.0 0.2 0.1 0.3 0.4 1.8 1.8 1.0 0.5 5.3 6.1 0.5.8 1.2 6.1 1.5 0.0 C11 Nasopharynx 2.5 C73 Thyroid 1.2 0.4 3.1 0.9 1.4 5.2 0.6 C33-C34 Trachea.4 1.2 0.3 4.4 3.2 C09 Tonsil 0.6 0.3 C92-C94 Myeloid Leukemia 1.7 0.1 0.3 0.2 0.3 2.8 1.0 0.5 0.3 1.1 0.5 67.5 2.3 2.8 C07-C08 Salivary glands 0.9 7.1 1.1 C81 Hodgkin disease 2.0 0.6 0.7 0.7 0.0 0.3 Age Adjusted Incidence Rate by Primary Site and Years among Saudi Males.3 0.2 0.0 1.4 5.6 C45 Mesothelioma 0.0 0.1 2.1 0.9 2.0 1.1 6.9 0.2 0.8 1.5 0.1 0.9 0.1 1.3 1.2 2.0 2.1 0.2 0.1 0.4 0.4 0.3 0.3 1.0 0.5 3.6 4.7 0.0 0.1 1.1 0.1 0.0 0.3 0.8 1.2 0.9 5.6 1.3 2.2 1.3 0.8 2.8 0.3 0.1 0.3 0.7 3.0 C10 Other Oropharynx 0.5 0.7 1.0 4.0 0.9 2.1 3.3 0.3 0.6 0.3 0.2 C40-C41 Bone 0.8 1.2 0.0 0.2 0.3 C19-C20 Rectum 2.6 5.0 0.0 0.4 0.9 74.7 0.1 0.4 0.4 1.1 0.4 1.7 1.1 0.0 0.0 2.5 0.1 0.5 0.3 3.0 0.4 0.1 0.9 1.7 1.2 0.5 1.9 1.6 1.1 0.3 0.0 0.7 2.7 3.1 0.7 0.6 0.2 0.6 1.1 0.6 3.2 0.4 3.8 3.3 0.1 0.3 0.1 0.8 3.6 2.6 0.5 3.0 0.1 0.1 0.5 65.5 0.0 0.1 0.1 0.9 1.4 4.6 C88 Immunoproliferative dis.9 1.6 5.9 0.0 0.3 1.1 2.6 3.0 0.3 0.4 6.1 0.0 3.2 0.8 1.0 3.0 0.3 73.0 0.1 0.4 C16 Stomach 3.2 C46 Kaposi sarcoma 0.4 2.3 0.0 0.1 8.0 0.7 0.8 5.2 1.3 0.1 C15 Oesophagus 2.9 1.5 0.8 2.9 3.6 0.2 0.0 0.1 0.6 2.5 4.0 0.2 0.5 2.4 2.2 1.1 5.8 6.2 0.1 0.6 1.0 0.0 0.3 0.9 1.5 0.1 0.6 79.3 0.5 1.3 4.3 0.3 0.1 0.1 0.7 6.C49 Connective.1 C68 Other Urinary organs 0.1 0.3 0.0 0.7 C12-C13 Hypopharynx 0.6 1.7 2.1 0.1 0.1 0.6 0.1 1.3 6.6 0.4 C21 Anus 0.4 2.3 1.4 0.1 0.2 0.9 1.8 2.0 C61 Prostate 4.1 0.1 C66 Ureter 0.1 0.2 0.2 C14 Pharynx unspecified 0.4 1.2 0.1 0.8 2.1 0.1 C74 Adrenal gland 0.8 1.2 0.3 0.1 2.2 C32 Larynx 1.5 0.0 0.Table 5.1 0.2 0.0 0.3 0.6 3.9 3.0 0.0 0.8 3.7 1.0 0.2 0.6 0.9 2.5 2. Bronchus.1 0.3 0.3 0.0 0.7 3.0 5.0 C67 Bladder 4.6 0.5 0.5 0.9 2.5 3.2 C75 Other Endocrine 0.8 60.7 5.1 0.2 0.6 7.0 0.2 4.1 2.0 C90 Multiple Myeloma 1.4 5.1 C64 Kidney 1.1 4.6 1.9 2.0 2.8 2.7 2.1 0.0 0. 1994-2006 ICD-10 Site 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 C00 Lip 0.8 0.9 1.2 1.1 0.7 0.1 0.7 2.7 0.0 0.8 1.8 1.1 2.2 0.0 0.5 0.2 0.7 0.0 0.1 0.2 0.0 2.0 0.3 0.0 0.8 8.0 1.1 2.3 0.6 1.0 0.9 0.5 7.2 0.4 76.

2 0.8 0.0 C90 Multiple Myeloma 0.6 0.6 1.8 2.0 5.1 0.7 6.0 C37-C38 Other Thoracic organs 0.8 0.8 0.0 0.8 2.0 2.4 1.2 0.8 1.7 0.8 4.7 2.9 1.9 C45 Mesothelioma 0.7 0.0 1.5 0.2 0.0 0.3 14.0 0.0 0.6 0.3 1.2 68.6 1.7 0.9 2.7 2.6 0.0 0.3 1.1 0.7 12.6 2.2 0.5 2.2 0.4 0.0 5.2 0.0 0.0 0.1 0.5 1. 1994-2006 ICD-10 Site 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 C00 Lip 0.1 0.0 0.4 Age Adjusted Incidence Rate by Primary Site and Years among Saudi Females.5 1.1 1.0 0.7 0.2 2.1 0.1 C81 Hodgkin disease 1.1 64.2 0.2 0.1 0.5 0.1 0.3 0.2 1.0 0.1 1.3 1.1 0.0 0.0 0.8 1.2 0.6 3.1 1.2 0.3 3.0 0.4 4.0 1.0 2.8 1.0 1.8 C88 Immunoproliferative dis.7 2.7 6.6 65.1 0.3 1.2 0.1 0.3 1.2 0.2 0.7 1.Table 5.5 1.1 0.0 0.1 0.1 0.1 0.0 0.3 0.7 1.5 67.2 0.2 0.7 1.5 C55 Uterus unspecified.6 1.1 1.7 0.3 4.1 0.2 1.3 0.9 0.0 0.2 0.2 1.8 C57 Other Female Genital 0.7 1.3 0.0 0.1 C75 Other Endocrine 0.2 0.7 1.9 0.9 2.2 0.9 2.4 0.7 C12-C13 Hypopharynx 0.9 3.1 4.0 0.0 0.5 2.1 0.1 0.6 2.6 0.6 1.0 0.5 5.0 0.0 1.1 0.4 0.1 1.4 0.1 3.5 1.1 0.5 C65 Renal Pelvis 0.1 C22 Liver 3.6 1.0 0.1 0.2 Other Other & unspecified 3.9 1.1 0.0 0.1 0.1 0.4 2. 0.2 0.7 1.2 0.0 0.6 C73 Thyroid 5.4 0.1 0.8 3.0 2.1 0.1 0.0 0.0 1.0 1.2 0.3 0.3 0.4 2.0 0.8 0. Lung 1.2 0.0 0.7 1.2 68.1 0.1 0.3 4.0 0.5 0.7 78.3 0.3 1.7 61.5 1.5 0.1 0.2 C58 Placenta 0.0 1.0 0.6 16.9 2.2 0.2 0.0 1.2 0.1 0.2 2.3 C69 Eye 0.4 2.2 0.5 0.1 0.3 2.0 1.0 1.5 0.0 0.4 1.1 1.8 2.2 0.0 0.8 4.8 1.3 0.2 0.2 2.7 2.0 0.5.0 0.5 0.0 0.3 4.0 C95 Leukemia unspecified.5 C50 Breast 13.9 14.1 0.1 C66 Ureter 0.2 0.0 0.3 1.4 1.8 79.0 0.4 13.3 5.5 75.0 0.1 0.0 0.2 0.1 0.0 0.0 0.1 0.1 1.4 4.2 4.7 5.9 1.0 1.3 1.4 1.0 0.7 2.3 12. 0.1 2.4 1.8 2.3 0.8 0.2 0.2 0.4 0.1 0.2 0.7 C25 Pancreas 1.7 0.5 1.6 82.2 C91 Lymphoid Leukemia 1.7 1.9 3.1 0.0 1.9 2.5 0.2 0.5 0.1 0.1 0.5 0.3 1.1 0.0 1.7 18.0 0.2 0.4 0.0 0.0 0.0 0.0 0.3 C21 Anus 0.7 0.2 4.0 0.7 0.4 6.2 0.2 0.9 0.2 2.2 C14 Pharynx unspecified 0.8 2.2 0.1 1.8 C07-C08 Salivary glands 0.1 0.0 0.5 18.1 5.3 0.2 2.1 0.9 89 .6 73.1 0.1 0.2 0.3 0.5 C74 Adrenal gland 0.4 0.5 0. Nervous system 1.1 0.4 0.2 0.0 0.3 C70-C72 Brain.1 1.0 0.3 3.0 0.0 0.8 C30-C31 Nose.1 0.7 1.2 0.4 C43 Melanoma of Skin 0.0 0.4 1.1 0.0 2.8 1.2 0.0 0.7 3.0 0.0 C44 Other Skin 2.0 5.4 59.5 0.1 All Not C44 All sites Total All sites but C44 71.0 0.1 C52 Vagina 0. Soft tissue 0.0 71.0 C10 Other Oropharynx 0. Bronchus.0 0.3 75.2 0.0 0.0 0.3 1.1 0. sinuses etc.4 0.8 1.3 0.6 C82-C85.2 0.6 C23-C24 Gallbladder etc.1 0.4 0.5 2.3 0.0 0.0 1.2 0.7 C17 Small intestine 0.3 3.9 2.8 1.1 0.9 1.0 0.3 0.1 0.6 1.2 0.0 13.5 1.3 4.1 0.2 3.1 0.2 1.0 4.9 2.3 C47.4 1.2 1.9 64.6 0.1 0.4 3.0 0.1 0.8 1.0 1.1 0.2 2.4 1.1 0.0 0.2 0.2 1.3 0.1 0.0 0.2 0.1 0.4 0.0 0.0 0.0 1.2 0.8 0.2 0.0 0.5 0.2 0.0 0.5 1.8 1.6 1.9 3.1 0. 1.4 1.6 0.2 0.6 1.3 1.9 0.1 0.2 1.6 1.3 C18 Colon 2.7 1.0 0.1 0.4 0.1 0.1 0.3 0.1 0.3 0.7 1.1 3.8 0.1 0.2 0.9 2.1 62.2 3.9 0.2 C40-C41 Bone 0.2 1.1 0.3 0.6 0.6 0.5 C54 Corpus Uteri 2. 0.6 1.1 0.2 0.2 C64 Kidney 1.3 2.6 1.0 1.2 0.6 1.8 0.0 0.3 0.2 0.3 C19-C20 Rectum 1.2 0.0 62.5 0.3 70.9 4.0 0.5 1.0 C67 Bladder 1.9 3.5 1.0 C92-C94 Myeloid Leukemia 1.2 64.0 C68 Other Urinary organs 0.0 0.0 0.1 0.0 5.3 0.4 1.1 0.3 0.4 1.4 4.2 0.9 1.0 1.1 3.4 C56 Ovary 2.1 0.2 0.1 1.0 0.2 0.8 1.8 1.7 1.3 0.4 0.0 0.3 1.1 0.0 0.0 0.4 2.6 0.2 0.1 0.0 0.3 0.6 0.9 0.4 0.0 0.3 0.4 0.1 0.1 0.0 0.5 0.3 2.2 0.0 2.5 2.1 0.9 0.9 2.4 2.6 1.2 0.2 0.7 3.1 0.8 64.6 1.3 1.8 0. 0.4 0.0 0.1 0.3 0.2 2.2 0.1 0.1 0.1 2.0 0.2 0.6 1.5 1.0 0.1 3.9 1.6 1.1 1.5 1.0 0.0 0.1 0.8 1.7 1.0 C53 Cervix Uteri 2.1 0.1 0.2 0.4 1.0 0.7 0.6 3.6 C03-C06 Mouth 0.6 5.2 0.2 C09 Tonsil 0.1 C46 Kaposi sarcoma 0.1 2.9 63.1 2.4 1.2 0.5 3.8 2.2 0.0 0.2 0.8 1.9 2.1 0.3 0.0 2.3 0.7 0.1 0.2 0.3 1.4 61.6 0.7 1.3 1.3 0.1 0.8 2.2 2.0 0.7 3.1 0.1 0.1 0.6 2.1 1.0 0.1 3.0 0.1 1.1 0.0 0.5 2.4 1.4 5.7 0.7 1.4 13.0 0.2 0.1 0.0 0.9 1.2 0.4 1.8 1.0 0.2 0.2 0.2 62.4 0.3 2.2 0.1 0.2 2.0 0.0 C15 Oesophagus 2.1 0.8 0.5 1.1 0.3 4.1 0.0 0.1 0.1 0.0 0.7 0.0 0.1 0.6 C16 Stomach 2. C96 Non-Hodgkin lymphoma 4.0 0.1 0.2 C32 Larynx 0.9 66. C49 Connective.2 0.9 0.0 0.4 2.3 0.1 C51 Vulva 0.7 72.0 0.2 C33-C34 Trachea.6 4.0 0.4 2.6 13.8 3.3 0.4 1.1 0.0 0.0 1.4 0.6 1.1 4.4 1.1 0.8 C11 Nasopharynx 0.2 1.1 0.2 0.2 0.6 1.1 0.1 0.1 13.0 0.6 2.2 1.1 C01-C02 Tongue 0.

.

PART VI APPENDICES .

NGHA (DM) Jabir Eye & ENT Hospital Jubail General Hospital Jubail Military Hospital Jufer Hospital (Hofuf) Khafji General Hospital Khafji Joint Operation King Abdul Aziz Airbase King Abdul Aziz Port Clinic King Abdul Aziz Navy Base King Abdulaziz (NGH Hospital King Fahad Hospital (Hofuf) King Fahad Hospital of the University (Khobar) King Fahad Military Medical Complex (AFH) King Fahad Specialist Hospital (DM) King Khalid General Hospital King Khalid Military Complex Mana General Hospital (DM) Mana General Hospital (Hofuf) Mana General Hospital (Jubail) Mana General Hospital (Khobar) Maternity & Children's Hospital (Hofuf) Maternity & Children's Hospital (Khobar) Mousa Hospital (Hofuf) Mouwasat Hospital (DM) Naireia General Hospital Prince Saud Bin Jalawi Hospital Qatif Central Hospital Qatif General Hospital Ras Tanura Center (ARAMCO Clinic) Rowdha Dispensary Saad Specialist Hospital Center (Khobar) Saddiq Hospital Salama Hospital Saudi ARAMCO Medical Services Organizations Tadawy General Hospital Tapline Qaisuma Hospital (ARAMCO) Yousif Hospital Zamil Hospital Hail Region AlBorg Lab (Hail) Baqa Hospital Hail General Hospital King Khaled General Hospital Maternity & Children's Hospital 92 Rashid Hospital Safa Polyclinic (RY) Salamat Private Hospital Shamli (Hail) . Noor Khan Hospital (Hafr Al Batin) Eastern Province Hospital Fanateer Hospital Faraby Dispensary Huwaylat Hospital Imam Abdul Rahman Bin Faisal. AFH (Khamis Mushayt) King Faisal Military Hospital Mahael General Hospital Majaridah General Hospital Namas General Hospital Prince Abdul Bin Abdul Aziz Hospital Rijal Al Maa Hospital Sarat Obeidah General Hospital Saudi German Hospital (Abha) Tathleeth General Hospital Baha Region Baha National Hospital Baljurashi General Hospital Ghodran Hospital King Fahad Hospital (Baha) Mandaq Hospital Mikhwah Hospital Eastern Province Ahsa Hospital (Hofuf) AL Borg Lab (DM) Anak General Hospital ARAMCO Clinic Armed Forces Hospital (Hafr Al Batin) Astoon Hospital (Thomairy) Badr Rubaie Dispensary Dammam Central Hospital Dossary Hospital (Khobar) Dr. Fakhry & Mouhawis Hospital Dr.APPENDIX: A Reporting Health care Facilities Asir Region Abha General Hospital (Maternity) Abha Private Hospital AFH Military Hospital Ahli Hospital (Abha) Asir Central Hospital (Abha) Balasmar General Hospital Bisha General Hospital Dhahran Janoob Hospital Khamis Mushayt Civil Hospital King Fahad Hospital.

) Jazan Region Abu Arish General Hospital Baysh General Hospital Darb Hospital Jazan General Hospital Jazan Hospital NOS Jazan Military Hospital King Fahad Central Hospital Samtah General Hospital Jouf Region Dawamat Jandal Hospital Maternity & Children's Hospital Pr AbdulRahman Sudairi General Hospital Qurayat General Hospital Tabarjal General Hospital Madinah Region Al Borg Lab Aneis Al Khair Lab Ansar Hospital (MD) Ansary Specialist Hospital Badr General Hospital (Yanbu) Dr Erfan Saadi Hospital (Yanbu) Hanakyah General Hospital Khaybar General Hospital King Abdul Aziz NGH Hospital King Fahad Hospital (MD) Madina Hospital. NOS Madina National Hospital Madinah Maternity & Children's Hospital Magrabi Eye Hospital (MD) Mahd General Hospital Meeqat Hospital Mouwasat Hospital (Madinah) Ohoud Hospital Prince Abdul Mohsen Ola General Hospital Royal Commission Medical Center (Yanboa) Saudi German Hospital (MD) Yanboa General Hospital Zahra Private Hospital Zen Laboratory Makkah Region Abdul Rahman Qari Center Abdullah Saeim Daher Abuzinada Hospital Adwani General Hospital (Taif) Ahli Clinic Ajiyad General Hospital (MK) Alawi Tunsi & Bros Hospital AlBorg Lab (JD) AlBorg Lab (MK) Amen Hospital (Taif) Ansar Hospital (JD) Bugshan General Hospital (JD) Chest Disease Hospital (Taif) Dr Abdul Rahman Bakhsh Hospital Dr Erfan & Bagedo Hospital Dr Ghassan Pharaon Hospital Dr Khalid Idrissi Hospital Dr Solaiman Fakeeh Hospital Elaj Laboratory (JD) Eye Hospital (JD) Ghannam Clinic Hada Military Hospital (AFH) Hai Jamea Hospital Hayat Hospital (JD) Hera General Hospital (MK) International Medical Jazerah Hospital (JD) King Faisal Hospital (Taif) King Faisal Specialist Hospital (JD) King Saud Hospital (JD) Leeth Hospital Maghraby Eye Hospital (JD) Makkah Hospital NOS Maternity & Children's Hospital (JD) Maternity & Children's Hospital (TF) Maternity & Children's Hospital (MK) Muhammad Saleh Bashrahi Misan Blhareth (Taif) Mustaqbal Hospital (Dhagastani) Nahda National Hospital (TF) National Saudi Hospital (JD) New Jeddah Clinic Noor Specialist Hospital (MK) Nourah Oncology Center Pioneers Laboratory Qunfudah General Hospital Rabegh General Hospital Rafie Hospital (MK) Rahmah Polyclinic (JD) Royal Commission Medical Center (Yanboa) Salam Hospital Salamah Hospital (Closed) Saudi German Hospital (JD) Saudi Hospital 93 ..APPENDIX: A (continued..

.APPENDIX: A (continued.. Jedaani Hospital Jeddah Clinic Hospital Jeddah General Hospital Khadra Lab (JD) King AbdulAziz Hospital & Oncology Center (JD) King AbdulAziz Hospital (Al Zaher) (MK) King AbdulAziz Specialist Hospital (Taif) King AbdulAziz University Hospital (JD) King Fahad General Hospital King Fahad Hospital. AFH (JD) King Fahd Air Base Hospital King Faisal (Al Shesha) Hospital (MK) Saudia Airlines Medical Services Shaty Hospital (Closed) Sheffaa Hospital Taif Chest Hospital Taif Children's Hospital (Taif) Taif Medical Center Thagher Hospital Torbah Hospital Umm Qura General Hospital United Doctors Hospital (Shaty Hospital) Zahra Hospital (JD) Zahra Hospital (JD) Najran Region Dhafer Hospital (Najran) King Khaled Hospital (Najran) Maternity & Children's Hospital Najran Armed Forces Hospital Najran General Hospital Najran Hospitalital NOS Sharourah Armed Forces Sharourah General Hospital Northern Region Arar Central Hospital Rafha General Hospital Turayf General Hospital Qassim Region Bukairiya General Hospital Buraidah Central Hospital King Fahd Specialist Hospital King Saud University Hospital Maternity & Children's Hospital Midhnab General Hospital Qassim Hospital NOS Rass General Hospital Wafa Hospital Riyadh Region Abdullah Medical Clinic Adama Hospital Advance Cell Laboratory AFH Millitary (RKH) Afif General Hospital Aflaj General Hospital Ahad Madina Polyclinic Alam Medical Center AlBorg Lab (RY) Amal Clinic (1) Amal Psychiatric Hospital Ameed Polyclinic (Kharj) Anda Medical Laborator Armed Forces (Wadi Dawasir) Artwiyah Clinic Ashbelia Medical Clinic Aziziah Medical Laboratory Basheer Obaid Dental Clinic Bustan Clinic Chest Diseases Hospital (Kharj) Consultative Medical Center 94 Ismail Raslan Polyclinic Jafel International Ho Jazeera Laboratories Jazeera Medical Clinic Khaleejy Medical Clinic King Abdul Aziz Medical City King Abdul Aziz University King Fahad Medical City King Faisal Specialist Hospital & Research Center King Khaled Eye Specialist Hospital King Khaled General Hospital King Khaled University Hospital Maghraby Eye Hospital (RY) Mamlaka Hospital (Kingdom) Masaudi Clinic Maternity & Children's Hospital (RY) Mobarak Hospital Mouwasat Hospital (Ry) Mowed Medical Center Obeid Hospital (RY) Olaya Medical Center .) Makkah Region continued…..

Consulting Radiologist Dallah Hospital Dar Hekma Clinic (RY) Dar Shifa Hospital Dawadmi General Hospital Dawssary Polyclinic (Kharj) Delta Medical Laboratory Digits Clinic Dilem General Hospital (Kharj) Dr Abdul Rahman Mishari Hospital Dr Fahd Sheduokhy Polyclinic Dr Hamed Mutabagani Med Dr Moagel's Polyclinic Dr Mofarreh Polyclinic Dr Mohamed Anazi Medical Center Dr Mohamed Shaker Heto Dr Suliman Habib Medical Center Elaj Laboratory Elite Medical & Surgical Eman General Hospital ENT Medical Center Faiha Medical Center Faleh International Hospital Finger Print Laboratory Green Cresent Hospital Gulf Radiology Center Hammadi Hospital Hayat Polyclinic (Kharj) Hilah Medical Clinic Hotta Bani Tammim Hospital Howtat Sudair Hospital Huraymila General Hospital Ibn Sina Lab (RY) Osrah Clinic Osrah International Hospital Prince Nasser Bin Saad Prince Salman Bin Abdulaziz Hospital Quwayiyah General Hospital Rathawiah Medical Spec Rawabi Qurtuba Clinic Riyadh Care Hospital (Social Insurance) Riyadh Hospital NOS Riyadh Medical Center Riyadh Medical Complex Saati Medical Center Clinic Safa Makka Polyclinic Saudi German Hospital Saudi Medical Services Security Forces Hospital Shaqra General Hospital Shibel National Clinic Shifa Health Center Specialized Medical Center Sports Medicine Hospital Sughayyer Clinic Sulail Hospital Taif Medical Center (RY) Tumayr (Majmaah) United Medical Laboratory Wadi Dawasser Hospital Watan Clinic Watani Hospital (RY) Wroud Medical Clinic Yamamah Hospital Zulfi General Hospital Tabuk Region Badaa Hospital (Tabuk) Dhuba General Hospital King Abd Aziz Military King Fahad Hospital (Tabuk) King Khalid Civil King Khalid General Hospital Maternity & Children's Hospital North West Armed Forces Hospital Prince Fahad Bin Sultan Hospital Taima General Hospital Umlujj General Hospital Wajh General Hospital International Hospitals in the following Countries Bahrain Bangladesh Canada China Cyprus Egypt Eritrea Ethiopia France Germany India Iraq Ireland Japan Jordan Kuwait Lebanon Nigeria Pakistan Philippines Qatar Sudan Syrian Arab Republic United Arab Emirates United Kingdom United States of America Yemen 95 .) Riyadh Region continued…...APPENDIX: A (continued...

442 -3924 Email: bazarbashi@kfshrc.com Director: Prof.624-0000 x 18244/18253 Fax: 02.442-4286 Fax: 01. Director: Tumor Registrar: Asst. MD Eastern Region King Fahd Hospital of the University PO Box 40004. Mohmoud Shaheen Al Ahwal. Jeddah 21589 Tel: 02. Tumor Registrar: Secretary: Haya Al Eid.896-6741 Fax: 03. Riyadh 11159 Tel: 01.477 -6743 x 6743 Email: rhalasiri@hotmail. Hassan Al Idrissi.sa Director: Abdulaziz Al Humaidi. MD King Abdulaziz University Hospital Faculty of Medicine PO Box 80215.442-4542 Email: alisaz@kfshrc. DFE. MD.442 -3929 Fax: 01. PhD 96 .com Director: Prof.sa Directors: Shouki Bazarbashi.APPENDIX: B SCR Board Member Contact Information SCR Main Office MBC 64 PO Box 3354. CTR Maisoun Khaled Marielen S.sa Chairman: Shouki Bazarbashi.scr.869-6741 Email: halidrissi@yahoo.288-1965 Email: aalhumaidi@kfmc.med. MD King F aisal Specialist Hospital & Research Center MBC-64 PO Box 3354.sa Website: www.617-1412 Email: kau_vdca@yahoo. Al Khobar 31952 Tel: 03. MD Admin.com Director: Rizqullah Assiri. BDS.477 -7714 x 6747 Fax: 01. CTR Mohamed Hayder.edu. Riyadh 11211 Saudi Arabia Tel: 01 . Riyadh 11525 Tel: 01.sa haleid@kfshrc.edu.edu.org. MD Ali Al-Zahrani. MD Central Region King Fahad Medical City PO Box 59046. Riyadh 11211 Tel: 01. Manalo Armed Forces Hospitals Riyadh Military Hospital PO Box 7897.288-9999 x 7086 Fax: 01.

com Director: Hasnah Al Ghamdi.624-0000 x 24081 Email: awandejani@yahoo. MD Southern Region King Khalid University PO Box 641. Chairman 1992 . Jeddah 21423 Tel: 02. MD Ministry of Health Kingdom of Saudi Arabia PO Box 335157.December 2009 Susan E. Director March 2003. & Oncology Center PO Box 31467.April 2006 Hadir Meir. MD National Guard Hospitals King Abdulaziz Medical City (KKNGH) PO Box 9515..475-3814 Email: aabahussein@hotmail.624-0000 x 24082 Fax: 02.475-0426 x 201 Fax: 01.635-6410 Email: hasnah_ncr_w@hotmail. Saeedi. Riyadh 11314 Tel: 01.836-0937 Email: tarawah@yahoo. MD Director November 2001 .224-0711 / 224 -7800 x 118 Fax: 07.June 2007 Dahish Ajarim. CTR Admin.May 2006 97 . Jeddah 21497 Tel: 02.com Director: Abdulaziz Saleh Aba Hussein. Madinah & Northern Region King Fahad Hospital Madinah Al Monawarah Tel: 04-836-2000 x 2465/2462 Fax: 04.com Director: Ahmed Tarawa..August 2005 Hassan Trabulsi. Abha Tel: 07.475-0428 Email: mysa88@yahoo. MD Nasser Al Hamdan.com Director: Abdulwahab Andejani. MD Security Forces Hospital PO Box 3643.637-5555 x 2276 Fax: 02. CCHRA©. PhD Director January 2001 .APPENDIX: B Continued.224-0964 / 224 -7570 Director: Abdul Rahman Al Shehri. Dep. MD Director January 2001 .477-4480 x 1193 Fax: 01. Riyadh 11481 Tel: 01.2006 Edward De Vol. Young. MD Director 1999 . MD Western Region King Abdulaziz Hosp..com Representative: Mohammad Y.

Cytology / Hematology 6. Malignant/Invasive 28. Undifferentiated / Anaplastic 5. GRANDFATHER 6. Morphology Code 25. Left 3. Not paired (unknown. In situ 3. ill defined) 1. Surgery (Visualization without Biopsy) 4. Medical Imaging (Radiology) 3. use 01/07/_ _ _ _ ) 23. laterally not stated 98 30. NOS 2. Regional by direct extent 4. Extension 1 19. Poorly Differentiated 4. Address Details City: Suburb /District y 13. Unknown * for leukemias & lymphomas only 29. Date of Diagnosis (First time physician states that patient has a malignancy clinically or pathologically) (if only year is known. Telephone Number 2 TUMOR 20. NOS 7. laterality origin unknown 9. Extension 2 (Must be filled) 21. Grade 2. DCO (death certificate only) 1. Unknown* 1. Morphology Text (Must be filled) / 26. B-Cell/Pre-B/B-cursor* 7. Histology of Primary 8. Regional (both 3 and 4) 6. Clinical 2. Revised 03.APPENDIX C: Cancer Registration Abstract Form SAUDI CANCER REGISTRY Ministry of Health Kingdom of Saudi Arabia CANCER REGISTRATION ABSTRACT 1. Topography Text (Must be filled) 22. Saudi ID/Passport/ Iqama Number 8. but unknown 4. Marital Status 1. use 01/07//_ _ _ _ ) 12. Divorced (Must be filled) P. Natural Killer cell* 9. Widowed 9. Moderately / Moderately well differentiated 3. Bilateral involvement. Single 2. In situ 2. One side. Address Code (Must be filled) 15.Nationality Code d d 10. Right 2. Histology of Metastasis 7. Behavior (behavior) 27. 2010 (Accession Number) d d m m y y y y (Computer Assigned) PATIENT 3. T-Cell* 6. FATHER (Must be filled) 5. Sex 1-Male 2-Female 9-Unknown 11. Married 3. ACCESSION DATE 2. FAMILY (Must be filled) Use SCR standardized name spellings 7. Regional. CanReg-4 No. Distant Metastasis / Systemic disease 9. Null Cell/Non-T-Non-B* 8. Regional by lymph node 5. Lab test (tumor marker) 5. Box 4.Autopsy 9. SEER Summary Stage (Extent) 1. Date of Birth - m m y y y (if only year is known. First (Must be filled ) 4. Age at Diagnosis 9. Unknown . Basis of Diagnosis 0. Nationality Text (Must be filled) 14. Paired site. Laterality 0.O. Well differentiated / Differentiated. Telephone Number 1 (Must be filled) 18. Mobile Number (Must be filled) 17. Topography Code 0B d d m m y y y y C 24. Unknown Zip Code: 16. Localized 3.

MRN 3 43. Path 3 44. MRN 4 47.APPENDIX C: Cancer Registration Abstract Form HOSPITAL 31. MRN 1 35. Referral Hospital Text 54. Source 2 37. Last Contact d d m 57. Path 6 FOLLOW-UP 56. Data Entry ID # Signature: __________________________________ : QUESTIONS / QUERIES / PROBLEMS 99 . Unknown 1. Referral Hospital Text 50. Path 4 48. Coder ID # Signature: ___________________________________ 58. Referral Hospital Text 42. Source 6 53. Path 1 36. Status m y y y y 59. Not Applicable 9. Alive 9. Source 1 33. Other 3. Cancer 2. Path 5 52. Dead 2. Date first seen at Source1 for this cancer (Must be filled) d d m m y y y y 32. Source 4 45. Source 3 41. Referral Hospital Text 46. MRN 2 39. Source 5 49. MRN 6 55. Reporting Hospital Text 34. MRN 5 51. Unknown 60. Referral Hospital Text 38. Path 2 40. Cause of Death 1.

‫‪٤۱٥٦‬‬ ‫ﺇﻧﺎﺙ‬ ‫‪٪۲۳٫٦‬‬ ‫‪۹۸۱‬‬ ‫ﺍﻟﺛﺩﻱ‬ ‫‪٪۱۰٫٦‬‬ ‫ﺫﻛﻭﺭ‬ ‫‪۳۸۹۸‬‬ ‫ﺍﻟﻘﻭﻟﻭﻥ ﻭﺍﻟﻣﺳﺗﻘﻳﻡ‬ ‫‪٤۱٤‬‬ ‫‪٪۱۰٫۲‬‬ ‫‪٤۲٤‬‬ ‫ﺍﻟﻐﺩﺓ ﺍﻟﺩﺭﻗﻳﺔ‬ ‫‪٪۹٫۰‬‬ ‫‪۳٥۱‬‬ ‫ﻻ ﻫﻭﺩﺟﻛﻥ‬ ‫‪٪۸٫۹‬‬ ‫‪۳۷۰‬‬ ‫ﺍﻟﻘﻭﻟﻭﻥ ﻭﺍﻟﻣﺳﺗﻘﻳﻡ‬ ‫‪٪۷٫٦‬‬ ‫‪۲۹٦‬‬ ‫ﺍﺑﻳﺿﺎﺽ ﺍﻟﺩﻡ‬ ‫‪٪٥٫٦‬‬ ‫‪۲۳٤‬‬ ‫ﻻ ﻫﻭﺩﺟﻛﻥ‬ ‫‪٪۷٫٥‬‬ ‫‪۲۹۱‬‬ ‫ﺍﻟﻛﺑﺩ‬ ‫‪٪٥٫۱‬‬ ‫‪۲۱۲‬‬ ‫ﺍﺑﻳﺿﺎﺽ ﺍﻟﺩﻡ‬ ‫‪٪٦٫۰‬‬ ‫‪۲۳۲‬‬ ‫ﺍﻟﺭﺋﺔ‬ ‫‪٪۳٫٤‬‬ ‫‪۱٤۰‬‬ ‫ﺍﻟﺭﺣﻡ‬ ‫‪٪٥٫۸‬‬ ‫‪۲۲۸‬‬ ‫ﺍﻟﺑﺭﻭﺳﺗﺎﺕ‬ ‫‪٪۳٫۲‬‬ ‫‪۱۳٤‬‬ ‫ﺍﻟﺟﻠﺩ‬ ‫‪٪٥٫۰‬‬ ‫‪۱۹۳‬‬ ‫ﺍﻟﺟﻠﺩ‬ ‫‪٪۳٫۲‬‬ ‫‪۱۳۲‬‬ ‫ﺍﻟﻣﺑﻳﺽ‬ ‫‪٪٤٫٤‬‬ ‫‪۱۷۳‬‬ ‫ﻣﺭﺽ ﻫﻭﺩﺟﻛﻥ‬ ‫‪٪۳٫۰‬‬ ‫‪۱۲٥‬‬ ‫ﺍﻟﻛﺑﺩ‬ ‫‪٪٤٫۳‬‬ ‫‪۱٦۹‬‬ ‫ﺍﻟﻣﺛﺎﻧﺔ‬ ‫‪٪۲٫۹‬‬ ‫‪۱۲۰‬‬ ‫ﻣﺭﺽ ﻫﻭﺩﺟﻛﻥ‬ ‫‪٪٤٫۲‬‬ ‫‪۱٦۲‬‬ ‫ﺍﻟﻣﻌﺩﺓ‬ ‫ﺍﻟﺳﺭﻁﺎﻧﺎﺕ ﺍﻟﻌﺷﺭﺓ ﺍﻷﻛﺛﺭ ﺇﻧﺗﺷﺎﺭﺍً ﺑﻳﻥ ﺍﻟﺳﻌﻭﺩﻳﻳﻥ ﺣﺳﺏ ﺍﻟﺟﻧﺱ‪۲۰۰٦ .‬‬ ‫‪۲٤۰‬‬ ‫‪ ۳۲۷‬ﺃﻭﻻﺩ‬ ‫ﺑﻧﺎﺕ‬ ‫‪٪۳۳٫۳‬‬ ‫‪۸۰‬‬ ‫ﺃﺑﻳﺿﺎﺽ ﺍﻟﺩﻡ‬ ‫‪٪۳۰٫٦‬‬ ‫‪٪۱٤٫٦‬‬ ‫‪۳٥‬‬ ‫ﺍﻟﺩﻣﺎﻍ‬ ‫‪٪۱٤٫۱‬‬ ‫‪٤٦‬‬ ‫‪٪۱۱٫۳‬‬ ‫‪۲۷‬‬ ‫ﻣﺭﺽ ﻫﻭﺩﺟﻛﻥ‬ ‫‪٪۱۱٫٦‬‬ ‫‪۳۸‬‬ ‫‪٪٥٫۸‬‬ ‫‪۱٤‬‬ ‫ﻻ ﻫﻭﺩﺟﻛﻥ‬ ‫‪٪۱۰٫۱‬‬ ‫‪۳۳‬‬ ‫ﻣﺭﺽ ﻫﻭﺩﺟﻛﻥ‬ ‫‪٪٥٫٤‬‬ ‫‪۱۳‬‬ ‫ﺍﻟﻌﻅﺎﻡ‬ ‫‪٪۷٫۰‬‬ ‫‪۲۳‬‬ ‫ﺍﻟﻌﻅﺎﻡ‬ ‫‪٪٥٫٤‬‬ ‫‪۱۳‬‬ ‫ﺍﻟﻌﻳﻥ‬ ‫‪٪٥٫٥‬‬ ‫‪۱۸‬‬ ‫ﺍﻟﻌﻳﻥ‬ ‫‪٪٥٫۰‬‬ ‫‪۱۲‬‬ ‫ﺍﻟﻛﻠﻰ‬ ‫‪٪٤٫۳‬‬ ‫‪۱٤‬‬ ‫ﺍﻟﻛﻠﻰ‬ ‫‪٪٤٫۲‬‬ ‫‪۱۰‬‬ ‫ﺍﻷﻧﺳﺟﺔ ﺍﻟﺿﺎﻣﺔ ﻭﺍﻟﺭﺧﻭﺓ‬ ‫‪٪۳٫۷‬‬ ‫‪۱۲‬‬ ‫ﺍﻟﻐﺩﺓ ﺍﻟﻛﻅﺭﻳﺔ‬ ‫‪٪۳٫۸‬‬ ‫‪۹‬‬ ‫ﺍﻟﻐﺩﺓ ﺍﻟﻛﻅﺭﻳﺔ‬ ‫‪٪۳٫٤‬‬ ‫‪۱۱‬‬ ‫ﺍﻷﻧﺳﺟﺔ ﺍﻟﺿﺎﻣﺔ ﻭﺍﻟﺭﺧﻭﺓ‬ ‫‪٪۲٫۹‬‬ ‫‪۷‬‬ ‫ﺍﻟﻐﺩﺓ ﺍﻟﺩﺭﻗﻳﺔ‬ ‫‪٪۱٫٥‬‬ ‫‪٥‬‬ ‫ﺍﻟﺑﻠﻌﻭﻡ ﺍﻷﻧﻔﻲ‬ ‫‪۱۰۰‬‬ ‫ﺃﺑﻳﺿﺎﺽ ﺍﻟﺩﻡ‬ ‫ﺍﻟﺩﻣﺎﻍ‬ ‫ﻻ ﻫﻭﺩﺟﻛﻥ‬ ‫ﺍﻟﺳﺭﻁﺎﻧﺎﺕ ﺍﻟﻌﺷﺭﺓ ﺍﻷﻛﺛﺭ ﺇﻧﺗﺷﺎﺭﺍً ﺑﻳﻥ ﺍﻷﻁﻔﺎﻝ ﺍﻟﺳﻌﻭﺩﻳﻳﻥ ﺣﺳﺏ ﺍﻟﺟﻧﺱ‪۲۰۰٦ .‬‬ ‫‪100‬‬ .

APPENDIX D: Summary of Cancer Statistics in Saudi Arabia for the Year 2006 101 .

Sign up to vote on this title
UsefulNot useful